ticlopidine has been researched along with Coronary Disease in 596 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study explores the associations between PIK3CG single nucleotide polymorphisms (SNPs, rs1129293 and rs17398575) and patient responsiveness to clopidogrel to evaluate the risks of ischemia in patients with coronary heart disease (CHD)." | 9.24 | PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. ( Li, KC; Yu, SH; Zhuge, BZ, 2017) |
| "The goal of this study was to investigate the antiplatelet efficacy and tolerability of clopidogrel resinate in patients with coronary heart disease (CHD) or CHD-equivalent risks." | 9.15 | Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial ( Choi, YJ; Gwak, CH; Hong, SJ; Joo, SJ; Kim, HS; Kim, KS; Kim, SH; Park, TH; Seung, KB; Suh, JW; Tahk, SJ, 2011) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 9.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 9.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 9.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| "The VERIfy Thrombosis risk ASsessment (VERITAS) was a prospective study designed to measure platelet response to clopidogrel therapy in subjects with multiple risk factors or history of vascular disease using this novel point-of-care assay." | 9.12 | Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. ( Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M, 2007) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 9.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 9.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 9.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation." | 9.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 9.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 9.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "Six months of clopidogrel and aspirin and a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well tolerated and associated with a reduction in the late thrombosis rate compared with a similar cohort treated with only 1 month of clopidogrel and aspirin." | 9.09 | Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). ( Ajani, AE; Bui, AB; Dieble, R; Gruberg, L; Kent, KK; Lindsay, J; Mintz, GS; Pichard, AD; Pinnow, E; Satler, LF; Taaffe, M; Waksman, R; White, RL, 2001) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 9.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "A number of randomized double-blind studies have been conducted for comparative assessment of the pharmacodynamic properties of high loading and maintenance doses of clopidogrel (600-900 mg loading dose and 150 mg maintenance dose) and standard dose of prasugrel (60 mg loading dose and 10 mg maintenance dose) in patients with coronary heart disease, including those with acute coronary syndrome." | 8.88 | [Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome]. ( Pakhomov, IaM, 2012) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 8.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial." | 8.82 | CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005) |
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 8.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| "To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs)." | 7.83 | Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. ( He, Y; Jin, L; Li, A; Liu, B; Ou, W, 2016) |
| "We recruited 162 coronary heart disease patients treated with aspirin and clopidogrel, and we genotyped them for the CES1A2 A(-816)C, CYP2C19 *2/*3, PON1 Q192R, and ABCB1 C3435T polymorphisms." | 7.80 | The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. ( Ding, X; Gao, J; Hang, Y; Jiang, B; Miao, L; Wang, H; Xie, C; Zhang, H; Zhang, J, 2014) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 7.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "To determine the association between the discontinuation of clopidogrel therapy prior to 1 year and the risk of acute myocardial infarction (AMI) hospitalization, coronary intervention or all-cause mortality in a cohort of managed-care patients following AMI hospitalization or stent insertion." | 7.75 | Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. ( Berenson, K; Casciano, R; Corbelli, J; Lamerato, L; Makenbaeva, D; Mozaffari, E; Stern, L; Wiederkehr, D, 2009) |
| "To evaluate the association between discontinuation of clopidogrel therapy and risk of acute myocardial infarction (AMI) hospitalization or cardiac revascularization in a nationally-representative patient population following hospitalization for an AMI or coronary stent insertion." | 7.75 | Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. ( Casciano, R; Corbelli, J; Makenbaeva, D; Mozaffari, E; Ogbonnaya, A; Wiederkehr, D, 2009) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 7.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 7.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 7.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 7.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 7.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 7.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 7.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 7.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel." | 7.71 | Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001) |
| "Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease." | 7.71 | Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. ( Coxson, PG; Gaspoz, JM; Goldman, L; Goldman, PA; Hunink, MG; Kuntz, KM; Williams, LW, 2002) |
| "This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non-Q-wave myocardial infarctions (MIs)." | 7.70 | The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. ( Ellis, SG; Lauer, MS; Lincoff, AM; Moliterno, DJ; Mukherjee, DP; Steinhubl, SR; Topol, EJ, 1998) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 7.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine." | 7.70 | Ticlopidine-induced thrombocytopenia. ( de Vries, CJ; Koornstra, JJ; Loualidi, A, 1999) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 7.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "A 64-year-old man presented with worsening dyspnea on exertion and hemothorax of the left chest 7 days after discharge from the hospital on ticlopidine and aspirin after coronary stent placement to his left circumflex artery." | 7.70 | Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. ( Dillard, TA; Quinn, MW, 1999) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 7.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)." | 7.69 | Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 6.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 6.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| " This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI." | 5.46 | Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). ( Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y, 2017) |
| "Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease." | 5.31 | Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent--a case report. ( Buyukberber, S; Sari, R; Sevinc, A, 2000) |
| "This study explores the associations between PIK3CG single nucleotide polymorphisms (SNPs, rs1129293 and rs17398575) and patient responsiveness to clopidogrel to evaluate the risks of ischemia in patients with coronary heart disease (CHD)." | 5.24 | PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease. ( Li, KC; Yu, SH; Zhuge, BZ, 2017) |
| "We aimed to investigate the relationship between platelet microRNA (miR-223 and miR-96) expression and clopidogrel responsiveness in patients with coronary heart disease (CHD)." | 5.17 | Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. ( Ge, L; Ji, WJ; Jiang, TM; Li, YM; Liu, X; Lu, RY; Shi, R; Zeng, S; Zhang, WC; Zhang, YY; Zhao, JH; Zhou, X, 2013) |
| "The goal of this study was to investigate the antiplatelet efficacy and tolerability of clopidogrel resinate in patients with coronary heart disease (CHD) or CHD-equivalent risks." | 5.15 | Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial ( Choi, YJ; Gwak, CH; Hong, SJ; Joo, SJ; Kim, HS; Kim, KS; Kim, SH; Park, TH; Seung, KB; Suh, JW; Tahk, SJ, 2011) |
| "This was a prospective observational study of 15 532 patients enrolled in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial who were randomly assigned to clopidogrel or placebo, and followed-up for a median of 28 months for the occurrence of the primary endpoint (cardiovascular death, myocardial infarction, or stroke), all-cause mortality, and bleeding complications." | 5.14 | The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. ( Bhatt, DL; Fox, KA; Haffner, SM; Hamm, CW; Hankey, GJ; Johnston, SC; Mak, KH; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2009) |
| "Despite the use of anti-platelet agents such as acetylsalicylic acid (ASA) and clopidogrel in coronary heart disease, some patients continue to suffer from atherothrombosis." | 5.14 | Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study. ( Eriksson, AC; Hedbäck, B; Jonasson, L; Lindahl, TL; Whiss, PA, 2009) |
| "The use of dual antiplatelet therapy for a period longer than 12 months in patients who had received drug-eluting stents was not significantly more effective than aspirin monotherapy in reducing the rate of myocardial infarction or death from cardiac causes." | 5.14 | Duration of dual antiplatelet therapy after implantation of drug-eluting stents. ( Chae, JK; Cheong, SS; Choi, YJ; Chung, WS; Han, KH; Hur, SH; Jang, JS; Jeon, DS; Jeong, MH; Kang, SJ; Kim, KS; Kim, YH; Lee, BK; Lee, CW; Lee, K; Lee, NH; Lee, SG; Lee, SW; Lim, DS; Nah, DY; Park, DW; Park, HS; Park, SJ; Park, SW; Rha, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2010) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 5.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "The PRODIGY trial aims to assess whether 24 months of clopidogrel therapy improves cardiovascular outcomes after coronary intervention in a broad all-comer patient population receiving a balanced mixture of stents with various anti-intimal hyperplasia potency." | 5.14 | Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment ( Arcozzi, C; Borghesi, M; Campo, G; Cangiano, E; Cavazza, C; Colombo, F; Ferrari, F; Ferrari, R; Frangione, A; Kubbajeh, M; Marchesini, J; Minarelli, M; Monti, M; Parrinello, G; Percoco, G; Scalone, A; Tebaldi, M; Tumscitz, C; Valgimigli, M; Zuffi, A, 2010) |
| "Clopidogrel in mild or moderate CKD patients may not have the same beneficial effect as it does in patients with normal renal function, but was not associated with a greater relative risk of bleeding based on renal function." | 5.13 | The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. ( Berger, PB; Best, PJ; Brennan, DM; Califf, RM; Dasgupta, A; Steinhubl, SR; Szczech, LA; Topol, EJ, 2008) |
| "Although clopidogrel and aspirin (dual therapy, DT) are used for acute coronary syndrome (ACS), sometimes treatment with warfarin (triple therapy, TT) is required." | 5.12 | Aspirin, warfarin and a thienopyridine for acute coronary syndromes. ( Behar, S; Gottlieb, S; Hammerman, H; Hasdai, D; Hod, H; Iakobishvili, Z; Konstantino, Y; Porter, A; Sandach, A; Zahger, D, 2006) |
| "The VERIfy Thrombosis risk ASsessment (VERITAS) was a prospective study designed to measure platelet response to clopidogrel therapy in subjects with multiple risk factors or history of vascular disease using this novel point-of-care assay." | 5.12 | Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. ( Atar, D; Defranco, A; Mahmud, E; Malinin, A; Pokov, A; Schwartz, D; Schwartz, K; Serebruany, V; Spergling, M, 2007) |
| " The antiplatelet agent clopidogrel has become a mainstay of treatment for patients with acute coronary syndromes and stroke, and to reduce ischemic complications after percutaneous coronary and peripheral interventions." | 5.12 | Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. ( Fasano, MB; Horwitz, PA; Walker, NE, 2006) |
| " Approximately 13,000 patients with moderate to high-risk ACS undergoing PCI (9500 unstable angina/non-ST-segment elevation myocardial infarction [MI], 3500 ST-segment elevation MI) will be randomized to prasugrel 60 mg loading dose followed by 10 mg daily or clopidogrel 300 mg loading dose followed by 75 mg daily for up to 15 months." | 5.12 | Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar ( Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Riesmeyer, J; Warmke, JW; Weerakkody, G; Winters, KJ; Wiviott, SD, 2006) |
| "120 in-hospital coronary heart disease patients with coronary stenting were randomized to two groups receiving either triple antiplatelet drugs of aspirin and clopidogrel combined with cilostazol or dual antiplatelet drugs of aspirin and clopidogrel." | 5.12 | [The effects of post coronary stenting triple antiplatelet therapies on platelet functions]. ( Han, YL; Kang, J; Li, Y; Su, QF; Wang, SL; Yan, CH, 2006) |
| "Aspirin reduces several pro-inflammatory markers in patients with coronary heart disease (CHD), while limited data exists with clopidogrel." | 5.12 | No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. ( Arnesen, H; Pettersen, AA; Seljeflot, I; Solheim, S, 2006) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "This study was designed to investigate the efficacy of cilostazol on the prevention of in-stent neointimal hyperplasia as measured by both quantitative coronary angiography (CAG) and volumetric intravascular ultrasound (IVUS)." | 5.12 | Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. ( Choi, D; Jang, Y; Jung, JH; Ko, YG; Min, PK; Shim, WH, 2007) |
| "To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)." | 5.11 | [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004) |
| "Among 2,159 patients with coronary disease who underwent percutaneous coronary intervention (PCI) in the ISAR-REACT trial, we examined clinical outcomes relative to the duration of pretreatment with a 600-mg dose of clopidogrel: (2 to 3 h, 3 to 6 h, 6 to 12 h, or >12 h)." | 5.11 | Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. ( Berger, PB; Bollwein, H; Dirschinger, J; Dotzer, F; Kandzari, DE; Kastrati, A; Mehilli, J; Neumann, FJ; Schömig, A; Steinhubl, SR; Ten Berg, JM, 2004) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| "We sought to evaluate the long-term cost-effectiveness of clopidogrel for up to one year after an acute coronary syndrome (ACS) without ST-segment elevation." | 5.11 | Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. ( Caro, J; Culler, S; Gabriel, S; Lamy, A; Mahoney, EM; Weintraub, WS; Yuan, Y; Yusuf, S, 2005) |
| "Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents." | 5.10 | A paclitaxel-eluting stent for the prevention of coronary restenosis. ( Choi, D; Ho, DS; Hong, MK; Jang, Y; Lam, R; Lee, CW; Mintz, GS; Park, SJ; Park, SW; Raizner, AE; Shim, WH; Weissman, NJ, 2003) |
| "Whether thienopyridines (ticlopidine or clopidogrel) produce similar effects on fibrinolysis in patients with non ST elevation acute coronary syndrome (NSTEACS) was not well elucidated." | 5.10 | [Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel]. ( Averkov, OV; Dobrovol'skiĭ, AB; Gratsianskiĭ, NA; Slavina, NN, 2003) |
| "In patients receiving intracoronary stents, stent thrombosis is reduced when ticlopidine therapy is combined with aspirin after the procedure." | 5.09 | Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. ( Bell, MR; Berger, PB; Grill, DE; Hasdai, D; Holmes, DR; Melby, S, 1999) |
| " Furthermore, the simpler dosing regimen, the absence of neutropenia, and the lower frequency of other side effects make it a safe alternative to ticlopidine." | 5.09 | Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. ( Collins, M; Colombo, A; Iyer, S; Kreps, E; Maida, R; Moses, JW; Moussa, I; Oetgen, M; Roubin, G; Wang, X, 1999) |
| "Six months of clopidogrel and aspirin and a reduction in re-stenting for patients with in-stent restenosis treated with gamma-radiation is well tolerated and associated with a reduction in the late thrombosis rate compared with a similar cohort treated with only 1 month of clopidogrel and aspirin." | 5.09 | Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). ( Ajani, AE; Bui, AB; Dieble, R; Gruberg, L; Kent, KK; Lindsay, J; Mintz, GS; Pichard, AD; Pinnow, E; Satler, LF; Taaffe, M; Waksman, R; White, RL, 2001) |
| "One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)." | 5.08 | Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997) |
| "Previous studies have shown that stents can be inserted in coronary arteries of patients who are subsequently treated safely with antiplatelet therapy only (ticlopidine and/or aspirin) with a low incidence of stent thrombosis, provided that stent expansion is adequate and there are no other flow-limiting lesions present." | 5.08 | Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy. ( Albiero, R; Blengino, S; Colombo, A; Ferraro, M; Hall, P; Itoh, A; Martini, G; Nakamura, S, 1997) |
| "As compared with aspirin alone and a combination of aspirin and warfarin, treatment with aspirin and ticlopidine resulted in a lower rate of stent thrombosis, although there were more hemorrhagic complications than with aspirin alone." | 5.08 | A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. ( Baim, DS; Cutlip, DE; Diver, DJ; Giambartolomei, A; Gordon, PC; Ho, KK; Kuntz, RE; Lasorda, DM; Leon, MB; Pocock, SJ; Popma, JJ; Williams, DO, 1998) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 5.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "Dual antithrombotic regimen of warfarin and clopidogrel is comparable to the recommended triple therapy in respect to the prevention of thromboembolic outcomes of MI/ death and ischemic stroke, while the risk of bleeding is similar in those patients with indications for chronic oral anticoagulation undergoing percutaneous coronary intervention with stent implantation." | 4.93 | [Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation]. ( Du, M; Ma, G; Shi, Y; Zhang, D, 2016) |
| "A number of randomized double-blind studies have been conducted for comparative assessment of the pharmacodynamic properties of high loading and maintenance doses of clopidogrel (600-900 mg loading dose and 150 mg maintenance dose) and standard dose of prasugrel (60 mg loading dose and 10 mg maintenance dose) in patients with coronary heart disease, including those with acute coronary syndrome." | 4.88 | [Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome]. ( Pakhomov, IaM, 2012) |
| " The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel in decreasing the risk of adverse events in coronary heart disease patients has been well established in the past 20 years." | 4.85 | Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working ( Arnesen, H; Budaj, A; De Caterina, R; Filipiak, K; Golanski, J; Gorski, J; Huber, K; Kristensen, SD; Kuliczkowski, W; Opolski, G; Polonski, L; Pregowski, J; Sitkiewicz, D; Watala, C; Witkowski, A; Zembala, M, 2009) |
| "After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established." | 4.84 | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. ( Agostoni, P; Andreotti, F; Crea, F; Porto, I; Testa, L; Trotta, G; Zoccai, GB, 2007) |
| "Clopidogrel was shown to have added benefits to aspirin in patients with acute coronary syndromes without ST-segment elevation in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial." | 4.82 | CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction. ( Doggrell, SA, 2005) |
| " In elective de novo lesions has shown remarkably clear lumens at follow-up angiography and intravascular ultrasound within the stented segments were observed with no lesion progression at the stent margins or thrombosis after a 2 month regimen of aspirin, and ticlopodine or clopidogrel." | 4.81 | Sirolimus-eluting stents: a review of experimental and clinical findings. ( Albiero, R; Colombo, A; Corvaja, N; Di Mario, C; Falotico, R; Stankovic, G; Takagi, T; Toutouzas, K, 2002) |
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 4.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| "A total of 168 patients with coronary heart disease who underwent PCI operation and received clopidogrel treatment were enrolled." | 3.88 | CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. ( Fang, W; Gan, Q; Han, W; Hou, X; Liu, Y, 2018) |
| "Dialysis did not affect the antiplatelet effects of aspirin and clopidogrel in uremic patients with coronary heart disease." | 3.85 | Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease. ( Fu, DL; Gao, YX; Li, XL; Liu, XF; Lu, HK; Peng, WH; Wang, Q; Wang, Y; Yang, P; Zhang, H; Zhao, TT; Zheng, JG, 2017) |
| "The present study indicated that long-term oral low-dose aspirin was safe for patients with both TBAD and coronary heart disease who underwent EVAR." | 3.85 | Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease. ( Fu, WX; He, RX; Jing, QM; Liu, HW; Liu, YJ; Wang, XZ; Yuan, WJ; Zhang, L; Zhou, TN, 2017) |
| "To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs)." | 3.83 | Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. ( He, Y; Jin, L; Li, A; Liu, B; Ou, W, 2016) |
| " The association between plasma miRNAs targeting CYP3A4/5 mRNA and clopidogrel pharmacokinetics was analyzed in 31 patients with coronary heart disease who received 300 mg loading dose of clopidogrel." | 3.83 | Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. ( Chen, JY; He, GD; Li, HP; Li, XX; Lin, HM; Liu, JE; Meng, JX; Tang, L; Tang, QJ; Wang, LY; Wu, H; Zhang, MZ; Zhong, SL; Zhong, WP, 2016) |
| "CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361 coronary heart disease patients (male, mean age 69yrs), and the risk of cardiovascular events over a 3-month follow-up was assessed to evaluate the impact of co-administration of esomeprazole during dual antiplatelet therapy with aspirin and clopidogrel." | 3.81 | Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. ( Akasaka, T; Arima, Y; Hokimoto, S; Kaikita, K; Kumagae, N; Morita, K; Nakagawa, K; Ogawa, H; Oniki, K; Sakamoto, K; Tabata, N; Tsujita, K; Yamamoto, E, 2015) |
| "Patients with high PR on clopidogrel have a greater incidence of adverse ischemic events after stent implantation, whereas low PR may increase bleeding." | 3.81 | Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). ( Brodie, BR; Cox, DA; Duffy, PL; Généreux, P; Henry, TD; Kirtane, AJ; Maehara, A; Mazzaferri, EL; Mehran, R; Metzger, DC; Neumann, FJ; Parikh, PB; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B; Xu, K, 2015) |
| "A 62-year-old woman with hypertension, type 2 diabetes mellitus, hyperlipemia and coronary heart disease started taking clopidogrel, with no addition of any other new drugs." | 3.80 | Acquired pure red cell aplasia due to treatment with clopidogrel: first case report. ( Li, G; Li, ZQ; Yang, JD; Yang, QY, 2014) |
| " Optimal use of 4 oral drugs (aspirin, β-blockers, statins, and angiotensin-converting enzyme inhibitors) in all eligible patients with AMI or unfractionated heparin in non-ST-segment-elevation myocardial infarction was a highly cost-effective strategy (incremental cost-effectiveness ratios approximately US $3100 or less)." | 3.80 | Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China. ( Coxson, PG; Goldman, L; Gu, D; He, J; Heidenreich, PA; Liu, J; Moran, AE; Wang, M; Zhao, D, 2014) |
| "We recruited 162 coronary heart disease patients treated with aspirin and clopidogrel, and we genotyped them for the CES1A2 A(-816)C, CYP2C19 *2/*3, PON1 Q192R, and ABCB1 C3435T polymorphisms." | 3.80 | The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. ( Ding, X; Gao, J; Hang, Y; Jiang, B; Miao, L; Wang, H; Xie, C; Zhang, H; Zhang, J, 2014) |
| " We aim to document the prevalence of aspirin and clopidogrel resistance in Saudi patients with coronary heart disease (CHD) and to probe the possible responsible mechanism[s]." | 3.80 | Evaluation of resistance to anti-platelet therapy in patients with coronary heart disease in a developing country. ( Abdel Gader, AM; Al Shamiri, MQ; Bayoumy, NM, 2014) |
| "In 1 605 patients with coronary heart disease (CHD), salvianolate injection was most frequently (51%) combined with clopidogrel and isosorbide dinitrate." | 3.79 | [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world]. ( Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013) |
| "Female subjects (n = 28) with stable coronary disease who were not taking clopidogrel were recruited." | 3.79 | Clopidogrel variability: role of plasma protein binding alterations. ( Cherala, G; Ganesan, S; Maslen, CL; Williams, C, 2013) |
| "This survey depicts individual discrepancies in the clinical management of patients receiving NSAIDs and/or aspirin, regarding the prophylaxis of gastroduodenal ulcer disease." | 3.78 | [Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori]. ( Armbruster, S; Mann, J; Schepp, W; Schneider, AR; Schuster, T; von Römer, W, 2012) |
| "Between January 1, 2009 and August 31,2009, 267 patients with coronary heart disease who received PCI and treated with clopidogrel for 12 months were enrolled." | 3.77 | [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention]. ( Chen, J; Chen, JL; Chen, ZJ; Dai, J; Gao, RL; He, C; Li, JJ; Liu, HB; Meng, XM; Qiao, SB; Qin, XW; Tang, XF; Wu, Y; Wu, YJ; Yang, YJ; Yao, M; You, SJ; Yuan, JQ, 2011) |
| "To determine the association between the discontinuation of clopidogrel therapy prior to 1 year and the risk of acute myocardial infarction (AMI) hospitalization, coronary intervention or all-cause mortality in a cohort of managed-care patients following AMI hospitalization or stent insertion." | 3.75 | Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. ( Berenson, K; Casciano, R; Corbelli, J; Lamerato, L; Makenbaeva, D; Mozaffari, E; Stern, L; Wiederkehr, D, 2009) |
| "To evaluate the association between discontinuation of clopidogrel therapy and risk of acute myocardial infarction (AMI) hospitalization or cardiac revascularization in a nationally-representative patient population following hospitalization for an AMI or coronary stent insertion." | 3.75 | Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. ( Casciano, R; Corbelli, J; Makenbaeva, D; Mozaffari, E; Ogbonnaya, A; Wiederkehr, D, 2009) |
| "Rate of resistance to aspirin and clopidogrel was assessed in 44 patients with non ST elevation acute coronary syndrome." | 3.74 | [Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome]. ( Aĭnetdinova, DKh; Sulimov, VA; Udovichenko, AE, 2008) |
| "This multicenter retrospective study investigated the management and outcome of patients with peptic ulcer/erosion-related aspirin and clopidogrel (A + C) cotherapy." | 3.74 | Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel. ( Chan, P; Cheung, TK; Kng, C; Kwanching, CP; Lai, ST; Loo, CK; Ng, FH; Ng, KM; Wong, BC; Wong, SY, 2008) |
| "To describe data and insights from a national quality improvement initiative known as Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines (CRUSADE), for managing non-ST-segment elevation acute coronary syndrome (ACS), as well as the findings and implications of Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY), a study of bivalirudin with or without a glycoprotein (GP) IIb/IIIa inhibitor in patients with non-ST-segment elevation ACS who were undergoing an invasive intervention, and the results of two recent studies of clopidogrel in patients with ST-segment elevation myocardial infarction (MI) that are not reflected in current ACC/AHA guidelines for managing ST-segment elevation MI." | 3.74 | Managing acute coronary syndrome: evidence-based approaches. ( Spinler, SA, 2007) |
| "Statins are frequently given in conjunction with clopidogrel for prophylaxis and therapy of coronary heart disease." | 3.74 | [Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention]. ( Gawaz, M; Geisler, T; Paterok, M; Zürn, CS, 2008) |
| "We report a case of a severe hypersensitivity syndrome reaction to clopidogrel that resolved with dechallenge and recurred on rechallenge." | 3.73 | Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia. ( Begg, EJ; Bridgman, P; Doogue, MP, 2005) |
| "The authors describe a case of a 74-year-old man with advanced coronary heart disease in whom pulmonary hemorrhagic complications during therapy with ticlopidine and subsequently with clopidogrel and amiodarone were observed." | 3.73 | [Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma]. ( Cofta, S; Elikowski, W; Mańczak, J; Nowicki, A; Psuja, P, 2005) |
| "We investigated whether a combination of clopidogrel and glycoprotein (GP) IIb/IIIa inhibitors safely decreases hospital mortality, reinfarction, and major bleeding beyond either therapy alone in patients with non-ST-elevation myocardial infarction (NSTEMI)." | 3.73 | Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4). ( Bromberg-Marin, G; Canto, JG; Marin-Neto, JA; Parsons, LS; Rogers, WJ, 2006) |
| "Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS)." | 3.73 | A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital. ( Chan, WK; Lee, KK; Lee, VW, 2006) |
| "In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy." | 3.72 | Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. ( Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H, 2003) |
| "We performed a retrospective analysis of the Mayo Clinic PCI database and identified 66 consecutive patients who were discharged from hospital after PCI between January 2000 and August 2002 (inclusive) receiving a combination of dual antiplatelet therapy (aspirin and clopidogrel) and systemic anticoagulation (warfarin) to determine the incidence of bleeding and other clinical events during the treatment period." | 3.72 | Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. ( Berger, PB; Burger, K; Fasseas, P; Holmes, DR; Melby, S; Orford, JL; Steinhubl, SR, 2004) |
| "Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease." | 3.72 | Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. ( Abdelnoor, M; Arnesen, H; Pettersen, AA; Seljeflot, I, 2004) |
| "We compared the combination of aspirin plus clopidrogrel (A+C) with aspirin and ticlopidine (A+T) for prevention of subacute stent thrombosis in 827 patients." | 3.71 | Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. ( Abizaid, AS; Curry, BH; Dangas, G; Kent, KM; Lansky, AJ; Leon, MB; Mehran, R; Paliou, M; Pichard, AD; Satler, LF; Stone, GW, 2001) |
| "Pulmonary hemorrhage following percutaneous coronary intervention is a very rare complication that has been previously reported in association with abciximab and tirofiban, but not with clopidogrel." | 3.71 | Diffuse alveolar hemorrhage after clopidogrel use. ( Kilaru, PK; Kozman, HA; Schweiger, MJ; Weil, TR, 2001) |
| "Both aspirin and clopidogrel reduce the rate of cardiovascular events in patients with coronary heart disease." | 3.71 | Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. ( Coxson, PG; Gaspoz, JM; Goldman, L; Goldman, PA; Hunink, MG; Kuntz, KM; Williams, LW, 2002) |
| "This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non-Q-wave myocardial infarctions (MIs)." | 3.70 | The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. ( Ellis, SG; Lauer, MS; Lincoff, AM; Moliterno, DJ; Mukherjee, DP; Steinhubl, SR; Topol, EJ, 1998) |
| "We report 3 cases of fatal neutropenia and thrombocytopenia associated with ticlopidine after coronary stenting." | 3.70 | Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. ( Ball, MW; Linnemeier, TJ; Szto, GY, 1999) |
| "A case is presented of a 58-year-old woman developing profound thrombocytopenia within one week after starting treatment with ticlopidine." | 3.70 | Ticlopidine-induced thrombocytopenia. ( de Vries, CJ; Koornstra, JJ; Loualidi, A, 1999) |
| "In patients receiving coronary stents treated with aspirin and coumadin, the peak incidence of stent thrombosis occurs on the fifth and sixth days following the implantation procedure." | 3.70 | Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. ( Bell, MR; Berger, PB; Holmes, DR; Rihal, CS; Velianou, JL; Wilson, SH, 1999) |
| "A 64-year-old man presented with worsening dyspnea on exertion and hemothorax of the left chest 7 days after discharge from the hospital on ticlopidine and aspirin after coronary stent placement to his left circumflex artery." | 3.70 | Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. ( Dillard, TA; Quinn, MW, 1999) |
| "Combination antiplatelet therapy using aspirin and ticlopidine has been the standard of care for prevention of subacute thrombosis following coronary stent implantation." | 3.70 | Combination therapy with clopidogrel and aspirin after coronary stenting. ( Curran, SC; Herrmann, HC; Hirshfeld, JW; Klugherz, BD; Kolansky, DM; Magness, K; Wilensky, RL, 2000) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 3.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "We examined the antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 [(WxB)F1] male mice with myocardial infarction (MI) and systemic lupus erythematosus (SLE)." | 3.69 | Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus. ( Fujiwara, H; Nakamura, Y; Shibata, Y; Suzuka, H; Tanaka, M; Yoshifusa, H, 1995) |
| " A significant increase in postoperative hemorrhage and a higher percentage of reoperations for this reason was observed in the patients treated with ticlopidine." | 3.67 | Ticlopidine as a hemorrhagic risk factor in coronary surgery. ( Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C, 1985) |
| " The PRASugrel For Japanese PatIenTs with Coronary Artery Diseases Undergoing Elective PCI (PRASFIT-Elective) study investigated the efficacy and safety of different prasugrel dosing regimens in Japanese patients undergoing elective PCI." | 2.79 | Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Aspirin-treated patients with coronary artery disease were randomly assigned to either prasugrel 10 mg or clopidogrel 75 mg daily for 7 days." | 2.77 | Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. ( Angiolillo, DJ; Baker, BA; Heiselman, DE; Jakubowski, JA; Li, W; Logan, DK; Price, MJ; Walder, JS; Winters, KJ, 2012) |
| " We hypothesized that decreased CYP2C19 activity affects the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel." | 2.74 | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. ( Brandt, JT; Braun, OO; Close, SL; Erlinge, D; James, S; Man, M; Siegbahn, A; Varenhorst, C; Walker, J; Wallentin, L; Winters, KJ, 2009) |
| "Treatment with citalopram was associated with greater increase in tNO over 12 weeks compared to placebo (P = 0." | 2.74 | Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. ( Atar, D; Frasure-Smith, N; Laliberté, MA; Lespérance, F; Malinin, AI; Serebruany, VL; van Zyl, LT, 2009) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.72 | A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. ( Chen, YD; Jin, ZN; Lü, SZ; Lu, YL; Yuan, F, 2006) |
| "At the dosing regimens chosen in the JUMBO trial, it seems that prasugrel is a more potent antiplatelet agent than clopidogrel." | 2.72 | Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study. ( Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL, 2006) |
| "Aspirin 100 mg/d was administrated concomitantly with cilostazol or ticlopidine." | 2.71 | [Effects of cilostazol on long-term clinical outcomes after coronary stenting]. ( Deng, J; Ge, JB; Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, SL; Yang, GT; Yu, HB, 2005) |
| "Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use." | 2.70 | Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002) |
| "Cilostazol is an antiplatelet agent that increases the intracellular concentration of cyclic adenosine monophosphate by inhibiting phosphodiesterase III; it has been shown to reduce neointimal hyperplasia in animal balloon injury models." | 2.70 | Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. ( Ayabe, S; Hara, K; Ikari, Y; Kozuma, K; Kuroda, Y; Morino, Y; Tamura, T; Tanabe, K; Yamasaki, M, 2001) |
| " Monotherapy with ticlopidine is as safe and effective as a combined regimen of ticlopidine plus aspirin after coronary artery stenting in an unselected patient population." | 2.70 | Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study. ( Barmeyer, J; Bojara, W; Deneke, T; Germing, A; Grewe, P; Jaeger, D; Lawo, T; Lemke, B; Lindstaedt, M; Machraoui, A; von Dryander, S, 2001) |
| "Ticlopidine reduces stent thrombosis and other adverse events among patients receiving coronary stents." | 2.70 | Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA). ( Berger, PB; Buller, CE; Catellier, D; Dzavik, V; Penn, IM, 2001) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| " No in-hospital adverse cardiac events occurred." | 2.69 | beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. ( Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| " These results suggest that while waiting for the technological advancements of stents, postprocedural treatment that includes a low dosage of ticlopidine, aspirin, and low-molecular-weight heparin is a very effective alternative to conventional poststenting therapy." | 2.68 | Intracoronary stenting without coumadin: one month results of a French multicenter study. ( Benveniste, E; Biron, Y; Bourdonnec, C; Faivre, R; Fajadet, J; Gaspard, P; Glatt, B; Joly, P; Morice, MC; Zemour, G, 1995) |
| " Side-effects of ticlopidine were rare and patient management with the standard dosage of this drug was easier than oral anticoagulation." | 2.66 | Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. ( Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M, 1985) |
| " Dans certaines situations de risque par contre, une adaption du dosage est conseillée pour minimiser les effets secondaires négatifs: Chez les patients de plus de 75 ans, et/ou d'un poids corporel de moins de 60 kg, une réduction du dosage de prasugrel est conseillée en raison d'un risque élevé d'hémorragie." | 2.49 | [Thrombocyte aggregation inhibitors: what are the risks?]. ( Curkovic, I; Egbring, M; Kullak-Ublick, GA, 2013) |
| "Multidrug therapy increases the risk for drug-drug interactions." | 2.47 | Clopidogrel-drug interactions. ( Angiolillo, DJ; Bates, ER; Lau, WC, 2011) |
| " Thus, two major paradoxes in cardiovascular medicine today are: 1) despite the overwhelming evidence that platelet reactivity strongly influences the development of potentially catastrophic events including myocardial infarction and stent thrombosis in the PCI patient, no measurement is made in clinical practice to assess the presence of blood vulnerability (platelet reactivity) and 2) despite the overwhelming evidence that the effect of dual antiplatelet therapy with aspirin and P2Y12 receptor blockers is variable, the guidelines largely recommend a uniform, "one size fits all" dosing of these agents in the PCI patient without any confirmation of an adequate antiplatelet effect." | 2.45 | Platelet monitoring for PCI: is it really necessary? ( Gurbel, PA; Tantry, US, 2009) |
| "Despite many recent advancements in the treatment of coronary heart disease, it continues to be an important source of patient morbidity and mortality as well as a significant source of healthcare-related expenditures." | 2.44 | The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes. ( Collins, JS; Gurm, HS, 2007) |
| " Despite the unambiguous clinical benefit associated with clopidogrel, accumulating experience with this drug has also led to identification of some of its drawbacks, which are related to inadequate platelet inhibition with standard dosage regimens as well as to its irreversible antiplatelet effects." | 2.44 | ADP receptor antagonism: what's in the pipeline? ( Angiolillo, DJ, 2007) |
| "Aspirin has proven benefits in primary and secondary prevention of coronary artery disease." | 2.42 | Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. ( Badimon, JJ; Bhatt, DL; Corti, R; Francis, GS; Fuster, V; Jneid, H, 2003) |
| " Intravenous glycoprotein IIb/IIIa inhibitors effectively prevent periprocedural thrombotic complications, but their short duration of action and parenteral dosing don't allow for long-term protection." | 2.42 | What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention? ( Berger, P; Steinhubl, S, 2003) |
| " Primary endpoints were a composite of death and non-fatal myocardial infarction (MI) (efficacy endpoint) as well as a composite of major adverse side effects (safety endpoint) as considered in every single study." | 2.42 | Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis. ( Bracchetti, D; Casella, G; Fontanelli, A; Galvani, M; Ottani, F; Pavesi, PC; Rubboli, A; Sangiorgio, P, 2003) |
| "Aspirin, however, has become a lifelong therapy for many patients, based on clinical trials and medical experience." | 2.42 | Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice. ( Kerr, JL; Oppelt, TF; Rowen, RC, 2004) |
| "To review systematically the clinical effectiveness and the cost-effectiveness of clopidogrel used in combination with standard therapy including aspirin, compared with standard therapy alone for the treatment of non-ST-segment elevation acute coronary syndromes (ACS)." | 2.42 | Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation. ( Griffin, S; Hawkins, N; Henderson, R; Jones, L; Main, C; Orton, V; Palmer, S; Riemsma, R; Sculpher, M; Sudlow, C, 2004) |
| "She developed aplastic anemia seven weeks after initiation of ticlopidine." | 2.41 | Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review. ( Ammash, Z; Dabajah, B; Mourad, FH; Nasrallah, A; Taher, A, 2000) |
| " Despite the growing use of GP IIb/IIIa antagonists, much information remains unknown as to the proper dosing and the effects these agents have on other elements of the hemostatic and vascular systems." | 2.41 | Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. ( Frelinger III, AL; Furman, MI; Michelson, AD, 2000) |
| "This may reflect a reduction in restenosis, although this remains to be proven." | 2.40 | Pharmacologic prevention of acute ischemic complications of coronary angioplasty. ( Cumberland, D; Wheeldon, N, 1997) |
| "Aspirin has a role in secondary prevention of coronary artery disease; among patients who are allergic to or intolerant of aspirin, ticlopidine has a role in patients with unstable angina and clopidogrel has a potential role in patients with ischemic heart or vascular disease." | 2.40 | Antiplatelet therapy in coronary artery disease: review and update of efficacy studies. ( Tisdale, JE, 1998) |
| "Ticlopidine has become an established therapy in patients with stroke, and during stenting in patients with coronary artery disease." | 2.40 | Clopidogrel: the future choice for preventing platelet activation during coronary stenting? ( Cummings, CC; Gurbel, PA; O'Connor, CM; Serebruany, VL, 1999) |
| "Aspirin is a weak antiplatelet agent; however, its side effects can cause in tolerance, and between 15% and 45% of patients are resistant to its antiplatelet effects." | 2.40 | The thienopyridines in coronary artery disease. ( Berger, PB, 1999) |
| " This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI." | 1.46 | Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI). ( Chen, S; Geng, Y; Gu, J; Hao, Q; Qi, P; Wang, H; Wang, L; Zhang, Y, 2017) |
| "Genetic variants in the pharmacokinetic (PK) mechanism are the main underlying factors affecting the antiplatelet response to clopidogrel." | 1.46 | Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel. ( Chen, JY; He, GD; Lei, HP; Li, HP; Li, XX; Lin, HM; Liu, SW; Ma, DL; Mai, LP; Sun, S; Tang, L; Wang, XP; Wu, H; Zhang, B; Zhang, ZW; Zhong, SL; Zhong, WP; Zhou, HK, 2017) |
| "In order to understand the treatment of coronary heart disease with parenterally administered Shenmai and the efficacy of combination therapies, the study selected 18 hospitals for analysis." | 1.39 | [Real-world study in analysis of effects on concomitant medications with parenterally administered shenmai for coronary heart disease]. ( Jiang, JJ; Tang, H; Xie, YM; Yang, H; Zhuang, Y, 2013) |
| " Regarding the postoperative course, significant results could be demonstrated for: adrenaline dosage (0." | 1.36 | Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG. ( Adamczak, M; Boulesteix, AL; Eifert, S; Kilian, E; Lamm, P; Mair, H; Reichart, B, 2010) |
| "Stent thrombosis is a rare but devastating complication of coronary stent implantation." | 1.35 | Stent thrombosis: a poor man's disease? ( Danenberg, HD; Lotan, C; Marincheva, G; Nassar, H; Varshitzki, B, 2009) |
| "Stent thrombosis is associated with considerable morbidity and mortality." | 1.33 | Stent thrombosis is associated with an impaired response to antiplatelet therapy. ( Dörffler-Melly, J; Haeberli, A; Hess, OM; Imboden, K; Meier, B; Togni, M; Wenaweser, P; Windecker, S, 2005) |
| "ticlopidine) treatment remained the sole predictor of TSO (OR: 5." | 1.33 | Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. ( Amit, G; Cafri, C; Gilutz, H; Ilia, R; Wolak, A; Zahger, D, 2005) |
| "Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded." | 1.33 | Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| " We sought to establish an optimal clopidogrel dosing regimen for sustained platelet inhibition in stented patients." | 1.32 | Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. ( Alford, AB; Bell, CR; Cummings, CC; Gurbel, PA; Meister, AF; Serebruany, VL, 2003) |
| "Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease." | 1.31 | Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent--a case report. ( Buyukberber, S; Sari, R; Sevinc, A, 2000) |
| "We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) developing in a kidney/pancreas transplant recipient after the initiation of treatment with clopidogrel for symptomatic coronary artery disease." | 1.31 | Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. ( Chinnakotla, S; Fidler, ME; Hammeke, MD; Leone, JP; Tarantolo, S, 2000) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Reduced anticoagulation with antiplatelet therapy alone after coronary stenting, despite infrequent use of intravascular ultrasound, is an effective and safe strategy with a low rate of vascular complications, a relatively short hospital stay and a low incidence of clinical manifestations of stent thrombosis." | 1.30 | Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice. ( Buller, CE; Chauhan, A; Moscovich, MD; Penn, IM; Ricci, DR; Zubaid, M, 1997) |
| "Hemorrhage was present in 9 cases of group B (21." | 1.30 | [Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses]. ( Azaceta, G; Civeira, E; Cornudella, R; Iturbe, T; Moreno, JA; Olave, T; Peleato, J; Sánchez, C; Varo, MJ, 1997) |
| "Ticlopidine was withdrawn because of side effects in 11 patients." | 1.29 | [Treatment with ticlodipine after intracoronary stent implantation]. ( Golf, S; Myreng, Y; Mølstad, P, 1996) |
| "Ticlopidine appears to be an effective means of protecting graft patency as long as the biological effects of the drug are present." | 1.27 | Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. ( Chevigné, M; David, JL; Limet, R; Rigo, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (3.19) | 18.7374 |
| 1990's | 109 (18.29) | 18.2507 |
| 2000's | 347 (58.22) | 29.6817 |
| 2010's | 117 (19.63) | 24.3611 |
| 2020's | 4 (0.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, R | 1 |
| Zhou, W | 1 |
| Ye, Y | 1 |
| Zhang, X | 1 |
| Liu, Y | 3 |
| Wu, J | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 6 |
| De Caterina, R | 3 |
| Condorelli, G | 1 |
| Ferrante, G | 1 |
| Stefanini, GG | 1 |
| Silvain, J | 2 |
| Cayla, G | 2 |
| Beygui, F | 3 |
| Range, G | 2 |
| Lattuca, B | 1 |
| Collet, JP | 3 |
| Dillinger, JG | 1 |
| Boueri, Z | 2 |
| Brunel, P | 2 |
| Pouillot, C | 2 |
| Boccara, F | 1 |
| Christiaens, L | 1 |
| Labeque, JN | 1 |
| Lhermusier, T | 1 |
| Georges, JL | 1 |
| Bellemain-Appaix, A | 1 |
| Le Breton, H | 1 |
| Hauguel-Moreau, M | 1 |
| Saint-Etienne, C | 2 |
| Caussin, C | 1 |
| Jourda, F | 1 |
| Motovska, Z | 1 |
| Guedeney, P | 1 |
| El Kasty, M | 1 |
| Laredo, M | 1 |
| Dumaine, R | 1 |
| Ducrocq, G | 1 |
| Vicaut, E | 2 |
| Montalescot, G | 6 |
| Maret-Ouda, J | 1 |
| Santoni, G | 1 |
| Xie, S | 1 |
| Rosengren, A | 1 |
| Lagergren, J | 1 |
| Hou, X | 2 |
| Han, W | 2 |
| Gan, Q | 2 |
| Fang, W | 2 |
| Yuan, C | 1 |
| Zhong, L | 1 |
| Huang, RC | 1 |
| Fu, DL | 1 |
| Zhao, TT | 1 |
| Peng, WH | 1 |
| Yang, P | 1 |
| Liu, XF | 1 |
| Zhang, H | 3 |
| Li, XL | 1 |
| Wang, Y | 1 |
| Zheng, JG | 1 |
| Gao, YX | 1 |
| Lu, HK | 1 |
| Wang, Q | 1 |
| Harada, Y | 1 |
| Michel, J | 1 |
| Lohaus, R | 1 |
| Mayer, K | 2 |
| Emmer, R | 1 |
| Lahmann, AL | 1 |
| Colleran, R | 1 |
| Giacoppo, D | 1 |
| Wolk, A | 1 |
| Ten Berg, JM | 6 |
| Neumann, FJ | 14 |
| Han, Y | 1 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 3 |
| Maeng, M | 1 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Wöhrle, J | 1 |
| Kufner, S | 1 |
| Morath, T | 2 |
| Ibrahim, T | 1 |
| Bernlochner, I | 2 |
| Fischer, M | 1 |
| Schunkert, H | 1 |
| Laugwitz, KL | 1 |
| Mehilli, J | 7 |
| Byrne, RA | 3 |
| Kastrati, A | 16 |
| Schulz-Schüpke, S | 1 |
| Chen, S | 1 |
| Zhang, Y | 1 |
| Wang, L | 1 |
| Geng, Y | 1 |
| Gu, J | 1 |
| Hao, Q | 1 |
| Wang, H | 2 |
| Qi, P | 1 |
| Li, KC | 1 |
| Yu, SH | 1 |
| Zhuge, BZ | 1 |
| He, RX | 1 |
| Zhang, L | 2 |
| Zhou, TN | 1 |
| Yuan, WJ | 1 |
| Liu, YJ | 1 |
| Fu, WX | 1 |
| Jing, QM | 3 |
| Liu, HW | 1 |
| Wang, XZ | 2 |
| Hu, W | 1 |
| Tong, J | 1 |
| Kuang, X | 1 |
| Chen, W | 1 |
| Liu, Z | 1 |
| Shi, R | 1 |
| Ge, L | 1 |
| Zhou, X | 1 |
| Ji, WJ | 1 |
| Lu, RY | 1 |
| Zhang, YY | 1 |
| Zeng, S | 1 |
| Liu, X | 1 |
| Zhao, JH | 1 |
| Zhang, WC | 1 |
| Jiang, TM | 1 |
| Li, YM | 1 |
| Cattaneo, M | 3 |
| Fiorelli, EM | 1 |
| Bonzi, M | 1 |
| Lee, T | 1 |
| Lee, R | 1 |
| Stone, GW | 3 |
| Witzenbichler, B | 2 |
| Weisz, G | 2 |
| Rinaldi, MJ | 2 |
| Metzger, DC | 2 |
| Henry, TD | 2 |
| Cox, DA | 2 |
| Duffy, PL | 2 |
| Mazzaferri, E | 1 |
| Gurbel, PA | 10 |
| Xu, K | 2 |
| Parise, H | 1 |
| Kirtane, AJ | 2 |
| Brodie, BR | 2 |
| Mehran, R | 3 |
| Stuckey, TD | 2 |
| Curkovic, I | 1 |
| Egbring, M | 1 |
| Kullak-Ublick, GA | 1 |
| Gong, XX | 1 |
| Zhu, TT | 1 |
| Li, CJ | 1 |
| Yang, ZJ | 1 |
| Ebrahimi, R | 1 |
| Bakaeen, FG | 1 |
| Uberoi, A | 1 |
| Ardehali, A | 1 |
| Baltz, JH | 1 |
| Hattler, B | 1 |
| Almassi, GH | 1 |
| Wagner, TH | 1 |
| Collins, JF | 1 |
| Grover, FL | 1 |
| Shroyer, AL | 1 |
| Li, G | 1 |
| Li, ZQ | 1 |
| Yang, QY | 1 |
| Yang, JD | 1 |
| Wang, M | 2 |
| Moran, AE | 1 |
| Liu, J | 3 |
| Coxson, PG | 2 |
| Heidenreich, PA | 1 |
| Gu, D | 1 |
| He, J | 1 |
| Goldman, L | 2 |
| Zhao, D | 2 |
| Rebrova, TIu | 1 |
| Muslimova, EF | 1 |
| Afanas'ev, SA | 1 |
| Sergienko, TN | 1 |
| Repin, AN | 1 |
| Jiang, JJ | 2 |
| Tang, H | 1 |
| Xie, YM | 3 |
| Yang, H | 1 |
| Zhuang, Y | 3 |
| Chang, YP | 1 |
| Zeng, XB | 1 |
| Hu, J | 1 |
| Martínez-Quintana, E | 1 |
| Medina-Gil, JM | 1 |
| Rodríguez-González, F | 1 |
| Garay-Sánchez, P | 1 |
| Limiñana, JM | 1 |
| Saavedra, P | 1 |
| Tugores, A | 1 |
| Xie, C | 2 |
| Ding, X | 1 |
| Gao, J | 1 |
| Hang, Y | 1 |
| Zhang, J | 1 |
| Jiang, B | 1 |
| Miao, L | 1 |
| Liu, T | 2 |
| Yin, T | 1 |
| Li, Y | 4 |
| Song, LQ | 1 |
| Yu, J | 1 |
| Si, R | 1 |
| Zhang, YM | 1 |
| He, Y | 2 |
| Guo, WY | 1 |
| Wang, HC | 1 |
| Camargo, LM | 1 |
| França, CN | 2 |
| Izar, MC | 2 |
| Bianco, HT | 2 |
| Lins, LS | 1 |
| Barbosa, SP | 2 |
| Pinheiro, LF | 2 |
| Fonseca, FA | 2 |
| Gawron-Skarbek, A | 1 |
| Chrzczanowicz, J | 1 |
| Kostka, J | 1 |
| Nowak, D | 1 |
| Drygas, W | 1 |
| Jegier, A | 1 |
| Kostka, T | 1 |
| Hajj-Chahine, J | 1 |
| Sood, A | 1 |
| Trinh, QD | 1 |
| Schreiber, P | 1 |
| Fauchère, I | 1 |
| Wyss, C | 1 |
| Kounis, NG | 1 |
| Davlouros, P | 1 |
| Al Shamiri, MQ | 1 |
| Abdel Gader, AM | 1 |
| Bayoumy, NM | 1 |
| Isshiki, T | 1 |
| Kimura, T | 1 |
| Ogawa, H | 4 |
| Yokoi, H | 1 |
| Nanto, S | 1 |
| Takayama, M | 1 |
| Kitagawa, K | 1 |
| Nishikawa, M | 2 |
| Miyazaki, S | 1 |
| Ikeda, Y | 2 |
| Nakamura, M | 1 |
| Saito, S | 2 |
| Jaben, EA | 1 |
| Mulay, SB | 1 |
| Stubbs, JR | 1 |
| Li, GH | 1 |
| Jiang, HY | 1 |
| Yang, W | 1 |
| Zhao, W | 1 |
| Wang, YY | 1 |
| Bjerre, D | 1 |
| Ferrero, L | 1 |
| Madsen, M | 1 |
| Hansen, PR | 1 |
| Rasmussen, HB | 1 |
| Ding, XL | 1 |
| Chen, ZY | 1 |
| Miao, LY | 1 |
| Stiefelhagen, P | 3 |
| Jim, MH | 1 |
| Wong, KL | 1 |
| Yiu, KH | 1 |
| Hokimoto, S | 3 |
| Akasaka, T | 1 |
| Tabata, N | 1 |
| Arima, Y | 1 |
| Tsujita, K | 2 |
| Sakamoto, K | 1 |
| Kaikita, K | 3 |
| Morita, K | 2 |
| Kumagae, N | 1 |
| Yamamoto, E | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 2 |
| Adamo, M | 1 |
| Costa, F | 1 |
| Vranckx, P | 1 |
| Leonardi, S | 1 |
| Navarese, EP | 1 |
| Garcia-Garcia, HM | 1 |
| Valgimigli, M | 2 |
| Kopylov, FY | 1 |
| Mesitskaya, DF | 1 |
| Nikitina, YM | 1 |
| Aksenova, MG | 1 |
| Dobrovolsky, AV | 1 |
| Lomakin, OV | 1 |
| Chernyi, OV | 1 |
| Capranzano, P | 1 |
| Castiglioni, B | 1 |
| Siasos, G | 1 |
| Oikonomou, E | 1 |
| Zaromitidou, M | 1 |
| Kioufis, S | 1 |
| Kokkou, E | 1 |
| Mourouzis, K | 1 |
| Vlasis, K | 1 |
| Vavuranakis, M | 1 |
| Stone, PH | 1 |
| Papavassiliou, AG | 1 |
| Tousoulis, D | 2 |
| Zheng, XT | 1 |
| Chen, KY | 1 |
| Xu, LX | 1 |
| Che, JJ | 1 |
| Rha, SW | 3 |
| Li, GP | 1 |
| Parikh, PB | 1 |
| Mazzaferri, EL | 1 |
| Parvataneni, R | 1 |
| Maehara, A | 1 |
| Généreux, P | 1 |
| Yao, Y | 1 |
| Tang, XF | 2 |
| Zhang, JH | 1 |
| He, C | 2 |
| Ma, YL | 1 |
| Xu, JJ | 1 |
| Song, Y | 1 |
| Liu, R | 1 |
| Meng, XM | 2 |
| Song, L | 1 |
| Chen, J | 3 |
| Xu, B | 2 |
| Gao, RL | 3 |
| Yuan, JQ | 3 |
| Smilowitz, NR | 1 |
| Berger, JS | 1 |
| Ma, G | 1 |
| Du, M | 1 |
| Zhang, D | 2 |
| Shi, Y | 1 |
| Bockeria, OL | 1 |
| Kudzoeva, ZF | 1 |
| Shvarts, VA | 1 |
| Koasari, AK | 1 |
| Donakanyan, SA | 1 |
| Ou, W | 1 |
| Li, A | 1 |
| Liu, B | 1 |
| Jin, L | 1 |
| Kim, YG | 1 |
| Suh, JW | 3 |
| Kang, SH | 1 |
| Park, JJ | 1 |
| Yoon, CH | 1 |
| Cho, YS | 2 |
| Youn, TJ | 2 |
| Chae, IH | 3 |
| Choi, DJ | 2 |
| Kim, HS | 6 |
| Tang, QJ | 1 |
| Lin, HM | 2 |
| He, GD | 2 |
| Liu, JE | 1 |
| Wu, H | 2 |
| Li, XX | 2 |
| Zhong, WP | 2 |
| Tang, L | 2 |
| Meng, JX | 1 |
| Zhang, MZ | 1 |
| Li, HP | 2 |
| Chen, JY | 2 |
| Zhong, SL | 2 |
| Wang, LY | 1 |
| Yang, HH | 1 |
| Chen, Y | 1 |
| Gao, CY | 1 |
| Zhang, B | 1 |
| Zhang, ZW | 1 |
| Ma, DL | 1 |
| Sun, S | 1 |
| Mai, LP | 1 |
| Wang, XP | 1 |
| Lei, HP | 1 |
| Zhou, HK | 1 |
| Liu, SW | 1 |
| Pérez-Cuadrado-Robles, E | 1 |
| Quesada-Vázquez, N | 1 |
| Martínez-Andrés, B | 1 |
| Sánchez-Melgarejo, JF | 1 |
| Rubio-Mateos, JM | 1 |
| López-Higueras, A | 1 |
| Pérez-Cuadrado-Martínez, E | 1 |
| Hochholzer, W | 2 |
| Kleiner, P | 1 |
| Younas, I | 1 |
| Valina, CM | 2 |
| Löffelhardt, N | 1 |
| Amann, M | 1 |
| Bömicke, T | 1 |
| Ferenc, M | 1 |
| Hauschke, D | 1 |
| Trenk, D | 2 |
| Stratz, C | 2 |
| Lee, MS | 1 |
| Shlofmitz, E | 1 |
| Haag, E | 1 |
| Santiago, L | 1 |
| Pollack, S | 1 |
| Reichek, N | 1 |
| Shlofmitz, RA | 1 |
| Cubero, JL | 1 |
| Simó Sánchez, B | 1 |
| Millán, P | 1 |
| Colás, C | 1 |
| Janssen, PWA | 1 |
| Mol, EA | 1 |
| Geene, SMC | 1 |
| Barbato, E | 1 |
| Ng, FH | 2 |
| Lam, KF | 2 |
| Wong, SY | 2 |
| Chang, CM | 1 |
| Lau, YK | 2 |
| Yuen, WC | 1 |
| Chu, WM | 1 |
| Wong, BC | 2 |
| O'Kane, PD | 1 |
| Reebye, V | 1 |
| Ji, Y | 1 |
| Stratton, P | 1 |
| Jackson, G | 1 |
| Ferro, A | 1 |
| Angiolillo, DJ | 9 |
| Guzman, LA | 1 |
| Bass, TA | 4 |
| Weintraub, WS | 2 |
| Spertus, JA | 1 |
| Kolm, P | 1 |
| Maron, DJ | 1 |
| Zhang, Z | 1 |
| Jurkovitz, C | 1 |
| Zhang, W | 1 |
| Hartigan, PM | 1 |
| Lewis, C | 1 |
| Veledar, E | 1 |
| Bowen, J | 2 |
| Dunbar, SB | 1 |
| Deaton, C | 1 |
| Kaufman, S | 1 |
| O'Rourke, RA | 1 |
| Goeree, R | 1 |
| Barnett, PG | 1 |
| Teo, KK | 1 |
| Boden, WE | 2 |
| Mancini, GB | 1 |
| Alberts, MJ | 1 |
| Aĭnetdinova, DKh | 1 |
| Udovichenko, AE | 1 |
| Sulimov, VA | 1 |
| Asano, T | 1 |
| Kobayashi, Y | 1 |
| Fukushima, K | 1 |
| Iwata, Y | 1 |
| Kitahara, H | 1 |
| Ishio, N | 1 |
| Kuroda, N | 1 |
| Komuro, I | 1 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 1 |
| Iijima, R | 1 |
| Ndrepepa, G | 1 |
| Braun, S | 1 |
| Berger, PB | 15 |
| Schömig, A | 20 |
| Chan, P | 1 |
| Kwanching, CP | 1 |
| Loo, CK | 1 |
| Cheung, TK | 1 |
| Kng, C | 1 |
| Ng, KM | 1 |
| Lai, ST | 3 |
| Maegdefessel, L | 1 |
| Schlitt, A | 1 |
| Faerber, J | 1 |
| Bond, SP | 1 |
| Messow, CM | 1 |
| Buerke, M | 1 |
| Raaz, U | 1 |
| Werdan, K | 1 |
| Muenzel, T | 1 |
| Weiss, C | 1 |
| Serebruany, VL | 7 |
| Goto, S | 2 |
| Kuliczkowski, W | 1 |
| Witkowski, A | 2 |
| Polonski, L | 2 |
| Watala, C | 1 |
| Filipiak, K | 1 |
| Budaj, A | 4 |
| Golanski, J | 1 |
| Sitkiewicz, D | 1 |
| Pregowski, J | 1 |
| Gorski, J | 1 |
| Zembala, M | 1 |
| Opolski, G | 3 |
| Huber, K | 2 |
| Arnesen, H | 3 |
| Kristensen, SD | 2 |
| Sibbing, D | 2 |
| Stegherr, J | 1 |
| Latz, W | 1 |
| Koch, W | 3 |
| Dörrler, K | 1 |
| von Beckerath, N | 4 |
| Mak, KH | 3 |
| Bhatt, DL | 10 |
| Shao, M | 1 |
| Haffner, SM | 2 |
| Hamm, CW | 4 |
| Hankey, GJ | 3 |
| Johnston, SC | 2 |
| Steg, PG | 3 |
| Steinhubl, SR | 13 |
| Fox, KA | 7 |
| Topol, EJ | 14 |
| Jeong, YH | 1 |
| Lee, SW | 3 |
| Choi, BR | 1 |
| Kim, IS | 1 |
| Seo, MK | 1 |
| Kwak, CH | 1 |
| Hwang, JY | 1 |
| Park, SW | 7 |
| Niu, S | 1 |
| Zhu, J | 1 |
| Liu, Q | 1 |
| Wang, W | 1 |
| Smith, SC | 1 |
| Briasoulis, A | 1 |
| Dhamrait, SS | 1 |
| Antoniades, C | 1 |
| Stefanadis, C | 2 |
| Price, MJ | 2 |
| Nayak, KR | 1 |
| Barker, CM | 1 |
| Kandzari, DE | 2 |
| Teirstein, PS | 3 |
| Varenhorst, C | 1 |
| James, S | 1 |
| Erlinge, D | 1 |
| Brandt, JT | 1 |
| Braun, OO | 1 |
| Man, M | 1 |
| Siegbahn, A | 1 |
| Walker, J | 1 |
| Wallentin, L | 2 |
| Winters, KJ | 3 |
| Close, SL | 1 |
| Sambola, A | 1 |
| Ferreira-González, I | 2 |
| Angel, J | 1 |
| Alfonso, F | 4 |
| Maristany, J | 1 |
| Rodríguez, O | 2 |
| Bueno, H | 1 |
| López-Minguez, JR | 1 |
| Zueco, J | 1 |
| Fernández-Avilés, F | 1 |
| San Román, A | 1 |
| Prendergast, B | 1 |
| Mainar, V | 1 |
| García-Dorado, D | 1 |
| Tornos, P | 1 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Eriksson, AC | 1 |
| Jonasson, L | 1 |
| Lindahl, TL | 1 |
| Hedbäck, B | 1 |
| Whiss, PA | 1 |
| Harjai, KJ | 1 |
| Shenoy, C | 1 |
| Orshaw, P | 1 |
| Boura, J | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Wiederkehr, D | 2 |
| Berenson, K | 1 |
| Casciano, R | 2 |
| Stern, L | 1 |
| Makenbaeva, D | 2 |
| Mozaffari, E | 2 |
| Lamerato, L | 1 |
| Corbelli, J | 2 |
| Ogbonnaya, A | 1 |
| Guyer, KE | 1 |
| Perez, G | 1 |
| Rodriguez-Granillo, AM | 1 |
| Mieres, J | 1 |
| Llaurado, C | 1 |
| Rubilar, B | 1 |
| Risau, G | 1 |
| Fernandez-Pereira, C | 1 |
| Rodriguez, AE | 1 |
| Tetik, S | 1 |
| Ak, K | 1 |
| Isbir, S | 1 |
| Eksioglu-Demiralp, E | 1 |
| Arsan, S | 1 |
| Iqbal, O | 1 |
| Yardimci, T | 1 |
| Yasuda, H | 1 |
| Yamada, M | 1 |
| Sawada, S | 1 |
| Endo, Y | 1 |
| Inoue, K | 1 |
| Asano, F | 1 |
| Takeyama, Y | 1 |
| Yoshiba, M | 1 |
| Chatterjee, T | 1 |
| Akin, I | 1 |
| Rehders, TC | 1 |
| Chatterjee, A | 1 |
| Schüpfer, C | 1 |
| Nienaber, CA | 1 |
| Ince, H | 1 |
| Schuhmann, CG | 1 |
| Sohn, HY | 1 |
| Nagel, J | 1 |
| Spannagl, M | 1 |
| Klauss, V | 1 |
| Krötz, F | 1 |
| Toda, E | 1 |
| Geisler, T | 3 |
| Gawaz, M | 9 |
| Tantry, US | 4 |
| Bonello, L | 1 |
| Bonello-Palot, N | 1 |
| Armero, S | 1 |
| Bonello, C | 1 |
| Mokhtar, OA | 1 |
| Arques, S | 1 |
| Dignat-George, F | 1 |
| Camoin-Jau, L | 1 |
| Paganelli, F | 1 |
| Harmsze, A | 1 |
| van Werkum, JW | 2 |
| Bouman, HJ | 2 |
| Ruven, HJ | 1 |
| Breet, NJ | 1 |
| Hackeng, CM | 2 |
| Tjoeng, MM | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Deneer, VH | 1 |
| Danenberg, HD | 1 |
| Marincheva, G | 1 |
| Varshitzki, B | 1 |
| Nassar, H | 1 |
| Lotan, C | 4 |
| Momary, KM | 1 |
| Dorsch, MP | 2 |
| Park, SJ | 6 |
| Park, DW | 1 |
| Kim, YH | 2 |
| Kang, SJ | 1 |
| Lee, CW | 5 |
| Han, KH | 2 |
| Yun, SC | 1 |
| Lee, SG | 1 |
| Seong, IW | 1 |
| Jeong, MH | 2 |
| Hur, SH | 3 |
| Lee, NH | 3 |
| Yoon, J | 1 |
| Yang, JY | 1 |
| Lee, BK | 2 |
| Choi, YJ | 3 |
| Chung, WS | 1 |
| Lim, DS | 2 |
| Cheong, SS | 1 |
| Kim, KS | 3 |
| Chae, JK | 1 |
| Nah, DY | 2 |
| Jeon, DS | 1 |
| Seung, KB | 2 |
| Jang, JS | 2 |
| Park, HS | 1 |
| Lee, K | 1 |
| Tresukosol, D | 1 |
| Sudjaritruk, S | 1 |
| Pornratanarangsi, S | 1 |
| Chotinaiwattarakul, C | 2 |
| Phankingthongkum, R | 1 |
| Tungsubutra, W | 1 |
| Wongpraparat, N | 1 |
| Lerdwilai, T | 1 |
| Panchavinnin, P | 1 |
| Dixon, SR | 1 |
| Grines, CL | 2 |
| O'Neill, WW | 1 |
| Damani, SB | 1 |
| Shen, WF | 1 |
| Chen, JL | 2 |
| Gao, LJ | 1 |
| Yang, YJ | 2 |
| Li, JJ | 2 |
| Qiao, SB | 2 |
| Huang, JH | 1 |
| Yao, M | 2 |
| Qin, XW | 2 |
| Liu, HB | 2 |
| Wu, YJ | 2 |
| You, SJ | 2 |
| Dai, J | 2 |
| Storey, RF | 3 |
| Bliden, KP | 3 |
| Patil, SB | 1 |
| Karunakaran, A | 1 |
| Ecob, R | 1 |
| Butler, K | 1 |
| Teng, R | 1 |
| Wei, C | 1 |
| Okura, H | 1 |
| Eifert, S | 1 |
| Mair, H | 1 |
| Boulesteix, AL | 1 |
| Kilian, E | 1 |
| Adamczak, M | 1 |
| Reichart, B | 1 |
| Lamm, P | 1 |
| Memtsoudis, SG | 1 |
| Sharrock, NE | 1 |
| Rennings, AJ | 1 |
| Schouwenberg, BJ | 1 |
| van Onzenoort, HA | 1 |
| Knosalla, C | 1 |
| Dandel, M | 1 |
| Hetzer, R | 1 |
| Cai, J | 1 |
| Wu, Q | 1 |
| Fan, L | 1 |
| Liu, CF | 1 |
| Wang, ZG | 1 |
| Sun, J | 1 |
| Campo, G | 1 |
| Percoco, G | 1 |
| Monti, M | 1 |
| Ferrari, F | 1 |
| Tumscitz, C | 1 |
| Zuffi, A | 1 |
| Colombo, F | 1 |
| Kubbajeh, M | 1 |
| Cavazza, C | 1 |
| Cangiano, E | 1 |
| Tebaldi, M | 1 |
| Minarelli, M | 1 |
| Arcozzi, C | 1 |
| Scalone, A | 1 |
| Frangione, A | 1 |
| Borghesi, M | 1 |
| Marchesini, J | 1 |
| Parrinello, G | 1 |
| Ferrari, R | 1 |
| Menown, IB | 1 |
| Yamamoto, K | 2 |
| Chitose, T | 2 |
| Ono, T | 1 |
| Abe, T | 1 |
| Deguchi, M | 1 |
| Miyagawa, H | 1 |
| Saruwatari, J | 1 |
| Sumida, H | 1 |
| Sugiyama, S | 1 |
| Schömig, E | 2 |
| Velder, J | 1 |
| Hirschhäuser, C | 1 |
| Waldmann, C | 1 |
| Schmalz, HG | 1 |
| Taubert, D | 2 |
| Turner, D | 1 |
| Raftery, J | 1 |
| Cooper, K | 1 |
| Fairbank, E | 1 |
| Palmer, S | 2 |
| Ward, S | 1 |
| Ara, R | 1 |
| Lee, SP | 1 |
| Park, KW | 2 |
| Lee, HY | 1 |
| Kang, HJ | 2 |
| Koo, BK | 2 |
| Bae, JH | 1 |
| Kwon, TG | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Banerjee, S | 1 |
| Weideman, RA | 1 |
| Weideman, MW | 1 |
| Little, BB | 1 |
| Kelly, KC | 1 |
| Gunter, JT | 1 |
| Tortorice, KL | 1 |
| Shank, M | 1 |
| Cryer, B | 1 |
| Reilly, RF | 1 |
| Rao, SV | 1 |
| de Lemos, JA | 2 |
| Brilakis, ES | 1 |
| Martin-Yuste, V | 1 |
| Brugaletta, S | 1 |
| Cola, C | 1 |
| Alvarez-Contreras, L | 1 |
| de Antonio, M | 1 |
| Martí, V | 1 |
| García-Picart, J | 1 |
| Sabaté, M | 6 |
| Rassaf, T | 1 |
| Tsukahara, K | 1 |
| Kimura, K | 1 |
| Morita, S | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Hibi, K | 1 |
| Iwahashi, N | 1 |
| Endo, M | 1 |
| Maejima, N | 1 |
| Sugano, T | 1 |
| Umemura, S | 1 |
| Bates, ER | 1 |
| Lau, WC | 1 |
| Sharma, JC | 1 |
| Sharma, N | 1 |
| Massberg, S | 2 |
| Schulz, S | 1 |
| Tremmel, JA | 1 |
| Ng, MK | 1 |
| Ikeno, F | 1 |
| Hunt, SA | 1 |
| Lee, DP | 1 |
| Yeung, AC | 3 |
| Fearon, WF | 1 |
| Yang, TH | 1 |
| Kim, DI | 1 |
| Kim, DK | 2 |
| Kim, U | 1 |
| Seol, SH | 1 |
| Hong, GR | 1 |
| Park, JS | 1 |
| Shin, DG | 1 |
| Kim, YJ | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Kim, KB | 2 |
| Kim, DS | 1 |
| Muntner, P | 1 |
| Mann, DM | 1 |
| Woodward, M | 1 |
| Choi, JW | 1 |
| Stoler, RC | 1 |
| Shimbo, D | 1 |
| Farkouh, ME | 2 |
| Kim, MC | 1 |
| Gaglia, MA | 1 |
| Torguson, R | 1 |
| Pakala, R | 1 |
| Xue, Z | 1 |
| Sardi, G | 1 |
| Mahmoudi, M | 1 |
| Suddath, WO | 1 |
| Kent, KM | 2 |
| Satler, LF | 3 |
| Pichard, AD | 3 |
| Waksman, R | 3 |
| Gwak, CH | 1 |
| Hong, SJ | 1 |
| Park, TH | 1 |
| Kim, SH | 1 |
| Joo, SJ | 1 |
| Tahk, SJ | 1 |
| Cuisset, T | 3 |
| Morange, PE | 2 |
| Quilici, J | 3 |
| Bonnet, JL | 3 |
| Gachet, C | 1 |
| Alessi, MC | 2 |
| Dansette, PM | 1 |
| Rosi, J | 1 |
| Bertho, G | 1 |
| Mansuy, D | 1 |
| Camps, J | 1 |
| Joven, J | 1 |
| Mackness, B | 1 |
| Mackness, M | 1 |
| Tawfik, D | 1 |
| Draganov, D | 1 |
| Costa, LG | 1 |
| Paragh, G | 1 |
| Seres, I | 1 |
| Horke, S | 1 |
| James, R | 1 |
| Hernández, A | 1 |
| Reddy, S | 1 |
| Shih, D | 1 |
| Navab, M | 1 |
| Rochu, D | 1 |
| Aviram, M | 1 |
| Wu, Y | 1 |
| Chen, ZJ | 1 |
| Oshima, S | 1 |
| Nakao, K | 1 |
| Fujimoto, K | 1 |
| Miyao, Y | 1 |
| Shimomura, H | 1 |
| Tsunoda, R | 1 |
| Maruyama, H | 1 |
| Hirose, T | 1 |
| Mizobe, M | 1 |
| Nakamura, S | 4 |
| Pfisterer, M | 1 |
| Kaiser, C | 1 |
| Jeger, R | 1 |
| Gwon, HC | 1 |
| Hahn, JY | 1 |
| Song, YB | 1 |
| Han, KR | 1 |
| Choi, JH | 1 |
| Choi, SH | 1 |
| Ahn, T | 1 |
| Yoon, JH | 1 |
| Hong, TJ | 1 |
| Chung, WY | 1 |
| Kwon, HM | 1 |
| Jeon, DW | 1 |
| Kim, BO | 1 |
| Park, SH | 1 |
| Jeon, HK | 1 |
| Jang, Y | 4 |
| Jia, XQ | 1 |
| Dong, CM | 1 |
| Qin, J | 1 |
| Kasmas, SH | 1 |
| Mendes, GD | 1 |
| Povoa, RM | 1 |
| Azcona, L | 1 |
| López Farré, AJ | 1 |
| Jiménez Mateos-Cáceres, P | 1 |
| Segura, A | 1 |
| Rodríguez, P | 1 |
| Modrego, J | 1 |
| Zamorano-León, JJ | 1 |
| Macaya, C | 6 |
| Walder, JS | 1 |
| Baker, BA | 1 |
| Heiselman, DE | 1 |
| Jakubowski, JA | 1 |
| Logan, DK | 1 |
| Li, W | 1 |
| Pakhomov, IaM | 1 |
| Ganesan, S | 1 |
| Williams, C | 1 |
| Maslen, CL | 1 |
| Cherala, G | 1 |
| Elhadad, S | 1 |
| Henry, P | 2 |
| Motreff, P | 1 |
| Carrié, D | 1 |
| Belle, L | 1 |
| Van Belle, E | 3 |
| Rousseau, H | 1 |
| Aubry, P | 2 |
| Monségu, J | 1 |
| Sabouret, P | 1 |
| O'Connor, SA | 1 |
| Abtan, J | 1 |
| Kerneis, M | 1 |
| Barthélémy, O | 1 |
| Bobbert, P | 1 |
| Stellbaum, C | 1 |
| Steffens, D | 1 |
| Schütte, C | 1 |
| Bobbert, T | 1 |
| Schultheiss, HP | 1 |
| Rauch, U | 1 |
| Schneider, AR | 1 |
| Armbruster, S | 1 |
| Mann, J | 1 |
| von Römer, W | 1 |
| Schuster, T | 1 |
| Schepp, W | 1 |
| Hlatky, MA | 1 |
| Solomon, MD | 1 |
| Shilane, D | 1 |
| Leong, TK | 1 |
| Brindis, R | 1 |
| Go, AS | 1 |
| Kamishirado, H | 1 |
| Inoue, T | 1 |
| Mizoguchi, K | 1 |
| Uchida, T | 1 |
| Nakata, T | 1 |
| Sakuma, M | 1 |
| Takayanagi, K | 1 |
| Morooka, S | 1 |
| Bonz, AW | 1 |
| Lengenfelder, B | 1 |
| Strotmann, J | 1 |
| Held, S | 1 |
| Turschner, O | 1 |
| Harre, K | 1 |
| Wacker, C | 1 |
| Waller, C | 1 |
| Kochsiek, N | 1 |
| Meesmann, M | 1 |
| Neyses, L | 1 |
| Schanzenbächer, P | 2 |
| Ertl, G | 1 |
| Voelker, W | 1 |
| Turpie, AG | 1 |
| Cannon, CP | 1 |
| Yusuf, S | 7 |
| Mehta, SR | 4 |
| Tognoni, G | 1 |
| Zhao, F | 4 |
| Chrolavicius, S | 2 |
| Hunt, D | 1 |
| Keltai, M | 3 |
| Franzosi, MG | 1 |
| SoRelle, R | 1 |
| Bartorelli, AL | 3 |
| Trabattoni, D | 3 |
| McRedmond, J | 1 |
| Fitzgerald, D | 1 |
| Eikelboom, JW | 2 |
| Weitz, JI | 1 |
| Copland, I | 2 |
| Maciejewski, P | 1 |
| Johnston, M | 1 |
| Fitchett, D | 1 |
| Goodman, SG | 1 |
| Gupta, M | 1 |
| Langer, A | 1 |
| Otterstad, JE | 1 |
| Ziegler, S | 1 |
| Maca, T | 1 |
| Alt, E | 3 |
| Speiser, W | 1 |
| Schneider, B | 1 |
| Minar, E | 1 |
| Jagroop, IA | 1 |
| Mikhailidis, DP | 1 |
| Fischer, TC | 1 |
| Worm, M | 1 |
| Groneberg, DA | 1 |
| Pollack, CV | 2 |
| Atmaca, Y | 2 |
| Dandachi, R | 1 |
| Gülec, S | 2 |
| Dincer, I | 1 |
| Oral, D | 2 |
| Ertas, F | 1 |
| Pamir, G | 1 |
| Akinlade, BK | 1 |
| McGuire, DK | 1 |
| Armstrong, EC | 1 |
| Ramsey, SD | 1 |
| Yaes, RJ | 1 |
| Hézard, N | 1 |
| Metz, D | 1 |
| Nazeyrollas, P | 1 |
| Droullé, C | 1 |
| Potron, G | 1 |
| Nguyen, P | 1 |
| Cummings, CC | 2 |
| Bell, CR | 1 |
| Alford, AB | 1 |
| Meister, AF | 1 |
| Bauriedel, G | 1 |
| Skowasch, D | 1 |
| Schneider, M | 1 |
| Andrié, R | 1 |
| Jabs, A | 1 |
| Lüderitz, B | 1 |
| Toutouzas, K | 1 |
| Di Mario, C | 6 |
| Falotico, R | 1 |
| Takagi, T | 1 |
| Stankovic, G | 1 |
| Albiero, R | 2 |
| Corvaja, N | 1 |
| Colombo, A | 12 |
| Mann, T | 1 |
| Cubeddu, RJ | 1 |
| Raynor, L | 1 |
| Schneider, JE | 1 |
| Rose, G | 1 |
| Cubeddu, G | 1 |
| Raza, JA | 1 |
| Jobe, RL | 1 |
| Newman, W | 1 |
| Zellinger, M | 1 |
| Dardas, PS | 1 |
| Tsikaderis, DD | 1 |
| Mezilis, NE | 1 |
| Styliadis, G | 1 |
| Gerschutz, GP | 1 |
| Lecompte, T | 1 |
| Shim, WH | 3 |
| Ho, DS | 1 |
| Raizner, AE | 2 |
| Hong, MK | 5 |
| Choi, D | 2 |
| Lam, R | 1 |
| Weissman, NJ | 1 |
| Mintz, GS | 2 |
| Bartolozzi, JJ | 1 |
| Price, WF | 1 |
| Sauls, FC | 1 |
| Jneid, H | 1 |
| Corti, R | 1 |
| Badimon, JJ | 2 |
| Fuster, V | 2 |
| Francis, GS | 2 |
| Steinhubl, S | 2 |
| Berger, P | 1 |
| Saw, J | 3 |
| Moliterno, DJ | 4 |
| Genoni, M | 1 |
| Tavakoli, R | 1 |
| Hofer, C | 1 |
| Bertel, O | 1 |
| Turina, M | 3 |
| Wienbergen, H | 2 |
| Gitt, AK | 2 |
| Schiele, R | 2 |
| Juenger, C | 2 |
| Heer, T | 2 |
| Meisenzahl, C | 1 |
| Limbourg, P | 1 |
| Bossaller, C | 1 |
| Senges, J | 2 |
| Slavina, NN | 1 |
| Averkov, OV | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Gratsianskiĭ, NA | 3 |
| Gulba, DC | 1 |
| Lankes, W | 1 |
| Prasad, A | 1 |
| Mathew, V | 1 |
| Holmes, DR | 6 |
| Gersh, BJ | 1 |
| Sánchez-Delgado, E | 1 |
| Pekdemir, H | 1 |
| Cin, VG | 1 |
| Camsari, A | 1 |
| Cicek, D | 1 |
| Akkus, MN | 1 |
| Doven, O | 1 |
| Parmaksiz, T | 1 |
| Fernandez, JS | 1 |
| Sadaniantz, BT | 1 |
| Sadaniantz, A | 1 |
| Knight, CJ | 1 |
| Wodlinger, AM | 1 |
| Pieper, JA | 1 |
| Jessup, DB | 1 |
| Coletti, AT | 1 |
| Muhlestein, JB | 1 |
| Barry, WH | 1 |
| Shean, FC | 1 |
| Whisenant, BK | 1 |
| Neubauer, H | 1 |
| Günesdogan, B | 1 |
| Hanefeld, C | 1 |
| Spiecker, M | 1 |
| Mügge, A | 1 |
| Hansen, O | 1 |
| Mueller, I | 1 |
| Besta, F | 1 |
| Thomas, P | 1 |
| Tan, KT | 1 |
| Lip, GY | 1 |
| Werner, GS | 1 |
| Emig, U | 1 |
| Mutschke, O | 1 |
| Schwarz, G | 1 |
| Bahrmann, P | 1 |
| Figulla, HR | 1 |
| Phillips, EJ | 1 |
| Knowles, SR | 1 |
| Shear, NH | 1 |
| Casella, G | 1 |
| Ottani, F | 1 |
| Pavesi, PC | 1 |
| Sangiorgio, P | 2 |
| Rubboli, A | 1 |
| Galvani, M | 2 |
| Fontanelli, A | 1 |
| Bracchetti, D | 1 |
| Bélanger, P | 1 |
| Palisaitis, DA | 1 |
| Diodati, JG | 1 |
| Pharand, C | 1 |
| Schühlen, H | 7 |
| Dirschinger, J | 7 |
| Dotzer, F | 3 |
| Bollwein, H | 2 |
| Volmer, C | 1 |
| Lange, RA | 1 |
| Hillis, LD | 1 |
| Choussat, R | 1 |
| Borentain, M | 1 |
| Spencer, FA | 1 |
| Becker, RC | 2 |
| Orford, JL | 1 |
| Fasseas, P | 1 |
| Melby, S | 3 |
| Burger, K | 1 |
| Ho, WK | 1 |
| Karabulut, H | 1 |
| Toraman, F | 1 |
| Evrenkaya, S | 1 |
| Goksel, O | 1 |
| Tarcan, S | 1 |
| Alhan, C | 1 |
| Mitsios, JV | 2 |
| Papathanasiou, AI | 2 |
| Rodis, FI | 1 |
| Elisaf, M | 2 |
| Goudevenos, JA | 2 |
| Tselepis, AD | 2 |
| Lepäntalo, A | 1 |
| Virtanen, KS | 1 |
| Heikkilä, J | 1 |
| Wartiovaara, U | 1 |
| Lassila, R | 1 |
| Lindgren, P | 2 |
| Jönsson, B | 2 |
| Manor, SM | 1 |
| Guillory, GS | 1 |
| Jain, SP | 2 |
| Helø, OH | 1 |
| Madsen, JK | 1 |
| Kastrup, J | 1 |
| Vogel, C | 1 |
| Gottwik, M | 1 |
| Biondi-Zoccai, GG | 2 |
| Agostoni, P | 3 |
| Testa, L | 2 |
| Abbate, A | 1 |
| Parisi, Q | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| Mongiardo, R | 1 |
| Vassanelli, C | 1 |
| Biasucci, LM | 1 |
| Fernandez-Ortiz, A | 4 |
| Bernardo, E | 4 |
| Ramírez, C | 4 |
| Escaned, J | 4 |
| Moreno, R | 4 |
| Hernández-Antolin, R | 1 |
| Trabetti, E | 2 |
| Pignatti, PF | 2 |
| Wiviott, SD | 3 |
| Antman, EM | 2 |
| Genest, M | 1 |
| Pochmalicki, G | 1 |
| van der Heijden, DJ | 1 |
| Westendorp, IC | 1 |
| Riezebos, RK | 1 |
| Kiemeneij, F | 1 |
| Slagboom, T | 1 |
| van der Wieken, LR | 1 |
| Laarman, GJ | 1 |
| Stadius, ML | 1 |
| Joost, A | 1 |
| Pogatsa-Murray, G | 5 |
| Gorchakova, O | 1 |
| Vivekananthan, DP | 1 |
| Chew, DP | 1 |
| Zidar, FJ | 1 |
| Chan, AW | 1 |
| Ellis, SG | 4 |
| Locker, C | 1 |
| Mohr, R | 1 |
| Lev-Ran, O | 1 |
| Uretzky, G | 1 |
| Frimerman, A | 1 |
| Shaham, Y | 1 |
| Shapira, I | 1 |
| Koh, TW | 1 |
| Okazaki, S | 1 |
| Yokoyama, T | 1 |
| Miyauchi, K | 1 |
| Shimada, K | 1 |
| Kurata, T | 1 |
| Sato, H | 1 |
| Daida, H | 1 |
| Kerr, JL | 1 |
| Oppelt, TF | 1 |
| Rowen, RC | 1 |
| Lincoff, AM | 7 |
| DeSmet, W | 1 |
| Betriu, A | 1 |
| Rutsch, W | 2 |
| Wilcox, RG | 1 |
| Kleiman, NS | 5 |
| Wolski, K | 2 |
| Stein, PD | 1 |
| Schünemann, HJ | 1 |
| Dalen, JE | 1 |
| Gutterman, D | 1 |
| Main, C | 1 |
| Griffin, S | 1 |
| Jones, L | 1 |
| Orton, V | 1 |
| Sculpher, M | 1 |
| Henderson, R | 1 |
| Sudlow, C | 1 |
| Hawkins, N | 1 |
| Riemsma, R | 1 |
| Poponina, TM | 1 |
| Kapilevich, NA | 1 |
| Kisteneva, IV | 1 |
| Markov, VA | 1 |
| Novitskiĭ, VV | 1 |
| Boonstra, PW | 1 |
| van Oeveren, W | 1 |
| Claeys, MJ | 1 |
| Van der Planken, MG | 1 |
| Bosmans, JM | 1 |
| Michiels, JJ | 1 |
| Vertessen, F | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Vrints, CJ | 1 |
| Rajagopal, V | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| Tcheng, JE | 2 |
| Furman, MI | 2 |
| Krueger, LA | 1 |
| Linden, MD | 1 |
| Fox, ML | 1 |
| Ball, SP | 1 |
| Barnard, MR | 1 |
| Frelinger, AL | 1 |
| Michelson, AD | 3 |
| Hölschermann, H | 1 |
| Kapetanakis, EI | 1 |
| Medlam, DA | 1 |
| Boyce, SW | 1 |
| Haile, E | 1 |
| Hill, PC | 1 |
| Dullum, MK | 1 |
| Bafi, AS | 1 |
| Petro, KR | 1 |
| Corso, PJ | 1 |
| Stenestrand, U | 1 |
| Malmberg, K | 2 |
| Mahoney, EM | 1 |
| Lamy, A | 1 |
| Culler, S | 1 |
| Yuan, Y | 1 |
| Caro, J | 1 |
| Gabriel, S | 1 |
| Cuthill, JA | 1 |
| Young, S | 1 |
| Greer, IA | 1 |
| Oldroyd, K | 1 |
| von Beckerath, O | 1 |
| Eichinger, M | 1 |
| Ozkan, M | 1 |
| Sag, C | 1 |
| Yokusoglu, M | 1 |
| Uzun, M | 1 |
| Baysan, O | 1 |
| Erinc, K | 1 |
| Isik, E | 2 |
| Pettersen, AA | 2 |
| Seljeflot, I | 2 |
| Abdelnoor, M | 1 |
| Zimarino, M | 2 |
| Renda, G | 1 |
| Behan, MW | 1 |
| Fox, SC | 1 |
| Heptinstall, S | 2 |
| Kunz, I | 1 |
| Spada, S | 1 |
| Sütsch, G | 1 |
| Ruggieri, F | 1 |
| Wenaweser, P | 1 |
| Dörffler-Melly, J | 1 |
| Imboden, K | 1 |
| Windecker, S | 1 |
| Togni, M | 1 |
| Meier, B | 1 |
| Haeberli, A | 1 |
| Hess, OM | 1 |
| Ajzenberg, N | 1 |
| Huisse, MG | 1 |
| Cachier, A | 1 |
| El Amara, W | 1 |
| Feldman, LJ | 1 |
| Himbert, D | 1 |
| Baruch, D | 1 |
| Guillin, MC | 1 |
| Elsässer, A | 1 |
| Nef, H | 1 |
| Möllmann, H | 1 |
| Gluckman, TJ | 1 |
| Rade, JJ | 1 |
| Schulman, SP | 1 |
| Guthikonda, S | 1 |
| Lev, EI | 2 |
| Takeyasu, N | 1 |
| Watanabe, S | 1 |
| Noguchi, Y | 1 |
| Ishikawa, K | 1 |
| Fumikura, Y | 1 |
| Yamaguchi, I | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Thiele, H | 1 |
| Niebauer, J | 1 |
| Busch, I | 1 |
| Schuler, G | 1 |
| Karnon, J | 1 |
| Bakhai, A | 1 |
| Brennan, A | 1 |
| Pandor, A | 1 |
| Flather, M | 1 |
| Warren, E | 1 |
| Gray, D | 1 |
| Akehurst, R | 1 |
| Almsherqi, Z | 1 |
| McLachlan, C | 1 |
| Mossop, PJ | 1 |
| Deng, Y | 1 |
| Jimenez-Quevedo, P | 3 |
| Hernández, R | 3 |
| Bañuelos, C | 3 |
| Costa, MA | 3 |
| Doggrell, SA | 2 |
| Wolak, A | 1 |
| Amit, G | 1 |
| Cafri, C | 1 |
| Gilutz, H | 1 |
| Ilia, R | 1 |
| Zahger, D | 2 |
| Walsh, SJ | 1 |
| Spence, MS | 1 |
| Crossman, D | 1 |
| Adgey, AA | 1 |
| Hacke, W | 2 |
| Black, HR | 1 |
| Cacoub, P | 1 |
| Cohen, EA | 2 |
| Creager, MA | 1 |
| Easton, JD | 1 |
| Flather, MD | 1 |
| Mas, JL | 1 |
| Pearson, TA | 1 |
| Weber, MA | 1 |
| Booth, J | 1 |
| Smith, SM | 1 |
| Judge, HM | 1 |
| Peters, G | 1 |
| Armstrong, M | 1 |
| Dupont, A | 1 |
| Gaussem, P | 1 |
| Chen, WH | 1 |
| Kaul, U | 1 |
| Leung, SK | 1 |
| Tan, HC | 1 |
| Leung, AW | 1 |
| Lee, MK | 1 |
| Li, SK | 1 |
| Ng, W | 1 |
| Lee, PY | 1 |
| Tse, HF | 1 |
| Lau, CP | 1 |
| Doogue, MP | 1 |
| Begg, EJ | 1 |
| Bridgman, P | 1 |
| Cavallari, U | 1 |
| Chau, TN | 1 |
| Yim, KF | 1 |
| Mok, NS | 2 |
| Chan, WK | 2 |
| Leung, VK | 1 |
| Leung, MF | 1 |
| Tang, E | 1 |
| Wong, CK | 2 |
| Wilkins, G | 2 |
| Herbison, P | 1 |
| Williams, M | 2 |
| Kay, P | 2 |
| Restieaux, N | 1 |
| Boulman, N | 1 |
| Rozenbaum, M | 1 |
| Slobodin, G | 1 |
| Rosner, I | 1 |
| Soiza, RL | 1 |
| Leslie, SJ | 1 |
| Bull, S | 1 |
| Chahal, N | 1 |
| McKenna, CJ | 1 |
| Song, JM | 1 |
| Kang, DH | 1 |
| Song, JK | 1 |
| Kim, JJ | 4 |
| Konstantino, Y | 1 |
| Iakobishvili, Z | 1 |
| Porter, A | 1 |
| Sandach, A | 1 |
| Hod, H | 2 |
| Hammerman, H | 1 |
| Gottlieb, S | 1 |
| Behar, S | 1 |
| Hasdai, D | 2 |
| Salam, AM | 1 |
| Al Suwaidi, J | 1 |
| Han, YL | 3 |
| Wang, SL | 3 |
| Ma, YY | 2 |
| Deng, J | 1 |
| Yang, GT | 1 |
| Yu, HB | 1 |
| Ge, JB | 1 |
| Maslow, A | 1 |
| Bert, A | 1 |
| Ng, T | 1 |
| Din, JN | 1 |
| Lewis, BS | 3 |
| Halon, DA | 1 |
| Peters, RJ | 2 |
| Frere, C | 1 |
| Barbou, F | 1 |
| Hovasse, T | 1 |
| Brogan, GX | 1 |
| Peterson, ED | 1 |
| Mulgund, J | 1 |
| Ohman, EM | 1 |
| Gibler, WB | 1 |
| Roe, MT | 2 |
| Glowczynska, R | 1 |
| Malek, LA | 1 |
| Spiewak, M | 2 |
| Filipiak, KJ | 2 |
| Grabowski, M | 2 |
| Kisiel, B | 1 |
| Kochman, J | 1 |
| Kostrzewa, G | 1 |
| Ploski, R | 1 |
| Gurbuz, AT | 1 |
| Zia, AA | 1 |
| Vuran, AC | 1 |
| Cui, H | 1 |
| Aytac, A | 1 |
| Patel, P | 2 |
| Gonzalez, R | 1 |
| Gonzales, R | 1 |
| Dokainish, H | 1 |
| Lakkis, N | 1 |
| Ivandic, BT | 1 |
| Schlick, P | 1 |
| Staritz, P | 1 |
| Kurz, K | 1 |
| Katus, HA | 1 |
| Giannitsis, E | 1 |
| Klaus, T | 1 |
| Ahrens, I | 1 |
| Bode, C | 2 |
| Mitsudo, K | 1 |
| Sangiorgi, GM | 1 |
| Iakovou, I | 1 |
| Antoniucci, D | 1 |
| Grube, E | 1 |
| Tamburino, C | 2 |
| Michev, I | 1 |
| Goktekin, O | 1 |
| Airoldi, F | 1 |
| Chieffo, A | 1 |
| Cosgrave, J | 1 |
| Tassanawiwat, W | 1 |
| Kurşaklioğlu, H | 1 |
| Köz, C | 1 |
| Iyisoy, A | 1 |
| Ide, T | 1 |
| Yildirim, V | 1 |
| Töre, HF | 1 |
| Demirtaş, E | 1 |
| Urban, P | 1 |
| Gershlick, AH | 2 |
| Guagliumi, G | 1 |
| Guyon, P | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Wijns, W | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Chen, YD | 1 |
| Lu, YL | 1 |
| Jin, ZN | 1 |
| Yuan, F | 1 |
| Lü, SZ | 1 |
| Malinin, A | 1 |
| Pokov, A | 1 |
| Spergling, M | 1 |
| Defranco, A | 1 |
| Schwartz, K | 1 |
| Schwartz, D | 1 |
| Mahmud, E | 1 |
| Atar, D | 2 |
| Serebruany, V | 1 |
| Bavry, AA | 1 |
| Chetty, N | 1 |
| Naran, NH | 1 |
| Munster, M | 1 |
| Macdonald, J | 1 |
| Srinivasan, M | 1 |
| More, R | 1 |
| Midei, MG | 1 |
| Meilman, H | 1 |
| Malinin, AI | 4 |
| Lowry, DR | 2 |
| Su, QF | 2 |
| Wang, ZL | 1 |
| Wang, DM | 1 |
| Luan, B | 1 |
| Lyseng-Williamson, KA | 1 |
| Plosker, GL | 1 |
| Elikowski, W | 1 |
| Cofta, S | 1 |
| Nowicki, A | 1 |
| Mańczak, J | 1 |
| Psuja, P | 1 |
| Walker, NE | 1 |
| Fasano, MB | 1 |
| Horwitz, PA | 1 |
| Patel, TN | 1 |
| Kreindel, M | 1 |
| Coolong, A | 1 |
| Mauri, L | 1 |
| Davì, G | 1 |
| Santilli, F | 1 |
| Moore, RK | 1 |
| Lowe, R | 1 |
| Grayson, AD | 1 |
| Morris, JL | 1 |
| Perry, RA | 1 |
| Stables, RH | 2 |
| Gilard, M | 1 |
| Arnaud, B | 1 |
| Le Gal, G | 1 |
| Abgrall, JF | 1 |
| Boschat, J | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Gibson, CM | 1 |
| Riesmeyer, J | 1 |
| Weerakkody, G | 1 |
| Warmke, JW | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Yehudai, L | 1 |
| Feit, F | 1 |
| Cooke, GE | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Bromberg-Marin, G | 1 |
| Marin-Neto, JA | 1 |
| Parsons, LS | 1 |
| Canto, JG | 1 |
| Rogers, WJ | 1 |
| Gaku, N | 1 |
| Kengo, T | 1 |
| Aoki, J | 1 |
| Onuma, Y | 1 |
| Yamamoto, H | 1 |
| Higashikuni, Y | 1 |
| Nakajima, H | 2 |
| Hara, K | 3 |
| Kang, J | 1 |
| Yan, CH | 1 |
| Solheim, S | 1 |
| Lee, VW | 1 |
| Lee, KK | 1 |
| Münzel, TF | 1 |
| Post, F | 1 |
| Brinster, DR | 1 |
| Byrne, M | 1 |
| Rogers, CD | 1 |
| Baim, DS | 6 |
| Simon, DI | 1 |
| Couper, GS | 1 |
| Cohn, LH | 1 |
| Tang, WH | 1 |
| Van Lente, F | 1 |
| Brennan, D | 1 |
| McErlean, E | 1 |
| Maroo, A | 1 |
| Alviar, CL | 1 |
| Arikan, ME | 1 |
| Dave, BP | 1 |
| Granada, JF | 1 |
| DeLao, T | 1 |
| Tellez, A | 1 |
| Maresh, K | 1 |
| Vilahur, G | 1 |
| Choi, BG | 1 |
| Zafar, MU | 1 |
| Viles-Gonzalez, JF | 1 |
| Vorchheimer, DA | 1 |
| Chin, SP | 1 |
| Liew, CK | 1 |
| Tay, SP | 1 |
| Rapaee, A | 1 |
| Liew, HB | 1 |
| Ang, CK | 1 |
| Fong, YY | 1 |
| Ong, TK | 1 |
| Gudum, HR | 1 |
| Sim, KH | 1 |
| Anders, N | 1 |
| Paterok, M | 2 |
| Langer, H | 1 |
| Stellos, K | 1 |
| Lindemann, S | 1 |
| Herdeg, C | 1 |
| May, AE | 1 |
| Dániel, A | 1 |
| Pintér, T | 1 |
| Horváth, IG | 1 |
| Komócsi, A | 1 |
| Małek, ŁA | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Silva, MA | 1 |
| Donovan, JL | 1 |
| Gandhi, PJ | 1 |
| Volturo, GA | 1 |
| Vavouranakis, I | 1 |
| Hamilos, MI | 1 |
| Kochiadakis, GE | 1 |
| Vardas, PE | 1 |
| Hamdalla, H | 1 |
| Liao, JK | 1 |
| Sureddi, RK | 1 |
| Galassi, A | 1 |
| Serdoz, R | 1 |
| Sheiban, I | 3 |
| Piovaccari, G | 1 |
| Benassi, A | 1 |
| Chierchia, S | 2 |
| Tonelli, M | 1 |
| Mann, JF | 1 |
| Sitkei, E | 1 |
| Hawken, S | 1 |
| Lapostolle, F | 1 |
| Catineau, J | 1 |
| Lapandry, C | 1 |
| Adnet, F | 1 |
| Fefer, P | 1 |
| Matetzky, S | 1 |
| Spinler, SA | 1 |
| Tie, S | 1 |
| Yap, J | 1 |
| Gladding, P | 2 |
| Webster, M | 2 |
| Alison, P | 1 |
| Sidebotham, D | 1 |
| Zoccai, GB | 1 |
| Porto, I | 1 |
| Trotta, G | 1 |
| Andreotti, F | 1 |
| Crea, F | 1 |
| Hoppe, UC | 1 |
| Erdmann, E | 1 |
| Chow, G | 1 |
| Ziegelstein, RC | 1 |
| Collins, JS | 1 |
| Gurm, HS | 1 |
| Rupprecht, HJ | 2 |
| Min, PK | 1 |
| Jung, JH | 1 |
| Ko, YG | 1 |
| Mann, KG | 1 |
| van Zyl, LT | 1 |
| Lespérance, F | 1 |
| Frasure-Smith, N | 1 |
| Laliberté, MA | 1 |
| Frundi, D | 1 |
| Bestehorn, HP | 1 |
| Büttner, HJ | 1 |
| Fares, RR | 1 |
| Lansing, LS | 1 |
| Gallati, CA | 1 |
| Mousa, SA | 1 |
| Henriksen, PA | 1 |
| Palmer, K | 1 |
| Boon, NA | 1 |
| Serebrianyĭ, VL | 1 |
| Makarov, LM | 1 |
| Foley, P | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Ormiston, J | 1 |
| Olsen, S | 1 |
| White, H | 1 |
| Best, PJ | 1 |
| Dasgupta, A | 1 |
| Brennan, DM | 1 |
| Szczech, LA | 1 |
| Califf, RM | 2 |
| Atiemo, AD | 1 |
| Williams, MS | 1 |
| Zürn, CS | 1 |
| Ajani, AE | 2 |
| Lefkovits, J | 1 |
| Casterella, PJ | 1 |
| Pannu, R | 1 |
| Andraws, R | 1 |
| Alvarez, W | 1 |
| Fox, KM | 1 |
| Jonathan, A | 1 |
| Selwyn, AP | 1 |
| Numano, F | 1 |
| Kawai, C | 1 |
| Goebel, N | 2 |
| Pfluger, N | 2 |
| Speiser, K | 2 |
| Rothlin, M | 1 |
| Chevigné, M | 1 |
| David, JL | 1 |
| Rigo, P | 1 |
| Limet, R | 1 |
| Verstraete, M | 2 |
| Morice, MC | 4 |
| Zemour, G | 2 |
| Benveniste, E | 2 |
| Biron, Y | 2 |
| Bourdonnec, C | 1 |
| Faivre, R | 1 |
| Fajadet, J | 3 |
| Gaspard, P | 1 |
| Glatt, B | 2 |
| Joly, P | 1 |
| Mudra, H | 1 |
| Chaix, AF | 1 |
| Barragan, P | 4 |
| Silvestri, M | 4 |
| Comet, B | 3 |
| Bouvier, JL | 3 |
| Chaix, L | 1 |
| Latour, F | 1 |
| Camilleri, JF | 1 |
| Garcia, P | 1 |
| McFadden, EP | 2 |
| Lablanche, JM | 1 |
| Bauters, C | 1 |
| Hamon, M | 1 |
| Bertrand, ME | 4 |
| Suzuka, H | 1 |
| Fujiwara, H | 1 |
| Tanaka, M | 1 |
| Yoshifusa, H | 1 |
| Nakamura, Y | 1 |
| Shibata, Y | 1 |
| Sainsous, J | 2 |
| Siméoni, JB | 2 |
| Villain, P | 2 |
| Pietri, P | 2 |
| Quatre, JM | 1 |
| Bayet, G | 2 |
| Rozenman, Y | 2 |
| Mosseri, M | 2 |
| Gotsman, MS | 2 |
| Weber, E | 1 |
| Donckier, J | 1 |
| Hall, P | 3 |
| Almagor, Y | 1 |
| Maiello, L | 2 |
| Martini, G | 4 |
| Gaglione, A | 2 |
| Goldberg, SL | 1 |
| Tobis, JM | 1 |
| Kitazume, H | 1 |
| Ageishi, Y | 1 |
| Iwama, T | 1 |
| Kubo, I | 1 |
| Suzuki, A | 1 |
| Verheugt, FW | 1 |
| Serruys, PW | 3 |
| Emanuelsson, H | 1 |
| van der Giessen, W | 1 |
| Lunn, AC | 1 |
| Kiemeney, F | 1 |
| Heyndrickx, G | 1 |
| Suryapranata, H | 1 |
| Legrand, V | 4 |
| Goy, JJ | 1 |
| Materne, P | 1 |
| Bonnier, H | 3 |
| Belardi, J | 1 |
| Garcia, E | 1 |
| Ruygrok, P | 1 |
| de Jaegere, P | 1 |
| Morel, MA | 1 |
| Blasini, R | 4 |
| Hadamitzky, M | 4 |
| Walter, H | 5 |
| Zitzmann-Roth, EM | 2 |
| Richardt, G | 2 |
| Schmitt, C | 3 |
| Ulm, K | 3 |
| Handin, RI | 1 |
| Eeckhout, E | 1 |
| Kappenberger, L | 1 |
| Goy, JL | 1 |
| Porter, T | 1 |
| Leibovittz, E | 1 |
| Berliner, S | 1 |
| Elsman, P | 1 |
| Zijlstra, F | 1 |
| Myreng, Y | 1 |
| Mølstad, P | 1 |
| Golf, S | 1 |
| Lienhart, Y | 1 |
| Valeix, B | 1 |
| Louvard, Y | 1 |
| Lefevre, T | 1 |
| Guérin, Y | 2 |
| Hosokawa, FG | 1 |
| Kim, K | 1 |
| Tanaka, S | 1 |
| Miyake, S | 1 |
| Schöneberger, AA | 1 |
| Schmidt, K | 1 |
| Hasin, Y | 1 |
| Goods, CM | 2 |
| al-Shaibi, KF | 2 |
| Liu, MW | 2 |
| Yadav, JS | 2 |
| Mathur, A | 2 |
| Dean, LS | 2 |
| Iyer, SS | 2 |
| Parks, JM | 2 |
| Roubin, GS | 2 |
| Markert, T | 1 |
| Bertsch, G | 1 |
| Langenfeld, H | 1 |
| Paloncy, R | 1 |
| Moussa, I | 5 |
| Akiyama, T | 1 |
| Tobis, J | 2 |
| Gregorini, L | 2 |
| Marco, J | 2 |
| Bernies, M | 1 |
| Cassagneau, B | 1 |
| Bossi, IM | 1 |
| Mannucci, PM | 1 |
| Tiecco, F | 1 |
| Di Maggio, M | 1 |
| Hausleiter, J | 2 |
| Haushofer, A | 1 |
| Halbmayer, WM | 1 |
| Prachar, H | 1 |
| Carrozza, JP | 2 |
| Itoh, A | 1 |
| Blengino, S | 1 |
| Ferraro, M | 2 |
| Mahanonda, N | 1 |
| Kangkagate, C | 1 |
| Chaithiraphan, S | 1 |
| Roquebert, PO | 2 |
| Cho, SY | 2 |
| Jang, YS | 1 |
| Oh, DJ | 1 |
| Oh, BH | 1 |
| Kang, JC | 1 |
| Zubaid, M | 1 |
| Penn, IM | 2 |
| Buller, CE | 2 |
| Moscovich, MD | 1 |
| Ricci, DR | 1 |
| Chauhan, A | 1 |
| Dickfeld, T | 2 |
| Wehinger, A | 1 |
| Hobson, AG | 1 |
| Sowinski, KM | 1 |
| Moses, J | 1 |
| Di Francesco, L | 1 |
| Zitzmann-Roth, E | 1 |
| Elezi, S | 1 |
| Kereiakes, DJ | 2 |
| Kleiman, N | 1 |
| Ferguson, JJ | 2 |
| Runyon, JP | 2 |
| Broderick, TM | 1 |
| Higby, NA | 1 |
| Martin, LH | 1 |
| Hantsbarger, G | 1 |
| McDonald, S | 1 |
| Anders, RJ | 1 |
| Zanini, R | 1 |
| Bonandi, L | 1 |
| Curello, S | 1 |
| Bersatti, F | 1 |
| Giovannini, G | 1 |
| Metra, M | 1 |
| Dei Cas, L | 1 |
| Brown, RI | 1 |
| Cooper, TG | 1 |
| Wheeldon, N | 1 |
| Cumberland, D | 1 |
| Anzuini, A | 2 |
| Rosanio, S | 2 |
| Tocchi, M | 2 |
| Coppi, R | 2 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Pagnotta, P | 1 |
| Montorfano, M | 1 |
| Kulbertus, HE | 2 |
| Chierchia, SL | 2 |
| Reinhardt, R | 1 |
| Iturbe, T | 1 |
| Sánchez, C | 1 |
| Moreno, JA | 1 |
| Olave, T | 1 |
| Azaceta, G | 1 |
| Varo, MJ | 1 |
| Civeira, E | 1 |
| Peleato, J | 1 |
| Cornudella, R | 1 |
| Heublein, B | 1 |
| Ozbek, C | 1 |
| Pethig, K | 1 |
| Bell, MR | 3 |
| Grill, DE | 2 |
| Darius, H | 1 |
| Borkowski, U | 1 |
| Voigtländer, T | 1 |
| Nowak, B | 1 |
| Genth, S | 1 |
| Meyer, J | 1 |
| Stoupel, E | 1 |
| Ochoa, AB | 1 |
| Wolfe, M | 1 |
| Lewis, P | 1 |
| Lenihan, DJ | 1 |
| Oemrawsingh, PV | 1 |
| Tuinenburg, JC | 1 |
| Schalij, MJ | 1 |
| Jukema, JW | 1 |
| Reiber, JH | 1 |
| Bruschke, AV | 1 |
| Corcos, T | 1 |
| Favereau, X | 1 |
| Martínez Elbal, L | 1 |
| López Mínguez, JR | 1 |
| Alonso, M | 1 |
| Calvo, I | 1 |
| Insa, L | 1 |
| Lezaun, R | 1 |
| Colman, T | 1 |
| Esplugas, E | 1 |
| Vázquez, N | 1 |
| Picó, F | 1 |
| Amaro, A | 1 |
| Bennett, CL | 2 |
| Kiss, JE | 1 |
| Weinberg, PD | 2 |
| Pinevich, AJ | 1 |
| Green, D | 2 |
| Kwaan, HC | 1 |
| Feldman, MD | 2 |
| Boland, J | 1 |
| Fleck, E | 2 |
| Bonnier, J | 1 |
| Emmanuelson, H | 1 |
| Vrolix, M | 1 |
| Missault, L | 1 |
| Casaccia, M | 1 |
| Niccoli, L | 1 |
| Oto, A | 1 |
| White, C | 1 |
| Webb-Peploe, M | 1 |
| Madan, M | 1 |
| Marquis, JF | 1 |
| de May, MR | 1 |
| Laramee, LA | 1 |
| Leddy, D | 1 |
| O'Brien, E | 1 |
| Williams, WL | 1 |
| Higginson, LA | 1 |
| Jelley, J | 1 |
| Reid, F | 1 |
| Johansen, H | 1 |
| Labinaz, M | 1 |
| Zidar, JP | 3 |
| Tisdale, JE | 1 |
| Lauer, MS | 1 |
| Mukherjee, DP | 1 |
| Reifart, N | 1 |
| Störger, H | 1 |
| Schwarz, F | 1 |
| Rabe, A | 1 |
| Leon, MB | 3 |
| Popma, JJ | 2 |
| Gordon, PC | 1 |
| Cutlip, DE | 2 |
| Ho, KK | 2 |
| Giambartolomei, A | 1 |
| Diver, DJ | 2 |
| Lasorda, DM | 1 |
| Williams, DO | 1 |
| Pocock, SJ | 1 |
| Kuntz, RE | 3 |
| Ruf, A | 1 |
| Zohlnhöfer, D | 1 |
| Reffelmann, T | 1 |
| vom Dahl, J | 1 |
| Hendriks, F | 1 |
| Klues, HG | 1 |
| Hanrath, P | 1 |
| Jamar, S | 1 |
| Vanderheyden, M | 1 |
| Janssens, L | 1 |
| Hermans, L | 1 |
| Jamar, R | 1 |
| Verstreken, G | 1 |
| Szto, GY | 1 |
| Linnemeier, TJ | 1 |
| Ball, MW | 1 |
| Koornstra, JJ | 1 |
| Loualidi, A | 1 |
| de Vries, CJ | 1 |
| Wilson, SH | 1 |
| Rihal, CS | 1 |
| Velianou, JL | 1 |
| Ferrer, F | 1 |
| Moraleda, JM | 1 |
| Vicente, V | 1 |
| Oetgen, M | 1 |
| Roubin, G | 1 |
| Wang, X | 1 |
| Iyer, S | 1 |
| Maida, R | 1 |
| Collins, M | 1 |
| Kreps, E | 1 |
| Moses, JW | 3 |
| McCullough, PA | 2 |
| Marks, KR | 2 |
| Mazur, W | 1 |
| Kaluza, G | 1 |
| Ducas, J | 1 |
| Kramer, JH | 1 |
| Booth, JE | 1 |
| Sapp, SK | 1 |
| Cabot, CF | 1 |
| Quinn, MW | 1 |
| Dillard, TA | 1 |
| O'Connor, CM | 1 |
| Forbes, CD | 1 |
| Lowe, GD | 1 |
| MacLaren, M | 1 |
| Shaw, BG | 1 |
| Dickinson, JP | 1 |
| Kieffer, G | 1 |
| Yosipovitch, G | 1 |
| Rechavia, E | 1 |
| Feinmesser, M | 1 |
| David, M | 1 |
| Lee, HJ | 1 |
| Park, HK | 1 |
| Willerson, JT | 1 |
| Zoldhelyi, P | 1 |
| Jauhar, R | 1 |
| Bergman, G | 1 |
| Savino, S | 1 |
| Deutsch, E | 3 |
| Shaknovich, A | 1 |
| Parikh, M | 1 |
| Sanborn, TA | 1 |
| Quinn, MJ | 1 |
| Fitzgerald, DJ | 1 |
| Wardeh, AJ | 1 |
| Kay, IP | 1 |
| Coen, VL | 1 |
| Gijzel, AL | 1 |
| Ligthart, JM | 1 |
| den Boer, A | 1 |
| Levendag, PC | 1 |
| van Der Giessen, WJ | 2 |
| Davidson, CJ | 1 |
| Brookes, CI | 1 |
| Sigwart, U | 1 |
| Avran, A | 1 |
| Fourcade, L | 1 |
| Bory, M | 1 |
| Yoon, Y | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Jafary, FH | 1 |
| Kimmelstiel, CD | 1 |
| Robbins, MA | 1 |
| Marso, SP | 1 |
| Peterson, J | 1 |
| Brener, S | 1 |
| Taher, A | 1 |
| Ammash, Z | 1 |
| Dabajah, B | 1 |
| Nasrallah, A | 1 |
| Mourad, FH | 1 |
| Beverelli, F | 1 |
| Prost, C | 1 |
| Veyre, B | 1 |
| Ollivier, L | 1 |
| Daurat, MO | 1 |
| Vial, T | 1 |
| Augey, F | 1 |
| Kottke-Marchant, K | 1 |
| Powers, JB | 1 |
| Brooks, L | 1 |
| Kundu, S | 1 |
| Christie, DJ | 1 |
| Asplund, K | 1 |
| Foussas, S | 1 |
| Alexopoulos, D | 1 |
| Olympios, C | 1 |
| Voudris, V | 1 |
| Hatzimiltiadis, S | 1 |
| Sionis, D | 1 |
| Vavouranakis, E | 1 |
| Vrahatis, A | 1 |
| Fakiolas, C | 1 |
| Pissimisis, E | 1 |
| Stefanidis, A | 1 |
| Zairis, M | 1 |
| Pavlides, G | 1 |
| Vitakis, S | 1 |
| Louridas, G | 1 |
| Cokkinos, D | 1 |
| Toutouzas, P | 1 |
| Macaluso, G | 1 |
| Sannes, MR | 1 |
| Modi, KS | 1 |
| Kolansky, DM | 1 |
| Klugherz, BD | 1 |
| Curran, SC | 1 |
| Herrmann, HC | 1 |
| Magness, K | 1 |
| Wilensky, RL | 1 |
| Hirshfeld, JW | 1 |
| Block, PC | 1 |
| Sari, R | 1 |
| Sevinc, A | 1 |
| Buyukberber, S | 1 |
| Fitzgerald, PJ | 2 |
| Oshima, A | 1 |
| Hayase, M | 1 |
| Metz, JA | 1 |
| Bailey, SR | 1 |
| Cleman, MW | 1 |
| Oesterle, SN | 2 |
| Overlie, PA | 1 |
| Pepine, CJ | 1 |
| Safian, RD | 1 |
| Shani, J | 1 |
| Simonton, CA | 1 |
| Smalling, RW | 2 |
| Yock, PG | 1 |
| Gottsauner-Wolf, M | 1 |
| Zasmeta, G | 1 |
| Hornykewycz, S | 1 |
| Nikfardjam, M | 1 |
| Stepan, E | 1 |
| Wexberg, P | 1 |
| Zorn, G | 1 |
| Glogar, D | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Ruzyłło, W | 1 |
| Gil, R | 1 |
| Górecka, B | 1 |
| Purzycki, Z | 1 |
| Kośmider, M | 1 |
| Lekston, A | 1 |
| Gasior, M | 1 |
| Zmudka, K | 1 |
| Pieniazek, P | 1 |
| Buszman, P | 1 |
| Drzewiecki, J | 1 |
| Ciećwierz, D | 1 |
| Sadowski, Z | 1 |
| Dillon, WC | 1 |
| Eckert, GJ | 1 |
| Dillon, JC | 1 |
| Ritchie, ME | 1 |
| Chinnakotla, S | 1 |
| Leone, JP | 1 |
| Fidler, ME | 1 |
| Hammeke, MD | 1 |
| Tarantolo, S | 1 |
| Lim, YL | 1 |
| Vandertie, L | 1 |
| Chiu, JK | 1 |
| White, LR | 1 |
| Kaluza, GL | 1 |
| Ali, NM | 1 |
| Calver, AL | 1 |
| Blows, LJ | 1 |
| Harmer, S | 1 |
| Dawkins, KD | 1 |
| Gray, HH | 1 |
| Morgan, JH | 1 |
| Simpson, IA | 1 |
| Frelinger III, AL | 1 |
| Wengrower, D | 1 |
| Alter, P | 1 |
| Schaefer, JR | 1 |
| Maisch, B | 1 |
| Dieter, RS | 1 |
| Fry, JA | 1 |
| von Welser, N | 1 |
| Peter, K | 1 |
| Nordt, T | 1 |
| Müller, I | 2 |
| Rüdiger, S | 2 |
| Wolf, B | 2 |
| King, SB | 1 |
| Kozuma, K | 1 |
| Yamasaki, M | 1 |
| Morino, Y | 1 |
| Ayabe, S | 1 |
| Kuroda, Y | 2 |
| Tanabe, K | 1 |
| Ikari, Y | 2 |
| Tamura, T | 1 |
| Cannan, CR | 1 |
| Pache, J | 2 |
| Dangas, G | 2 |
| Abizaid, AS | 1 |
| Curry, BH | 1 |
| Lansky, AJ | 2 |
| Paliou, M | 1 |
| Naber, CK | 1 |
| Kaiser, CA | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Erbel, R | 1 |
| Baumgart, D | 1 |
| Cohen, DJ | 1 |
| Chauhan, MS | 1 |
| Nagaoka, N | 1 |
| Matsubara, T | 1 |
| Okazaki, K | 1 |
| Masuda, N | 1 |
| Shikaura, K | 1 |
| Hotta, A | 1 |
| Scheen, AJ | 1 |
| White, RL | 1 |
| Pinnow, E | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Taaffe, M | 1 |
| Gruberg, L | 1 |
| Kent, KK | 1 |
| Lindsay, J | 1 |
| Tanabe, Y | 1 |
| Ito, E | 1 |
| Nakagawa, I | 1 |
| Suzuki, K | 1 |
| Machraoui, A | 1 |
| Germing, A | 1 |
| Lindstaedt, M | 1 |
| von Dryander, S | 1 |
| Bojara, W | 1 |
| Lawo, T | 1 |
| Lemke, B | 1 |
| Jaeger, D | 1 |
| Grewe, P | 1 |
| Deneke, T | 1 |
| Barmeyer, J | 1 |
| Young, JJ | 1 |
| Shimshak, TM | 1 |
| Griffo, R | 1 |
| Nair, GV | 1 |
| Davis, CJ | 1 |
| McKenzie, ME | 1 |
| Kilaru, PK | 1 |
| Schweiger, MJ | 1 |
| Kozman, HA | 1 |
| Weil, TR | 1 |
| Calvin, JE | 1 |
| Klein, LW | 1 |
| Swanson, N | 1 |
| Hogrefe, K | 1 |
| Stephens Lloyd, A | 1 |
| Gershlick, A | 1 |
| Taniuchi, M | 2 |
| Kurz, HI | 1 |
| Lasala, JM | 2 |
| Kitai, T | 1 |
| Tanigawa, T | 1 |
| Okinaka, T | 1 |
| Wada, H | 1 |
| Shiku, H | 1 |
| Ito, M | 1 |
| Isaka, N | 1 |
| Nakano, T | 1 |
| De Servi, S | 1 |
| Liistro, F | 1 |
| Natarajan, MK | 1 |
| Rupprecht, H | 1 |
| Assali, AR | 1 |
| Salloum, J | 1 |
| Sdringola, S | 1 |
| Moustapha, A | 1 |
| Ghani, M | 1 |
| Hale, S | 1 |
| Schroth, G | 1 |
| Fujise, K | 1 |
| Anderson, HV | 2 |
| Rosales, OR | 1 |
| Dzavik, V | 1 |
| Catellier, D | 1 |
| Callahan, KP | 1 |
| Batchelor, WB | 1 |
| Mahaffey, KW | 1 |
| Meier, S | 1 |
| Hasselblad, V | 1 |
| Fry, ET | 1 |
| Ross, AM | 1 |
| Binanay, CA | 1 |
| L'Allier, PL | 1 |
| Allen, D | 1 |
| Cai, X | 1 |
| Shen, W | 1 |
| Schiele, F | 1 |
| Bassand, JP | 1 |
| Cannon, C | 1 |
| Montorsi, P | 1 |
| Fabbiocchi, F | 1 |
| Galli, S | 1 |
| Ravagnani, P | 1 |
| Grancini, L | 1 |
| Cozzi, S | 1 |
| Loaldi, A | 1 |
| Tsui, PT | 1 |
| Leung, WS | 1 |
| Wu, CW | 1 |
| Lau, ST | 1 |
| Choi, YC | 1 |
| Dörr, G | 1 |
| Schmidt, G | 1 |
| Gräfe, M | 1 |
| Regitz-Zagrosek, V | 1 |
| Maseri, A | 1 |
| Cianflone, D | 1 |
| Margonato, A | 1 |
| Pizzetti, G | 1 |
| Maggioni, AP | 1 |
| Ward, DJ | 1 |
| Taylor, R | 1 |
| Berjón Reyero, J | 1 |
| Gaspoz, JM | 1 |
| Goldman, PA | 1 |
| Williams, LW | 1 |
| Kuntz, KM | 1 |
| Hunink, MG | 1 |
| Wood, AJ | 1 |
| Lubbe, DF | 1 |
| Yao, SK | 1 |
| Ober, JC | 1 |
| McNatt, J | 1 |
| Benedict, CR | 1 |
| Rosolowsky, M | 1 |
| Cui, K | 1 |
| Maffrand, JP | 1 |
| Campbell, WB | 1 |
| Buja, LM | 1 |
| Kawakage, M | 1 |
| Shirakura, S | 1 |
| Karasawa, A | 1 |
| Takeda, M | 1 |
| Miki, I | 1 |
| Ishii, A | 1 |
| Kubo, K | 1 |
| Ramires, JA | 1 |
| Mansur, Ade P | 1 |
| Martins, JR | 1 |
| Raineri, A | 1 |
| Cesar, LA | 1 |
| Bellotti, G | 1 |
| Chamone, DF | 1 |
| Pileggi, F | 1 |
| Janzon, L | 1 |
| Bergqvist, D | 1 |
| Boberg, J | 1 |
| Boberg, M | 1 |
| Eriksson, I | 1 |
| Lindgärde, F | 1 |
| Persson, G | 1 |
| Almgren, B | 1 |
| Fagher, B | 1 |
| Kjellström, T | 1 |
| McTavish, D | 1 |
| Faulds, D | 1 |
| Goa, KL | 1 |
| Cox, JL | 1 |
| Gotlieb, AI | 1 |
| Hata, K | 1 |
| Kitada, N | 1 |
| Gomyo, T | 1 |
| Hamanaka, M | 1 |
| Koganei, A | 1 |
| Kan, Z | 1 |
| Kawaguchi, S | 1 |
| Amemiya, T | 1 |
| Harker, LA | 2 |
| Tomoda, H | 1 |
| Yokota, I | 1 |
| Berglund, U | 1 |
| Liusov, VA | 1 |
| Savenkov, MP | 1 |
| Brown, BG | 1 |
| Chesebro, JH | 1 |
| Ekeström, S | 1 |
| Henderson, AH | 1 |
| Jewitt, DE | 1 |
| Oliver, MF | 1 |
| Sleight, P | 1 |
| Khurmi, NS | 1 |
| Bowles, MJ | 1 |
| Kohli, RS | 1 |
| Raftery, EB | 1 |
| Yamazaki, H | 1 |
| Kawagoe, S | 1 |
| Yamaguchi, A | 1 |
| Munakata, J | 1 |
| Kuroki, S | 1 |
| Tanoue, K | 1 |
| Matsumura, H | 1 |
| Terashita, Z | 1 |
| Nishikawa, K | 1 |
| Imai, Y | 1 |
| Rothlin, ME | 1 |
| Krayenbühl, HP | 1 |
| Steinbrunn, W | 1 |
| Senning, A | 1 |
| Ugarte, M | 1 |
| de Teresa, E | 1 |
| Lorenz, P | 1 |
| Marin, MC | 1 |
| de Artaza, M | 1 |
| Martín-Júdez, V | 1 |
| Criado, A | 1 |
| Juffé, A | 1 |
| Carmona, J | 1 |
| Otero, C | 1 |
| Avello, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study[NCT02617290] | Phase 3 | 1,900 participants (Actual) | Interventional | 2017-01-09 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Effect of Low Dose of Colchicine on Platelet Reactivty in Patients With Chronic Coronary Disease[NCT05956145] | Phase 3 | 80 participants (Anticipated) | Interventional | 2021-06-17 | Recruiting | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris: Randomised, Double Blind, Placebo Controlled Trial[NCT04270071] | Phase 4 | 80 participants (Anticipated) | Interventional | 2020-12-31 | Not yet recruiting | ||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events[NCT05733208] | 766 participants (Anticipated) | Interventional | 2023-05-06 | Recruiting | |||
| CSP #424 - Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation[NCT00007657] | Phase 3 | 3,260 participants (Anticipated) | Interventional | 1998-12-31 | Completed | ||
| Quality of Life and Achievement of Target of Treatment After Optimized Medical Treatment, Physical Training and Smoking Cessation With or Without Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris.[NCT00825604] | Phase 2 | 0 participants (Actual) | Interventional | 2009-01-31 | Withdrawn (stopped due to Because of poor inclusion difficulties to find patient) | ||
| Impact of Coronary Artery Stenting on Quantitative Myocardial Blood Flow and Health Status[NCT04475094] | 75 participants (Anticipated) | Observational | 2019-12-23 | Recruiting | |||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation[NCT02176265] | 31 participants (Actual) | Interventional | 2014-09-30 | Completed | |||
| Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated With Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events[NCT00484926] | Phase 4 | 2,000 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events[NCT00590174] | Phase 4 | 1,175 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Prospective Single Arm Clinical Trial Evaluating the MitraClip System in Australia and New Zealand[NCT01301625] | 78 participants (Actual) | Observational | 2011-11-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea[NCT00528411] | Phase 2 | 123 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients[NCT02707445] | 5,000 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT00947843] | Phase 4 | 306 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions[NCT00698607] | Phase 4 | 1,466 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)[NCT02770651] | 69 participants (Anticipated) | Observational | 2016-05-31 | Enrolling by invitation | |||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Platelet Aggregometry to Drive the Surgical Timing in Elderlies With Hip Fracture and Receiving Clopidogrel.[NCT04642209] | 9 participants (Anticipated) | Observational | 2020-12-01 | Not yet recruiting | |||
| Recovery of Platelet Function Following Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Subjects With Stable Coronary Disease[NCT01014624] | Phase 4 | 56 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling[NCT02224131] | Phase 4 | 1,856 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry[NCT01824147] | 400 participants (Actual) | Observational | 2013-08-31 | Completed | |||
| A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771] | Phase 4 | 44 participants (Anticipated) | Interventional | 2007-11-30 | Not yet recruiting | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)[NCT00133003] | Phase 4 | 2,022 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3[NCT00262054] | Phase 4 | 4,570 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)[NCT00133250] | Phase 4 | 800 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)[NCT00140465] | Phase 4 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280] | Phase 4 | 2,505 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary S[NCT01572129] | Phase 4 | 240 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Influence of the Compression Method After Transradial Catheterization in Radial Artery[NCT02697526] | 274 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| Prevalence of Inadequate Platelet Inhibition After Oral Loading With Prasugrel/Clopidogrel in Patients With an Acute Coronary Syndrome Undergoing Early PCI[NCT01090336] | 26 participants (Anticipated) | Observational | 2009-08-31 | Recruiting | |||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease[NCT03150667] | Phase 4 | 220 participants (Anticipated) | Interventional | 2017-04-10 | Recruiting | ||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting[NCT00776633] | Phase 4 | 614 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022] | 300 participants (Anticipated) | Observational [Patient Registry] | 2022-06-15 | Recruiting | |||
| Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809] | Phase 4 | 240 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| A Multicenter, Randomized Trial Evaluating 30-day and 6-month Clinical Outcomes With Three Different Treatment Strategies (Coronary Angioplasty + Abciximab, Intracoronary Stent + Abciximab, and Intracoronary Stent + Placebo) in Patients Undergoing Percuta[NCT00271401] | Phase 3 | 2,399 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Post-Market, Prospective, Multi-Center, Study to Evaluate Safety and Efficacy of the StarClose™ Vascular Closure System in Patients Who Are Ambulated Early Post-Diagnostic Catheterization[NCT00736086] | 165 participants (Actual) | Observational | 2006-03-31 | Completed | |||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Gemini Angioplasty and Arterial Measurement Evaluation (GAAME) An Evaluation of the Metricath Gemini System, a Percutaneous Interventional Device Intended to Make Arterial Lumen Measurements and Perform Percutaneous Transluminal Angioplasty Dilations.[NCT00399646] | Phase 2 | 145 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome[NCT03007524] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
This is one of the Device and Procedure-Related Endpoints. Device Time is defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter. Device Time is shorter in duration than Procedure Time because it does not include the time required to perform transseptal access into the left atrium. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
| Intervention | Minutes (Mean) |
|---|---|
| MitraClip Implant | 91.2 |
This is one of the Device and Procedure-Related Endpoints. Mean fluoroscopy duration during the MitraClip procedure. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
| Intervention | Minutes (Mean) |
|---|---|
| MitraClip Implant | 41.2 |
Defined as successful MitraClip implantation with resulting MR of 2+ or less. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| MitraClip Implant | 39 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 8.3 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 0.0 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 6.1 |
"Clinical Endpoint.~Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality,cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery.)~Non-cardiac death is defined as a death not due to cardiac causes (as defined above)." (NCT01301625)
Timeframe: Baseline
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 0.0 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded. B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 91.5 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 85.3 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: 30 days
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 96.1 |
"Death: Defined as all causes of death for the primary safety Major Adverse Event (MAE) Endpoint.~Death is further divided into 2 categories:~A. Cardiac death is defined as death due to any of the following:~Acute myocardial infarction~Cardiac perforation/pericardial tamponade~Arrhythmia or conduction abnormality~Stroke within 30 days of the procedure or stroke suspected of being related to the procedure~Death due to any complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery~Any death for which a cardiac cause cannot be excluded.~B. Non-cardiac death is defined as a death not due to cardiac causes (as defined above).~Congestive Heart Failure (CHF): Defined as a documented diagnosis of CHF on the hospital admission report or discharge summary." (NCT01301625)
Timeframe: Baseline
| Intervention | percentage of participants (Number) |
|---|---|
| MitraClip Implant | 100 |
This is the Economic data reported to support the MitraClip System economic analysis. It is defined as the mean duration of time that patients spent in hospital following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
| Intervention | Days (Mean) |
|---|---|
| MitraClip Implant | 3.4 |
ICU and hospital stay is defined as the mean duration of time that patients spent in the ICU (Intensive Care Unit)/ CCU (Cardiac Care Unit)/ PACU (Post-Anesthesia Care Unit) following the MitraClip procedure. (NCT01301625)
Timeframe: Post index procedure within 30 days
| Intervention | Hours (Mean) |
|---|---|
| MitraClip Implant | 62.1 |
This is one of the Device and Procedure-Related Endpoints. Procedure Time is defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
| Intervention | Minutes (Mean) |
|---|---|
| MitraClip Implant | 133.5 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 12 months
| Intervention | Meters (Mean) |
|---|---|
| MitraClip Implant | 329.9 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 30 days
| Intervention | Meters (Mean) |
|---|---|
| MitraClip Implant | 297.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: 6 months
| Intervention | Meters (Mean) |
|---|---|
| MitraClip Implant | 324.3 |
The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. It is a measure of a patient's exercise capacity. (NCT01301625)
Timeframe: Baseline
| Intervention | Meters (Mean) |
|---|---|
| MitraClip Implant | 271.0 |
This is one of the Device and Procedure-Related Endpoints. (NCT01301625)
Timeframe: At day 0 (on the day of index procedure)
| Intervention | Milliliters (Mean) |
|---|---|
| MitraClip Implant | 10.6 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 12 months
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 12 months | Difference (12 months - Baseline) | |
| MitraClip Implant | 51.1 | 30.2 | -20.9 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 30 days
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 30 days | Difference (30 days - Baseline) | |
| MitraClip Implant | 50.4 | 26.4 | -24.0 |
"The Minnesota Living with Heart Failure Questionnaire(MLHFQ) is comprised of 21 questions.The response for each question ranges from 0(no affect on the patient's living) to 5(affected the patient's life very much during the past month).The total score for the 21 items can range from 0-105.A lower&higher MLHFQ score indicates less effect of heart failure&the worse impact of heart failure on a patient's QOL,respectively.Although the MLHFQ incorporates relevant aspects of the key dimensions of QOL (physical and emotional),the questionnaire was not designed to measure any particular dimension separately.The total score should be taken as the best measure of how heart failure and treatments impact QOL.~The total score is the sum of a)the physical dimension,measured using 8 questions (possible subscale score range 0-40) b)the emotional dimension,measured using 5 questions(possible subscale score from 0-25)&c) other factors,measured using 8 questions (possible subscale score from 0-40)." (NCT01301625)
Timeframe: 6 months
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | 6 months | Difference (6 months - Baseline) | |
| MitraClip Implant | 49.5 | 28.0 | -21.5 |
(NCT01301625)
Timeframe: 30 days
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
| MitraClip Implant | 8.4 | 18.38 | 2.87 | 7.44 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 148.5 | 132.4 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 140.4 | 138.8 |
Left atrial volume is assessed by echocardiography. Using the single plane method of disks, the left atrial volume is derived by planimetry in the 4-chamber view at end-systole. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 141.7 | 141.8 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 161.1 | 150.1 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 152.9 | 148.2 |
Left Ventricular end-diastolic volume (LVEDV) as determined by the core echo laboratory. Left Ventricular end-diastolic volume (LVEDV) measured using 2-dimensional echocardiography. The endocardium is traced at end-diastole (frame before mitral valve closure or maximum cavity dimension) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | Milliliters (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 158.2 | 151.3 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 12 months
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 46.9 | 47.4 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 48.4 | 46.5 |
Left ventricular ejection fraction is assessed by transthoracic echocardiography according to Simpson's rule (biplane method of disks). (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | percent (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 47.2 | 44.6 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 12 months
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 97.8 | 91.7 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 88.5 | 89.0 |
Left Ventricular end-systolic volume (LVESV) as determined by the core echo laboratory. Left Ventricular end-systolic volume (LVESV) measured using 2-dimensional echocardiography. The endocardium is traced at end-systole (frame prior to mitral valve opening or the minimum cavity area) in the 2- and 4-chamber views to calculate volumes. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | Milliliter (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 93.3 | 93.2 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 6.0 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 5.9 | 5.7 |
LVIDd is the measurements of the left ventricular internal dimension at end-diastole and normally corresponds to the largest cardiac dimension. LVIDd is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 5.9 | 5.7 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 4.6 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 4.5 | 4.5 |
LVIDs is the measurements of the left ventricular internal dimension at end-systole and normally corresponds to the smallest cardiac dimension. LVIDs is measured by transthoracic echocardiography and the results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 4.5 | 4.4 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | cm^2 (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 3.8 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | cm^2 (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 3.5 | 2.3 |
Measure of the area of the mitral valve orifice using transthoracic echocardiography. The pressure half time method is used to assess the presence and severity of mitral stenosis. Results are interpreted by the study's echocardiography core laboratory. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | cm^2 (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 3.5 | 2.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 2.3 | 3.4 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 2.3 | 3.5 |
Mitral valve mean gradient is defined as the mean pressure gradients across the mitral valve as measured by echocardiography. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | mmHg (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 2.3 | 3.7 |
This is the economic data reported to support the MitraClip System economic analysis. (NCT01301625)
Timeframe: < or = 12 days
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Home | Home with home health care | Skilled nursing facility | Nursing home | Death | Other | |
| MitraClip Implant | 70 | 4 | 1 | 0 | 2 | 1 |
This is one of the Device and Procedure-Related Endpoints. Implant Rate is defined as the rate of successful delivery and deployment of MitraClip device implant(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter. (NCT01301625)
Timeframe: Day 0 (On the day of procedure)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| 0 Mitra Clip devices | 1 Mitra Clip devices | 2 Mitra Clip devices | 3 Mitra Clip devices | |
| MitraClip Implant | 1 | 41 | 35 | 1 |
Mital Valve Surgery Post-MitraClip Procedure; Surgery Types includes Replacement and Repair. (NCT01301625)
Timeframe: 30 days of Post-MitraClip Procedure
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Recurring mitral regurgitation | Device failure | |
| MitraClip Implant | 1 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
| MitraClip Implant | 2 | 15 | 15 | 7 | 3 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
| MitraClip Implant | 1 | 26 | 25 | 12 | 5 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
| MitraClip Implant | 0 | 20 | 24 | 12 | 4 | 0 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: At discharge (≤7 days of index procedure)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
| MitraClip Implant | 1 | 38 | 22 | 9 | 3 | 1 |
"Mitral regurgitation severity was determined based on the American Society of Echocardiography (ASE) Recommendations for Evaluation of The Severity of Native Valvular Regurgitation with Two-Dimensional and Doppler Echocardiography. MR severity was scored using the integrative method based on qualitative and quantitative echocardiographic parameters as described in the ASE guidelines.Site-assessed mitral regurgitation severity using echocardiography.~MR severity was graded as follows: 0: None, 1+: Mild, 2+: Moderate, 3+: Moderate-to-Severe, 4+: Severe." (NCT01301625)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| 0: None | 1+:Mild | 2+: Moderate | 3+: Moderate-to-Severe | 4+: Severe | Not Evaluable | |
| MitraClip Implant | 0 | 0 | 0 | 22 | 55 | 0 |
Second MitraClip device interventions are reported by Abbott Vascular personnel on Procedural Observation Forms. A second MitraClip device intervention is a good option for patients with MR following placement of the original MitraClip device. (NCT01301625)
Timeframe: Through 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Recurring mitral regurgitation | Single leaflet device attachment (SLDA) | |
| MitraClip Implant | 2 | 1 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 12 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| NYHA I | NYHA II | NYHA III | NYHA IV | |
| MitraClip Implant | 52.5 | 42.5 | 2.5 | 2.5 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 30 days
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| NYHA I | NYHA II | NYHA III | NYHA IV | |
| MitraClip Implant | 36.2 | 44.9 | 15.9 | 2.9 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| NYHA I | NYHA II | NYHA III | NYHA IV | |
| MitraClip Implant | 33.3 | 56.7 | 8.3 | 1.7 |
"Class I Patients with cardiac disease but without resulting limitations of physical activity;~Class II Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain;~Class III Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain;~Class IV Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased." (NCT01301625)
Timeframe: Baseline
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| NYHA I | NYHA II | NYHA III | NYHA IV | |
| MitraClip Implant | 2.6 | 26.9 | 51.3 | 19.2 |
Defined as re-admission of patients to the hospital following discharge from the Clip procedure. (NCT01301625)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| All re-hospitalizations | Heart Failure-related re-hospitalizations | Other cardiac-related re-hospitalizations | Other non-cardiac-related re-hospitalizations | |
| MitraClip Implant | 35 | 10 | 11 | 22 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 44.6 | 36.8 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 40.5 | 15.2 |
Regurgitant fraction as determined by the core echo laboratory. Regurgitant fraction is defined as the regurgitant volume divided by the forward stroke volume through the regurgitant valve. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | Percentage (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 38.9 | 25.8 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 12 Months
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 12 Months | |
| MitraClip Implant | 49.8 | 73.3 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and 30 Days
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | 30 Days | |
| MitraClip Implant | 61.9 | 25.6 |
Regurgitant volume as determined by the core echo laboratory. In the presence of regurgitation of one valve, without any intracardiac shunt, the flow through the affected valve is larger than through other competent valves. The difference between the two represents the regurgitant volume. (NCT01301625)
Timeframe: At Baseline and Discharge (≤7 days of index procedure)
| Intervention | ml (Mean) | |
|---|---|---|
| Baseline | Discharge | |
| MitraClip Implant | 55.5 | 25.1 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 96.59 |
| Clopidogrel | 96.78 |
| Placebo | 97.58 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 57.96 |
| Clopidogrel | 61.91 |
| Placebo | 59.92 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.71 |
| Placebo | 2.94 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.72 |
| Clopidogrel | 3.73 |
| Placebo | 4.03 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.89 |
| Placebo | 2.91 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.88 |
| Clopidogrel | 2.70 |
| Placebo | 2.50 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 12.92 |
| Clopidogrel | 12.17 |
| Placebo | 12.06 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: Baseline
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 163.34 |
| Clopidogrel | 185.98 |
| Placebo | 145.41 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: Baseline
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 75.01 |
| Clopidogrel | 73.04 |
| Placebo | 73.13 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.94 |
| Clopidogrel | 2.01 |
| Placebo | 1.91 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 14.79 |
| Clopidogrel | 14.15 |
| Placebo | 15.5 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 17.00 |
| Clopidogrel | 17.29 |
| Placebo | 15.83 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.96 |
| Clopidogrel | 0.89 |
| Placebo | 0.89 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.78 |
| Clopidogrel | 5.83 |
| Placebo | 6.10 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.74 |
| Placebo | 2.95 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 74.71 |
| Clopidogrel | 72.84 |
| Placebo | 74.27 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.70 |
| Clopidogrel | 3.78 |
| Placebo | 3.98 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 16.38 |
| Clopidogrel | 16.53 |
| Placebo | 16.09 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 60.70 |
| Clopidogrel | 62.38 |
| Placebo | 60.73 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.67 |
| Placebo | 2.91 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.73 |
| Clopidogrel | 2.79 |
| Placebo | 2.75 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 139.88 |
| Clopidogrel | 214.43 |
| Placebo | 140.68 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 15.21 |
| Clopidogrel | 15.10 |
| Placebo | 14.91 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.88 |
| Clopidogrel | 1.97 |
| Placebo | 1.90 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percentage (Mean) |
|---|---|
| Ticagrelor | 97.73 |
| Clopidogrel | 97.35 |
| Placebo | 98.56 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.70 |
| Clopidogrel | 5.85 |
| Placebo | 5.96 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 13.69 |
| Clopidogrel | 13.14 |
| Placebo | 11.45 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.92 |
| Clopidogrel | 0.93 |
| Placebo | 0.83 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: At 2 hours after first dose of study drug
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 93.15 |
| Clopidogrel | 31.05 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0 hour before last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 74.53 |
| Clopidogrel | 51.75 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0.5 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 45.39 |
| Clopidogrel | 4.71 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 1 hour after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 86.71 |
| Clopidogrel | 15.83 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 120 hours - Day 5 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 21.15 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 168 hours - Day 7 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 6.32 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 2 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 91.49 |
| Clopidogrel | 62.96 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 87.29 |
| Clopidogrel | 49.64 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 55.18 |
| Clopidogrel | 53.91 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 240 hours - Day 10 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 1.64 |
| Clopidogrel | 0.98 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 98.39 |
| Clopidogrel | 40.87 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.10 |
| Clopidogrel | 61.80 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 48 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 30.94 |
| Clopidogrel | 45.79 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 72 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 11.76 |
| Clopidogrel | 21.09 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.99 |
| Clopidogrel | 46.90 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 88.31 |
| Clopidogrel | 61.31 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. (NCT00528411)
Timeframe: 4 to 72 Hours after last dose of study drug
| Intervention | Percentage/Hour (Least Squares Mean) |
|---|---|
| Ticagrelor | -1.037 |
| Clopidogrel | -0.482 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Inhibition of platelet aggregation was assessed by Accumetrics VerifyNow® P2Y12 reaction units (PRU). On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: Washout Day 1
| Intervention | percentage (Mean) |
|---|---|
| Prasugrel | 72.3 |
| Clopidogrel | 35.4 |
Time to return to baseline PRU (<= 60 units of baseline) dependent upon baseline PRU and platelet % inhibition on Washout Period Day 1 but independent of treatment. The following regression model was derived for predicting number of days to return to baseline PRU where PI(1) represents platelet percentage inhibition on Washout Day 1. Number days to return to baseline PRU derived from: Number days to return to baseline PRU=-3.350+0.079*PI(1)+0.014*baseline PRU. The predicted number of days to return to baseline based on device-derived platelet percentage inhibition is reported for each treatment group. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) |
|---|---|
| Prasugrel | 6.2 |
| Clopidogrel | 3.7 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participants met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 3 | 5 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/-6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/Baseline PRU less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 5 | 6 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hour (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to (<=) 20%. (NCT01014624)
Timeframe: up to 12 days after the last dose
| Intervention | days (Number) | ||
|---|---|---|---|
| Washout day 50% returned to baseline PRU | Washout day 75% returned to baseline PRU | Washout day 90% returned to baseline PRU | |
| Clopidogrel | 5 | 6 | 7 |
| Prasugrel | 6 | 7 | 9 |
On the first day of the Washout Period (Visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. The results are expressed as cumulative percentage of participants. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| return to baseline PRU by washout day 1 | return to baseline PRU by washout day 3 | return to baseline PRU by washout day 5 | return to baseline PRU by washout day 6 | return to baseline PRU by washout day 7 | return to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 84.6 | 96.2 | 96.2 | 100.0 |
| Prasugrel | 0 | 3.6 | 37.0 | 62.9 | 77.8 | 100.0 |
On the first day of the Washout Period (visit 3), the blood draw for platelet function testing was obtained 24 hours (+/- 6 hours) after the last dose of study medication. Following Visit 3, platelet function testing was performed during each visit of the Washout Period until the participant met the following exit criteria: (Baseline PRU-PRU) less than or equal to 60 units and (Baseline PRU-PRU)/(Baseline PRU) less than or equal to 20%. (NCT01014624)
Timeframe: up to 12 days after last dose
| Intervention | cumulative percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| returned to baseline PRU by washout day 1 | returned to baseline PRU by washout day 3 | returned to baseline PRU by washout day 5 | returned to baseline PRU by washout day 6 | returned to baseline PRU by washout day 7 | returned to baseline PRU by washout day 9 | |
| Clopidogrel | 30.8 | 53.9 | 80.8 | 88.5 | 96.2 | 100.0 |
| Prasugrel | 0.0 | 0.0 | 37.0 | 55.6 | 77.8 | 100.0 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
121 reviews available for ticlopidine and Coronary Disease
| Article | Year |
|---|---|
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
[Impact of different antithrombotic therapy strategy on prognosis in coronary heart disease patients combining with atrial fibrillation: a meta analysis].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Fibrinolytic Agents; He | 2017 |
Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibit | 2018 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions | 2013 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary D | 2014 |
Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Factor VIIa; Humans; Intracranial | 2015 |
Perioperative Management to Reduce Cardiovascular Events.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia; Anticoagulants; Arthroplasty, Replacement, Knee; Aspi | 2016 |
[Meta-analysis of the combination of warfarin and clopidogrel after coronary stenting in patients with indications for chronic oral anticoagulation].
Topics: Administration, Oral; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Hemorrhage; Humans; | 2016 |
Does percutaneous coronary stent implantation increase platelet reactivity?
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Humans; Percutaneous Coronary Intervention; Platelet | 2017 |
Current antiplatelet therapies: benefits and limitations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Dru | 2008 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Biomarkers; C-Reactive Prot | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
Topics: Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; | 2009 |
The present state of aspirin and clopidogrel resistance.
Topics: Anti-Inflammatory Agents; Aspirin; Clopidogrel; Coronary Disease; Drug Monitoring; Humans; Platelet | 2009 |
[Perioperative antiplatelet therapy of patients with coronary stents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Cohort S | 2009 |
Platelet monitoring for PCI: is it really necessary?
Topics: Blood Coagulation; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Monitoring, Physiologic; | 2009 |
Factors associated with clopidogrel nonresponsiveness.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; | 2010 |
The year in interventional cardiology.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Angiograp | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2011 |
Clopidogrel-drug interactions.
Topics: Animals; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Interactions; Humans; Hydroxy | 2011 |
[Comparative antiplatelet efficacy of prasugrel and high-dose clopidogrel in patients with coronary heart disease including acute coronary syndrome].
Topics: Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Piperazine | 2012 |
Clopidogrel and acute coronary syndrome.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Randomized Co | 2002 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
Contemporary antithrombotic strategies in patients undergoing coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinolytic A | 2002 |
Preventing thrombosis: update of first-line therapy in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Algorithms; Clopidogrel; Coronary Disease; Coronary Thrombosis; Enoxaparin; Fibrinoly | 2002 |
Clinical implications of CURE and PCI-CURE in patients with the acute coronary syndrome without persistent ST-elevation.
Topics: Acute Disease; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Electrocardiography; Heparin, | 2002 |
Utility of platelet adp receptor antagonism in the emergency department: a review.
Topics: Aspirin; California; Clopidogrel; Coronary Disease; Critical Care; Drug Utilization; Emergency Servi | 2003 |
Sirolimus-eluting stents: a review of experimental and clinical findings.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Animals; Aspirin; Clopidogrel; Coronary Angiography | 2002 |
[Platelet inhibitors: old and new].
Topics: Abciximab; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; Dipyrid | 2002 |
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2003 |
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Coronary Diseas | 2003 |
Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Di | 2003 |
Current management of non-ST-segment-elevation acute coronary syndrome: reconciling the results of randomized controlled trials.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Echocardiography, Stress; Heparin, Low-Molecular-Weig | 2003 |
Review of antithrombotic agents used for acute coronary syndromes in renal patients.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Fib | 2003 |
Antiplatelet treatment in stable coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Interactions; Humans; Platele | 2003 |
The role of clopidogrel in the management of acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; C | 2003 |
Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
Topics: Adult; Aged; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Coronary Disease; Dose-Re | 2003 |
[Role of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes].
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2003 |
Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therap | 2004 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis.
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials | 2004 |
[Acute coronary syndromes without ST segment elevation].
Topics: Acute Disease; Adrenergic beta-Antagonists; Analgesics, Opioid; Angina Pectoris; Angiotensin-Convert | 2004 |
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir | 2004 |
Role of clopidogrel in unstable angina and non-ST-segment elevation myocardial infarction: from literature and guidelines to practice.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; | 2004 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combinat | 2004 |
Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.
Topics: Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Synergi | 2004 |
[Antithrombotic therapy of acute coronary syndromes].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2005 |
Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2005 |
Clopidogrel in acute coronary syndrome: when, how much, how long?
Topics: Acute Disease; Angina, Unstable; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; D | 2005 |
Resistance to antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Tolera | 2005 |
CLARITY about the use of clopidogrel in patients with acute coronary syndromes and myocardial infarction.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Multicenter Studies as Topic; Myocardial Infar | 2005 |
Clopidogrel in non-ST segment elevation acute coronary syndromes: an overview of the submission by the British Cardiac Society and the Royal College of Physicians of London to the National Institute for Clinical Excellence, and beyond.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Electrocardiography; Humans; Platelet Aggregation Inhi | 2005 |
Clopidogrel in acute coronary heart disease.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Inf | 2005 |
[PCI: state of the art].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Humans; Japan; P | 2006 |
Is clopidogrel cardiovascular medicine's double-edged sword?
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combination; | 2006 |
Percutaneous coronary intervention in a patient with von Willebrand's disease presenting with an acute coronary syndrome.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Coronary Angiography; Co | 2006 |
Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analys | 2006 |
Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Disease; Humans; Pl | 2006 |
Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Combined Modality Therap | 2006 |
The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2006 |
Clinical applications of antiplatelet therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; D | 2006 |
Prasugrel.
Topics: Adenosine Diphosphate; Animals; Aspirin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 2006 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complic | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronar | 2007 |
Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
Oral antiplatelet therapy for percutaneous coronary revascularization.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therap | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Use of clopidogrel in coronary artery disease.
Topics: Clopidogrel; Coronary Disease; Electrocardiography; Humans; Platelet Aggregation Inhibitors; Ticlopi | 2007 |
Clopidogrel resistance--the cardiologist's perspective.
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Resistance; Humans; Platel | 2007 |
Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Internati | 2007 |
[Cardiology 2007].
Topics: Angioplasty, Balloon, Coronary; Cardiopulmonary Resuscitation; Cholesterol; Clopidogrel; Coronary Ar | 2007 |
The role of clopidogrel in revascularized and nonrevascularized patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass | 2007 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinica | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
ADP receptor antagonism: what's in the pipeline?
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Co | 2007 |
Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination.
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Drug The | 2008 |
[Clopidogrel resistance: myth or reality].
Topics: Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Prognosis; | 2007 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Antiplatelet drug nonresponsiveness.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet A | 2008 |
Clopidogrel use in coronary heart disease and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Intera | 2008 |
Review of the 2005 American College of Cardiology, American Heart Association, and Society for Cardiovascular Interventions guidelines for adjunctive pharmacologic therapy during percutaneous coronary interventions: practical implications, new clinical da
Topics: American Heart Association; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Co | 2008 |
Effects of glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel: a meta-analysis of randomized trials.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Confidence Int | 2008 |
Cyclic nucleotides, prostaglandins, and ischemic heart disease.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Coronary Disease; Diet, Atherogenic; Myocar | 1984 |
[Blood platelet aggregation inhibitors in the treatment of heart diseases].
Topics: Angina, Unstable; Aspirin; Coronary Artery Disease; Coronary Disease; Dipyridamole; Humans; Platelet | 1993 |
Stents for intracoronary placement: current status and future directions.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coro | 1996 |
[Ticlopidine in coronary artery diseases].
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Ticlopidi | 1995 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
[Antiplatelet therapy during coronary endoprosthesis placement].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin | 1996 |
Ticlopidine and aspirin therapy following implantation of coronary artery stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thromb | 1997 |
[Evolution in coronary stenting: use of ticlopidine with and without oral anticoagulants].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Humans; Sten | 1997 |
Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic | 1997 |
Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement.
Topics: Coronary Angiography; Coronary Disease; Diagnosis, Differential; Female; Follow-Up Studies; Humans; | 1998 |
Antiplatelet therapy in coronary artery disease: review and update of efficacy studies.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Dipyridamole; Humans; Imm | 1998 |
Clopidogrel with aspirin is the optimal antiplatelet regimen for intracoronary stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Co | 1999 |
Aspirin and ticlopidine after routine coronary stenting: the gold standard as of 1999.
Topics: Anemia, Aplastic; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Co | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; H | 1999 |
Clopidogrel: the future choice for preventing platelet activation during coronary stenting?
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Stents; | 1999 |
Future directions in thrombolysis.
Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Cyclooxygenase 2; Enzyme Inhibitors; Fibrinolyti | 1999 |
Ticlopidine and clopidogrel.
Topics: Adenosine Diphosphate; Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Angina, Unstable; Aspirin; Bo | 1999 |
[Acute complications of coronary angioplasty: prevention and management].
Topics: Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Human | 1999 |
Antiplatelet therapy in interventional cardiology: I. Newer oral antiplatelet agents.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; | 2000 |
Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Aspirin; Bone Marrow Cells; Coronary Disease; Female; Gas | 2000 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
Antiplatelet agents in cardiology: the choice of therapy.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 2000 |
The thienopyridines in coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; | 1999 |
Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiac Catheterization; Clopidog | 2000 |
Optimization of platelet therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; C | 2000 |
[Therapeutic inhibition of platelets in a acute coronary syndrome and in coronary intervention: mechanisms and clinical results].
Topics: Abciximab; Acute Disease; Adult; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; | 2000 |
Optimizing antiplatelet therapy in coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Hu | 2000 |
Antithrombotic therapy in cardiac stent patients.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Di | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Cor | 2001 |
The use of antiplatelet agents in acute cardiac care.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation; Platelet Aggregation Inhibitor | 2001 |
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Odds | 2002 |
[Role of clopidogrel in acute coronary syndromes without ST-segment elevation].
Topics: Acute Disease; Administration, Oral; Clopidogrel; Coronary Disease; Electrocardiography; Humans; Inf | 2002 |
The thienopyridines.
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Pyridines; Ticlopidine | 2002 |
Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.
Topics: Adult; Aged; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Drug Interactions; Humans | 1990 |
Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Cyclooxygenase Inhibitors | 1988 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
155 trials available for ticlopidine and Coronary Disease
| Article | Year |
|---|---|
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Humans; Myocardial Infarction; Percutaneo | 2020 |
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
Topics: Aged; Aspirin; Clinical Decision-Making; Clopidogrel; Coronary Disease; Coronary Thrombosis; Decisio | 2017 |
PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease.
Topics: Aged; Class Ib Phosphatidylinositol 3-Kinase; Clopidogrel; Coronary Disease; Drug Resistance; Female | 2017 |
Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity.
Topics: Aged; Blood Platelets; Clopidogrel; Coronary Disease; Down-Regulation; Female; Humans; Male; MicroRN | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Topics: Aspirin; Blood Coagulation Tests; Clopidogrel; Coronary Disease; Coronary Stenosis; Drug-Eluting Ste | 2013 |
[Effect of aspirin plus clopidogrel therapy on aspirin resistance after off-pump coronary artery bypass surgery].
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Disease; Drug Therapy, Combin | 2013 |
Effect of clopidogrel use post coronary artery bypass surgery on graft patency.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary | 2014 |
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy.
Topics: Aged; Anticholesteremic Agents; Aspirin; Azetidines; Cell-Derived Microparticles; Cholesterol, LDL; | 2014 |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP | 2014 |
Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial.
Topics: Aged; Clopidogrel; Coronary Disease; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; | 2015 |
[The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism].
Topics: Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; | 2016 |
Randomized Comparison of Oral P2Y
Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Corona | 2017 |
Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy: from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial.
Topics: Clopidogrel; Coronary Disease; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous | 2017 |
Aspirin and clopidogrel treatment impair nitric oxide biosynthesis by platelets.
Topics: Adrenergic beta-Antagonists; Adult; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Cross-O | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
Effect of PCI on quality of life in patients with stable coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; C | 2008 |
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease.
Topics: Aged; Aspirin; Body Mass Index; Clopidogrel; Coronary Disease; Female; Fibrinolytic Agents; Hemorrha | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
Topics: Cilostazol; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Plate | 2009 |
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Dru | 2009 |
Static platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over study.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; Cross-Over Studies; Female; Fibr | 2009 |
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Sc | 2010 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart | 2010 |
[Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Angioplasty, Balloon; Aspirin; Clopidogrel; Co | 2010 |
Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Vessels | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; | 2011 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.
Topics: Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; Coronary Restenosis; Drug T | 2012 |
[Changes in coagulation and fibrinolysis in the patients with coronary heart disease in acute period and effect of drug intervention].
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Coagulation; Case-Control Studies; | 2012 |
Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia.
Topics: Aged; Amino Acid Sequence; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Cytoskeletal Pro | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Topics: Adult; Aged; Aspirin; Blood Loss, Surgical; Blood Platelets; Clopidogrel; Confounding Factors, Epide | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Monitoring; Female; Humans; | 2012 |
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy | 2002 |
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Th | 2002 |
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Comb | 2002 |
Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes.
Topics: Antigens; Aspirin; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Clopidogrel; Cohort Stu | 2002 |
Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Co | 2003 |
PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Coronary Disease; Female; Flow Cytometry; | 2002 |
Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Clo | 2003 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
A paclitaxel-eluting stent for the prevention of coronary restenosis.
Topics: Angiogenesis Inhibitors; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2003 |
Durability of platelet inhibition by clopidogrel.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Aged; Pl | 2003 |
[Non ST elevation acute coronary syndrome. Parameters of fibrinolysis during short term use of ticlopidine or clopidogrel].
Topics: Acute Disease; Adult; Antithrombins; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinati | 2003 |
[Clopidogrel as adjunctive medication in patients with acute coronary syndrome].
Topics: Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2002 |
A comparison of 1-month and 6-month clopidogrel therapy on clinical and angiographic outcome after stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Admini | 2003 |
Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Cytochrome P-4 | 2003 |
Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug The | 2003 |
Effects of high ticlopidine doses on platelet function in acute coronary syndrome patients.
Topics: Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ma | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
Clopidogrel does not increase bleeding and allogenic blood transfusion in coronary artery surgery.
Topics: Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Disease; Female; Humans; Length of | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligan | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligan | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligan | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligan | 2004 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Coronary Disease; Cost of Illness; Cost-Benefit | 2004 |
Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
Topics: Aged; Aspirin; Blood Platelets; C-Reactive Protein; Clopidogrel; Cohort Studies; Coronary Angiograph | 2004 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiova | 2004 |
Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombins; Clopidogrel; Coronary Disease; | 2004 |
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female; | 2004 |
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2004 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Abciximab; Acute Disease; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Platel | 2005 |
Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Electrocardiography; Fema | 2005 |
The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; | 2005 |
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.
Topics: Aged; Cilostazol; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Adult; Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Coronary Disea | 2005 |
A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Co | 2005 |
Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene.
Topics: Adult; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Epi | 2005 |
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect)
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double- | 2005 |
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect)
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double- | 2005 |
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect)
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double- | 2005 |
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect)
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Double- | 2005 |
Aspirin, warfarin and a thienopyridine for acute coronary syndromes.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Hematologic Agents; Human | 2006 |
[Effects of cilostazol on long-term clinical outcomes after coronary stenting].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Co | 2005 |
Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Dise | 2005 |
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Th | 2006 |
A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent.
Topics: Adult; Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Double-Blind Method; F | 2006 |
Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
Topics: Adenosine Diphosphate; Adult; Aged; Alprostadil; Blood Platelets; Clopidogrel; Coronary Disease; Fem | 2007 |
Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Topics: Clopidogrel; Coronary Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Piperazines; Plate | 2006 |
[Short-term outcomes of triple antiplatelet therapy after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Thera | 2006 |
Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience.
Topics: Adult; Aged; Clopidogrel; Coronary Disease; Desensitization, Immunologic; Dose-Response Relationship | 2006 |
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Response Re | 2006 |
[The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Drug Therapy, Combinati | 2006 |
No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease.
Topics: Aspirin; Biomarkers; Chemokine CCL2; Clopidogrel; Coronary Disease; Humans; Inflammation; Ticlopidin | 2006 |
Normalization of platelet reactivity in clopidogrel-treated subjects.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Collagen; Cor | 2007 |
Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent.
Topics: Aspirin; Carbon; Cause of Death; Clopidogrel; Coated Materials, Biocompatible; Coronary Disease; Cor | 2007 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Vessels; Dr | 2007 |
Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.
Topics: Adult; Aged; Antidepressive Agents; Aspirin; beta-Thromboglobulin; Biomarkers; Blood Platelets; Cita | 2009 |
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiova | 2008 |
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema | 2008 |
Approaching an age of reason with antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibito | 2008 |
Effects of platelet inhibition on myocardial ischaemia.
Topics: Angina Pectoris; Animals; Clinical Trials as Topic; Coronary Circulation; Coronary Disease; Dogs; Do | 1982 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
Intracoronary stenting without coumadin: one month results of a French multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Ther | 1995 |
Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation: an alternative therapeutic strategy after bailout stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; | 1995 |
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Angiography; Coronar | 1995 |
[Ticlopidine may prevent subtotal or total occlusion of dilated lesions after percutaneous coronary angioplasty].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; F | 1993 |
Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Disease-Free Survival; Equipment | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1996 |
[Coronary artery stenting without antivitamin K. Results after a month].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Di | 1996 |
[Elective coronary implantation of a newly developed stent without conventional anticoagulation].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; H | 1996 |
Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures.
Topics: Angioplasty, Balloon, Coronary; Antifibrinolytic Agents; Aspirin; Atherectomy, Coronary; Coronary Di | 1997 |
High pressure assisted coronary stent implantation accomplished without intravascular ultrasound guidance and subsequent anticoagulation.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; Coronary Disease; Coronary Thro | 1997 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Results of a consecutive series of patients receiving only antiplatelet therapy after optimized stent implantation. Comparison of aspirin alone versus combined ticlopidine and aspirin therapy.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Eq | 1997 |
Coronary stenting (Cordis) without anticoagulation.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Evaluation Stu | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
Antiplatelet effect of ticlopidine after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Constriction, Pathologic; Cor | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial.
Topics: Administration, Oral; Aged; Angioplasty, Balloon; Anticoagulants; Coronary Angiography; Coronary Dis | 1997 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disea | 1997 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
Silicon carbide-coated stents: clinical experience in coronary lesions with increased thrombotic risk.
Topics: Adult; Aged; Angioplasty, Balloon; Carbon Compounds, Inorganic; Coronary Disease; Coronary Thrombosi | 1998 |
Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Drug Therapy, Combination; Fibrinogen; Hu | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Corona | 1998 |
Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.
Topics: Administration, Oral; Aged; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Coronary Disease; | 1998 |
Low molecular weight heparin in coronary stenting.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pilot Proj | 1998 |
PTCA of degenerated vein grafts: experience of two periods (1992-93 and 1996-97) in 780 patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Coronary Artery Bypass; Coro | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combi | 1998 |
Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Coronary Disease; Drug Administra | 1999 |
Advances in post stenting medication protocol.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1995 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Thrombosis; Diarrhea; D | 1999 |
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Corona | 1999 |
Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist.
Topics: Adrenergic beta-Antagonists; Adult; Arterial Occlusive Diseases; Atenolol; Calcium Channel Blockers; | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
beta-Particle-emitting radioactive stent implantation. A safety and feasibility study.
Topics: Adult; Aged; Aspirin; Beta Particles; Brachytherapy; Coronary Angiography; Coronary Disease; Feasibi | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chest Pain; Corona | 1999 |
[Acute coronary syndrome, stent and cardiac insufficiency. Advances in thrombosis prevention].
Topics: Acute Disease; Clopidogrel; Coronary Disease; Coronary Thrombosis; Coumarins; Humans; Platelet Aggre | 1999 |
The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100).
Topics: Abciximab; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; B | 1999 |
Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting.
Topics: Acenocoumarol; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coron | 2000 |
Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Coumarins; Female; Fibrinolytic A | 2000 |
Plasma levels of C-reactive protein after coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Coronary An | 2000 |
A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary D | 2000 |
Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Automation; Beta Particles; Combined Modality Therapy; Coro | 2000 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adju | 2000 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Ther | 2001 |
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation.
Topics: Cilostazol; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Ana | 2001 |
Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose- | 2001 |
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, | 2001 |
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Cilostazol; Coronary Angiography; Coronary Disease; Female; Fo | 2001 |
Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS).
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Gamma Rays; Hu | 2001 |
Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting: follow-up results of a randomized study.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; | 2001 |
Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
Topics: Adenine Nucleotides; Adult; Aged; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Administratio | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; F | 2001 |
Does ticlopidine reduce reocclusion and other adverse events after successful balloon angioplasty of occluded coronary arteries? Results from the Total Occlusion Study of Canada (TOSCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Restenosis; Drug Therapy, Combin | 2001 |
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Coronary Disease; Coronary Thrombosis; Double-B | 2001 |
Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Carbon; Coa | 2002 |
Clopidogrel: a CURE in acute coronary syndromes?
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Hemorrhage | 2002 |
Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Drug Synergism; Drug Therapy, C | 2002 |
Clopidogrel and the CURE results.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2001 |
[Effect of ticlopidine and dipyridamole on platelet aggregation and count in patients with chronic stable angina pectoris].
Topics: Coronary Disease; Dipyridamole; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Ag | 1991 |
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.
Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Intermittent Claudication; Ischem | 1990 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A | 1986 |
Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Bl | 1986 |
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypas | 1985 |
320 other studies available for ticlopidine and Coronary Disease
| Article | Year |
|---|---|
Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China.
Topics: Aged; Aspirin; Cerebral Infarction; China; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; | 2022 |
Proton Pump Inhibitor and Clopidogrel Use After Percutaneous Coronary Intervention and Risk of Major Cardiovascular Events.
Topics: Clopidogrel; Cohort Studies; Coronary Disease; Humans; Myocardial Infarction; Percutaneous Coronary | 2022 |
Relationship between thromboelastography and long-term ischemic events as gauged by the response to clopidogrel in patients undergoing elective percutaneous coronary intervention.
Topics: Clopidogrel; Coronary Disease; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhi | 2017 |
Recommendations on the Clinical Use of Compound Danshen Dripping Pills.
Topics: Angina Pectoris; Aspirin; Camphanes; Clopidogrel; Coronary Disease; Diabetes Mellitus; Diabetic Neph | 2017 |
Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregatio | 2017 |
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
Topics: Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Cytochrom | 2017 |
Safety and Necessity of Antiplatelet Therapy on Patients Underwent Endovascular Aortic Repair with Both Stanford Type B Aortic Dissection and Coronary Heart Disease.
Topics: Adult; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Female; Hemorrhage; Human | 2017 |
CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Topics: Aged; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Coronary Dis | 2018 |
Variability of platelet responses to adenosine diphosphate.
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Down-Regulation; Female; Humans; Male; MicroRNAs; Pl | 2013 |
Anti-thrombotic treatment in patients with a long-term indication for anticoagulant therapy undergoing coronary stenting.
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agents; Hemor | 2013 |
Ask the doctors. I recently had a drug-eluting stent placed in one of my coronary arteries after an episode of severe chest pain. My doctor told me I had to take Plavix every day. Now I feel perfectly fine-except for my right hip. I need a hip replace
Topics: Anticoagulants; Clopidogrel; Coronary Disease; Health Behavior; Hip Fractures; Humans; Platelet Aggr | 2013 |
Acquired pure red cell aplasia due to treatment with clopidogrel: first case report.
Topics: Clopidogrel; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hy | 2014 |
Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2014 |
[Resistance to clopidogrel and polymorphism of P2RY12 and GPIIIA genes in patients with chronic coronary heart disease].
Topics: Alleles; Chronic Disease; Clopidogrel; Coronary Disease; DNA; Drug Resistance; Female; Genotype; Hum | 2013 |
[Real-world study in analysis of effects on concomitant medications with parenterally administered shenmai for coronary heart disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Combination | 2013 |
[Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world].
Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drugs, Chinese He | 2013 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Topics: Aged; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP- | 2014 |
CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Topics: Aged; Biomarkers; Blood Platelets; Body Mass Index; Cell Adhesion Molecules; China; Clopidogrel; Cor | 2014 |
Factors determining the total serum antioxidant capacity in men with coronary heart disease--the powerful effect of treatment with thienopyridines.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cardiotonic Agents; Clopidogrel; Coronary Disease; Drug Thera | 2014 |
Clopidogrel after surgical coronary revascularization increases venous graft patency.
Topics: Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; Platelet | 2014 |
Perioperative aspirin: to give or not to give?
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Coronary Disease; Female; Fibrinolytic Agents; H | 2014 |
Bleeding complication with dual antiplatelet therapy: spontaneous uvula hematoma.
Topics: Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Hematoma; Humans; Lary | 2014 |
Evaluation of resistance to anti-platelet therapy in patients with coronary heart disease in a developing country.
Topics: Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Developing Countries; Drug Resistance; Hosp | 2014 |
[Analysis of traditional Chinese medicine syndrome, traditional Chinese medicine and western medicine in 84 697 patients with coronary heart disease based on big data].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drugs, Chinese Herbal; Femal | 2014 |
Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
Topics: Carboxylic Ester Hydrolases; Coronary Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Plate | 2015 |
Reply to the comment from Bjerre et al.
Topics: Carboxylic Ester Hydrolases; Coronary Disease; Cytochrome P-450 CYP2C19; Female; Humans; Male; Plate | 2015 |
[Paroxysmal atrial fibrillation well controlled. Why the sudden patient syncope?].
Topics: Amiodarone; Atrial Fibrillation; Clopidogrel; Coronary Disease; Diagnosis, Differential; Drug Therap | 2015 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery By | 2015 |
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Cytochrome P | 2015 |
[Positive effect of low-activity thromboxane A synthase gene on prognosis in coronary heart disease].
Topics: Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C19; Data Interpretation, Statistical; Drug Resi | 2015 |
[The ISAR-SAFE study].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Administr | 2015 |
Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
Topics: Activation, Metabolic; Aged; Aspirin; Brachial Artery; Clopidogrel; Coronary Disease; Cytochrome P-4 | 2015 |
Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Drug Int | 2016 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents).
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Coronary Thr | 2015 |
Association of PEAR1 genetic variants with platelet reactivity in response to dual antiplatelet therapy with aspirin and clopidogrel in the Chinese patient population after percutaneous coronary intervention.
Topics: Aged; Asian People; Aspirin; Blood Platelets; China; Clopidogrel; Coronary Disease; Female; Haplotyp | 2016 |
Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness.
Topics: Aged; Aged, 80 and over; Asian People; China; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP2C1 | 2016 |
Cigarette Smoking Does Not Enhance Clopidogrel Responsiveness After Adjusting VerifyNow P2Y12 Reaction Unit for the Influence of Hemoglobin Level.
Topics: Aged; Biomarkers; Blood Platelets; Clopidogrel; Coronary Disease; Drug-Eluting Stents; Female; Hemog | 2016 |
Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Disease; Cytochrome P-450 CYP3A; Female; Human | 2016 |
Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel.
Topics: Aged; Blood Platelets; Case-Control Studies; Chromatography, High Pressure Liquid; Clopidogrel; Coro | 2016 |
Genomewide Association Study Identifies Novel Genetic Loci That Modify Antiplatelet Effects and Pharmacokinetics of Clopidogrel.
Topics: Aged; ATP Binding Cassette Transporter 1; Biotransformation; China; Clopidogrel; Coronary Disease; F | 2017 |
Nonsteroidal anti-inflammatory drugs-induced small bowel enteropathy and obscure gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Capsule Endoscopy; Case-Control Studies | 2018 |
Aspirin desensitization in patients with coronary artery disease: Cost savings.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost Savings; Desensitization, Immunologic; Drug Hypersensit | 2017 |
Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; | 2008 |
CHARISMA revisited: is the glass half full or just empty?
Topics: Aspirin; Clopidogrel; Coronary Disease; Disease Progression; Humans; Platelet Aggregation Inhibitors | 2008 |
[Resistance to antiplatelet drugs in patients with non ST elevation acute coronary syndrome].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Resistan | 2008 |
Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombosis; Female; Huma | 2008 |
Management and outcome of peptic ulcers or erosions in patients receiving a combination of aspirin plus clopidogrel.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Disease; Female; Gastr | 2008 |
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspir | 2008 |
The challenge of monitoring platelet response after clopidogrel.
Topics: Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation In | 2008 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbi | 2008 |
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Disease; | 2009 |
Drug-coated coronary stents offer life-saving benefits. A 74-year-old Ohio judge is still presiding in court three years after receiving the implants to reopen a blocked artery.
Topics: Aged; Aspirin; Clopidogrel; Contraindications; Coronary Disease; Drug-Eluting Stents; Humans; Male; | 2008 |
The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary
Topics: Aged; China; Clopidogrel; Coronary Disease; Cross-Sectional Studies; Evidence-Based Medicine; Female | 2009 |
Effective platelet inhibition by aspirin and clopidogrel: where are we now?
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation Inhibito | 2009 |
Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.
Topics: Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Disease; Drug Interactions; Dr | 2009 |
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Chronic Disease; Clopidogrel; Coronary Disease | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; D | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network.
Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease; | 2009 |
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population.
Topics: Aged; Algorithms; Cardiovascular Surgical Procedures; Clopidogrel; Cohort Studies; Coronary Disease; | 2009 |
New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry.
Topics: Aged; Argentina; Clopidogrel; Coated Materials, Biocompatible; Coronary Angiography; Coronary Diseas | 2009 |
Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Co | 2009 |
Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Dose-Res | 2009 |
Antiplatelet therapy after coronary intervention in Asia and Japan: the Asian perspective of antiplatelet intervention.
Topics: Asia; Cerebral Hemorrhage; Cerebrovascular Disorders; Cilostazol; Clopidogrel; Coronary Disease; Eur | 2009 |
Individualized antiplatelet therapy: what can a clinical score contribute?
Topics: Adult; Aged; Clopidogrel; Coronary Disease; Coronary Vessels; Female; Humans; Male; Middle Aged; Pla | 2009 |
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
Topics: Aged; Alleles; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Coronary Artery Disease; Coron | 2010 |
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Topics: Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Coronary Disease; Cytochrome P | 2010 |
Stent thrombosis: a poor man's disease?
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Clopidogrel; Cohort St | 2009 |
Trial watch. DAPT study.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Drug-El | 2010 |
Optimal duration of clopidogrel use after implantation of drug-eluting stents--still in doubt.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug-Eluting Stents; Humans; Platelet | 2010 |
Early and intermediate outcomes of left main coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; | 2010 |
[Balancing act in antithrombotic therapy. Between hemorrhage and embolism].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Disease; Coronar | 2010 |
The case for routine genotyping in dual-antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Cytochrome P-450 Enzyme System; Genotype; Humans; Platelet Aggregatio | 2010 |
The case for routine genotyping in dual-antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Cytochrome P-450 Enzyme System; Genotype; Humans; Platelet Aggregatio | 2010 |
The case for routine genotyping in dual-antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Cytochrome P-450 Enzyme System; Genotype; Humans; Platelet Aggregatio | 2010 |
The case for routine genotyping in dual-antiplatelet therapy.
Topics: Clopidogrel; Coronary Disease; Cytochrome P-450 Enzyme System; Genotype; Humans; Platelet Aggregatio | 2010 |
Late and very late stent thrombosis after polymer-based sirolimus- or paclitaxel-eluting stent implantation in real-world clinical practice.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Humans; Paclitaxel | 2010 |
Comparison of the incidence of late stent thrombosis after implantation of different drug-eluting stents in the real world coronary heart disease patients: three-year follow-up results.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug-Eluting Stents; Female; Huma | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Mid-term outcomes of patients with PCI prior to CABG in comparison to patients with primary CABG.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Case-Control Studies; Clopidogrel; Coronary | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Clopidogrel; C | 2010 |
Duration of clopidogrel therapy with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronary Disease; Drug Administr | 2010 |
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Topics: Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Cardiovascular Diseases; Clopidogrel; Co | 2011 |
Paraoxonase-1 is a major determinant of clopidogrel efficacy.
Topics: Amino Acid Substitution; Aryldialkylphosphatase; Biotransformation; Clopidogrel; Coronary Disease; F | 2011 |
The CHD challenge: comparing four cost-effectiveness models.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Hydrox | 2011 |
Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Chi-Square Distribution; Clopidogrel; Coronary | 2011 |
Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coated Materials, Biocom | 2011 |
Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Disease; Drug Interactions; Female; Humans; Mal | 2011 |
Significance of cardiocoronary pathology in acute stroke.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2011 |
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin | 2011 |
[Tailored treatment with clopidogrel based on the results of platelet function tests should not be implemented, in the absence of clear indications on the methodology to be used].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Resistance; Evidence-Based Medic | 2011 |
Comparison of drug-eluting versus bare metal stents in cardiac allograft vasculopathy.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Disease; Drug-Eluting | 2011 |
Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chi-Square Distribution; Cilostazol; Clopidogrel; Cor | 2011 |
Predictors of low clopidogrel adherence following percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Humans; Male; Medication Adhe | 2011 |
Relation of body mass index to on-treatment (clopidogrel + aspirin) platelet reactivity.
Topics: Adenosine Diphosphate; Aspirin; Body Mass Index; Cell Adhesion Molecules; Clopidogrel; Coronary Dise | 2011 |
Paraoxonase-1 and clopidogrel efficacy.
Topics: Aryldialkylphosphatase; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidi | 2011 |
Paraoxonase-1 and clopidogrel efficacy.
Topics: Aryldialkylphosphatase; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidi | 2011 |
Paraoxonase-1 and clopidogrel efficacy.
Topics: Aryldialkylphosphatase; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; Ticlopidi | 2011 |
[Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Disease; | 2011 |
Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Asian People; Aspirin; Clopidogrel; Coronar | 2012 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
Pharmacokinetic interactions between clopidogrel and rosuvastatin: effects on vascular protection in subjects with coronary heart disease.
Topics: Cardiovascular Diseases; Clopidogrel; Coronary Disease; Drug Interactions; Female; Fluorobenzenes; H | 2012 |
Clopidogrel variability: role of plasma protein binding alterations.
Topics: Aged; Aryl Hydrocarbon Hydroxylases; Blood Proteins; Cell Adhesion Molecules; Chromatography, Liquid | 2013 |
Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2012 |
[Current clinical practice among German Internists regarding the prophylaxis of gastroduodenal ulcers associated with NSAIDs, aspirin and Helicobacter pylori].
Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Clopid | 2012 |
Use of medications for secondary prevention after coronary bypass surgery compared with percutaneous coronary intervention.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Chemoprevention; Clopidogrel; Cor | 2013 |
Evidence-based risk stratification to target therapies in acute coronary syndromes.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Biomarkers; Cardiac Catheterization; Clopidogrel; Co | 2002 |
CURE works patients with acute coronary syndromes at all risk levels.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet A | 2002 |
A partial CURE for acute coronary syndromes--but how did it happen?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platele | 2002 |
Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Blood Platelets; | 2002 |
Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.
Topics: Blood Platelets; Cell Size; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet A | 2003 |
Clopidogrel-associated angioedema.
Topics: Aged; Angioedema; Clopidogrel; Coronary Disease; Humans; Male; Platelet Aggregation Inhibitors; Ticl | 2003 |
The prevention of minor myocardial injury with ticlopidine pretreatment in patients undergoing elective coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Chi-Square Distribution; Coronary Disease; Female; Follow-Up S | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Industry; Fees, Phar | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Data Interpretation, Statistical; Dru | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Drug Industry; Fees, Phar | 2003 |
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Medically Uninsured; Platelet | 2003 |
Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Clopidogrel; Collagen; Coronary Disease; Coronar | 2003 |
Antiplatelet effects of angiotensin-converting enzyme inhibitors compared with aspirin and clopidogrel: a pilot study with whole-blood aggregometry.
Topics: Adenosine Diphosphate; Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Aspiri | 2003 |
A technique for type 4a coronary bifurcation lesions: initial results and 6-month clinical evaluation.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Angiography; Coronary Disease; | 2003 |
Acute coronary syndrome associated with coronary aneurysm: a case report.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coronary Aneurysm; Cor | 2003 |
Clopidogrel before urgent coronary artery bypass graft.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Art | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Dr | 2003 |
[Long-term therapy with clopidogrel in combination with ASA significantly reduces risk of death, myocardial infarct or stroke].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; H | 2003 |
Clopidogrel in acute coronary syndromes: can the cost effectiveness improve?
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Therapy, Combinat | 2003 |
[Clopidogrel should be added to aspirin for at least 1 year after percutaneous coronary interventions (CREDO) while before them its loading dose can reach 600mg (ISAR-COOL)].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; E | 2003 |
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia | 2003 |
[Long-term effect of clopidogrel do exist--but hardly worth the costs].
Topics: Clopidogrel; Coronary Disease; Drug Costs; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2003 |
Red vs white thrombi: treating the right clot is crucial.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2003 |
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Collateral Circulation; | 2003 |
Serum sickness-like reaction associated with clopidogrel.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Male; Middle Aged; Platelet Aggregation Inhibi | 2003 |
Antiplatelet therapy for ischemic heart disease.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopid | 2004 |
Lack of adverse clopidogrel-atorvastatin clinical interaction.
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Drug Interactions; Heptanoic Acids; Humans; Hydroxymeth | 2004 |
When guidelines collide...
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy | 2004 |
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2004 |
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disea | 2004 |
Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting.
Topics: Clopidogrel; Coronary Disease; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Platelet Aggreg | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment.
Topics: Adenosine Diphosphate; Aged; Clopidogrel; Collagen; Coronary Disease; Female; Humans; Integrin alpha | 2004 |
Clopidogrel resistance: a new chapter in a fast-moving story.
Topics: Angioplasty; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; | 2004 |
Diminishing returns...and too many choices...the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Blood Vessel Prosthesis Implantation; Clopidogrel; Coron | 2004 |
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Case-Control Studies; Clopidogrel; | 2004 |
Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibito | 2004 |
[Do low risk patients undergoing percutaneous coronary intervention after pretreatment with clopidogrel need abciximab infusion? Results of ISAR-REACT study].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clopidog | 2004 |
Clopidogrel and postoperative bleeding.
Topics: Aprotinin; Aspirin; Blood Transfusion; Cardiopulmonary Bypass; Clopidogrel; Coronary Artery Bypass; | 2004 |
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combinat | 2005 |
Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
Topics: Aged; Blood Loss, Surgical; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Coronary Disease | 2005 |
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Computer Simulation; | 2005 |
Anaesthetic considerations in a parturient with critical coronary artery disease and a drug-eluting stent presenting for caesarean section.
Topics: Adult; Anesthesia, Obstetrical; Cesarean Section; Clopidogrel; Coronary Disease; Female; Humans; Pre | 2005 |
P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose.
Topics: Adenosine Diphosphate; Aged; Aspirin; Clopidogrel; Coronary Disease; Female; Genotype; Haplotypes; H | 2005 |
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; | 2004 |
Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes.
Topics: Adenosine Monophosphate; Calcium Signaling; Clopidogrel; Coronary Disease; Dose-Response Relationshi | 2005 |
[Exercise-induced left arm pain and thrombocytosis].
Topics: Angioplasty, Balloon, Coronary; Bone Marrow Examination; Clopidogrel; Coronary Angiography; Coronary | 2005 |
Stent thrombosis is associated with an impaired response to antiplatelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fema | 2005 |
Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Clopidogrel; Coronary Disease; | 2005 |
The value of clopidogrel administered postoperatively following a non-ST-segment elevation acute coronary syndrome.
Topics: Clopidogrel; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Drug Admini | 2005 |
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents | 2005 |
A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
Topics: Acute Disease; Aged; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Electrocardio | 2006 |
Combined pharmacologic treatment with clopidogrel and statin for patients with acute coronary syndrome: is there a survival advantage?
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reducta | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disea | 2005 |
Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; D | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
Topics: Alleles; Blood Coagulation Factors; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; | 2005 |
Clopidogrel hypersensitivity syndrome with rash, fever, and neutropenia.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Drug Hypersensitivity; Female; | 2005 |
Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting.
Topics: Aged; Chemical and Drug Induced Liver Injury; Clopidogrel; Combined Modality Therapy; Coronary Disea | 2005 |
Use of evidence-based management for acute coronary syndrome.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoag | 2005 |
Acute polyarthritis associated with clopidogrel treatment.
Topics: Acute Disease; Arthritis; Clopidogrel; Coronary Disease; Humans; Male; Middle Aged; Platelet Aggrega | 2005 |
Prior clopidogrel use and outcome of acute coronary syndrome.
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Odds Ratio; Platelet Aggregation Inhibitors; Ticlopi | 2006 |
Letter regarding article by Valgimigli et al, "Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease".
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug Implants; H | 2005 |
Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis.
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; | 2005 |
Evolving role of clopidogrel in acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Syndrome; Tic | 2005 |
Case 6-2005 thoracotomy after myocardial infarction and intracoronary stenting: a balance between myocardial recovery and procedural risk.
Topics: Clopidogrel; Coronary Disease; Exercise Test; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Myo | 2005 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Clinical, biochemical and genetical resistance to clopidogrel in a patient with the recurrent coronary stent thrombosis--a case report and review of the literature.
Topics: Aged; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Resistance; Female; Humans; Platelet | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
Impact of adenosine diphosphate and calcium chelation on platelet aggregation testing in patients receiving clopidogrel therapy.
Topics: Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Chelating Agents; Citrates; Clopidogrel; Cor | 2006 |
Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.
Topics: Adolescent; Adult; Blood Platelets; Clopidogrel; Coronary Disease; Drug Resistance; Electric Impedan | 2006 |
[Inhibition of platelet aggregation for the secondary prevention after ACS: when clopidogrel instead of ASA, when clopidogrel and ASA?].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Synd | 2006 |
High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Disea | 2006 |
Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study.
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Female; Humans; Male; Middle Aged; Mult | 2006 |
[The effect of paclitaxel-eluting stents on restenosis].
Topics: Animals; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary Restenosis; Coronary | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Concurrent use of clopidogrel (Plavix) and atorvasatin (Lipitor) is contraindicated.
Topics: Atorvastatin; Clopidogrel; Contraindications; Coronary Disease; Drug Incompatibility; Drug Therapy, | 2006 |
[Recurrent hemoptysis following thienopyridines and amiodarone administration. therapeutic dilemma].
Topics: Aged; Amiodarone; Cardiovascular Agents; Clopidogrel; Coronary Disease; Drug Interactions; Drug Ther | 2005 |
Use of ticlopidine and cilostazol after intracoronary drug-eluting stent placement in a patient with previous clopidogrel-induced thrombotic thrombocytopenic purpura: a case report.
Topics: ADAM Proteins; ADAMTS1 Protein; Aged; Apoptosis; Aspirin; Autoantibodies; Cilostazol; Clopidogrel; C | 2006 |
Unveiling the inflammatory face of antiplatelet drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Di | 2006 |
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2006 |
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Cohort Studies; Coronary Disease; Creatine | 2007 |
Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.
Topics: Aged; Angioplasty; Aryl Hydrocarbon Hydroxylases; Aspirin; Cell Adhesion Molecules; Clopidogrel; Cor | 2006 |
Tackling the diabetic platelet: is high clopidogrel dosing the answer?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Pl | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
[Bleeding complications after treatment with antithrombotic agents after acute coronary syndrome].
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Fibrinolytic Agent | 2006 |
Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary | 2006 |
Clinical and angiographic outcomes of sirolimus-eluting stents implantation in Japanese patients in daily practice.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Coronary Restenosis; C | 2006 |
A cost analysis in patients with acute coronary syndrome using clopidogrel in addition to aspirin in a Hong Kong public hospital.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Costs and Cost Analysis; Female; Hong Kong; Humans; Ma | 2006 |
Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach").
Topics: Aged; Aged, 80 and over; Aortic Valve; Aortic Valve Stenosis; Aspirin; Clopidogrel; Coronary Disease | 2006 |
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Humans; Male; Middle Ag | 2007 |
Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Female; Flow Cytometry; | 2007 |
A new caution for patients with drug-coated stents.
Topics: Clopidogrel; Coronary Disease; Coronary Thrombosis; Humans; Platelet Aggregation Inhibitors; Stents; | 2006 |
Platelet non-responsiveness to dual antiplatelet therapy and relation to coronary disease among diabetes patients.
Topics: Adult; Aspirin; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Disease; Diabetes Melli | 2007 |
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Disease; Diabetic Angiopathies; Humans | 2007 |
Variability in response to clopidogrel: where is the threshold for 'low response'?
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platel | 2007 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
Acute coronary syndrome in an adult with anomalous origin of the left anterior descending coronary artery from the pulmonary trunk.
Topics: Adrenergic beta-Antagonists; Cardiac Catheterization; Clopidogrel; Coronary Angiography; Coronary Di | 2007 |
Endpoints in studies on myocardial infarction.
Topics: Clopidogrel; Coronary Disease; Endpoint Determination; Humans; Myocardial Infarction; Platelet Aggre | 2007 |
Managing acute coronary syndrome: evidence-based approaches.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Protocols; Clopidogrel; Coronary Disease; Dr | 2007 |
Timing of thrombotic events in patients receiving 2 weeks of clopidogrel therapy post bare metal coronary artery stenting: a New Zealand retrospective study.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Coronary Disease; Coronary | 2007 |
Clopidogrel and stent thrombosis after percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Restenosis; Coronary Thrombo | 2007 |
Surgery or percutaneous coronary intervention for three-vessel and left main coronary artery disease: a critical appraisal of the literature.
Topics: Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Coron | 2007 |
Clopidogrel: the good, the bad, and the ugly.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Hemorrhage; Humans; Platelet Ag | 2007 |
PCI for stable coronary disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Disease; D | 2007 |
[After coronary intervention. Which platelet inhibitor for whom?].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coated Materials, Biocompatible; Coronary Dise | 2007 |
[Coronary heart disease patient does not tolerate acetylsalicylic acid. Can clopidogrel be prescribed?].
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Disease; Drug Therapy, Combination; Humans; Peptic | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy.
Topics: Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Endoscop | 2008 |
A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Fe | 2008 |
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvas | 2008 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial | 2008 |
New horizons in cardiology.
Topics: Adult; Angina, Unstable; Anticoagulants; Coronary Disease; Coronary Vessels; Electrocardiography; Fe | 1984 |
[Changes in the unmodified vessels after aortocoronary bypass surgery].
Topics: Angina Pectoris; Anticoagulants; Arterial Occlusive Diseases; Coronary Artery Bypass; Coronary Disea | 1983 |
Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study.
Topics: Coronary Artery Bypass; Coronary Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Po | 1984 |
[Stent after-care: new approaches to coagulation inhibiting therapy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; | 1995 |
[Rotablator and endoprosthesis on the left main coronary trunk].
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Coronary Disease; Fem | 1995 |
Antithrombotic effect of ticlopidine on occlusive thrombi of small coronary arteries in (NZWxBXSB)F1 male mice with myocardial infarction and systemic lupus erythematosus.
Topics: Analysis of Variance; Animals; Antigen-Antibody Complex; Blood Urea Nitrogen; Coronary Disease; Coro | 1995 |
[Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coron | 1994 |
Relation of thrombotic occlusion of coronary stents to the indication for stenting, stent size, and anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Female; Heparin; Humans; Male | 1995 |
[Cholestatic jaundice due to ticlopidine: a new case].
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Coronary Disease; Diagnosis, Differential; Huma | 1994 |
Platelets and coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Heparin | 1996 |
Ticlopidine and renal function.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Creatinine; Drug Therapy, Combination; Hu | 1996 |
[Treatment with ticlodipine after intracoronary stent implantation].
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet | 1996 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
Antiplatelet and anticoagulant therapy after coronary-artery stenting.
Topics: Aged; Coronary Disease; Humans; Male; Neutropenia; Platelet Aggregation Inhibitors; Stents; Ticlopid | 1996 |
Improved outcome of coronary stenting by utilizing a modified treatment protocol.
Topics: Aged; Angioplasty, Balloon, Coronary; Clinical Protocols; Combined Modality Therapy; Coronary Diseas | 1996 |
Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting.
Topics: Aged; Aspirin; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Plate | 1996 |
Intracoronary stenting using slotted tubular stents with intravascular ultrasound and anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Mo | 1996 |
Intravascular ultrasound-guided emergency coronary Palmaz-Schatz stent placement without post-procedural systemic anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Follow-Up Studies; Humans; Male; | 1996 |
Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Causality; Coronary Angiography; Coronary Disease; Co | 1997 |
Ticlopidine and aspirin interactions.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C | 1997 |
Neutropenia with ticlopidine plus aspirin.
Topics: Agranulocytosis; Aspirin; Coronary Disease; Humans; Monitoring, Physiologic; Neutropenia; Platelet A | 1997 |
Ticlopidine in the prevention of thrombus formation after percutaneous transluminal coronary angioplasty (PTCA).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coronary Thrombosis | 1997 |
Antiplatelet therapy alone is safe and effective after coronary stenting: observations of a transition in practice.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Ar | 1997 |
Ticlopidine-carbamazepine interaction in a coronary stent patient.
Topics: Aged; Anticonvulsants; Carbamazepine; Coronary Disease; Drug Interactions; Epilepsy; Humans; Male; P | 1997 |
New stent delivery balloon: a technical note.
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Hu | 1997 |
Antithrombotic therapy with intracoronary stenting.
Topics: Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary D | 1997 |
Antiplatelet therapy following stent deployment.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Combined Modality Therapy; Coronary Disease; Humans; | 1997 |
[Comparative study of 2 antithrombotic regimens in 75 patients with coronary endoprostheses].
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation | 1997 |
Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Confounding Factors, Epidemiologic; Coronary Disease; Coron | 1998 |
[Coronary stents].
Topics: Aspirin; Belgium; Coronary Disease; Humans; Myocardial Revascularization; Platelet Aggregation Inhib | 1998 |
Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Vessel Prosthesis Implantation; Coro | 1998 |
Ticlopidine after stenting: "Render unto Caesar that which belongs to Caesar".
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; T | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
Thrombotic thrombocytopenic purpura after stenting and ticlopidine.
Topics: Coronary Disease; Humans; Platelet Aggregation Inhibitors; Purpura, Thrombotic Thrombocytopenic; Ret | 1998 |
Coronary stenting in unstable angina: early and late clinical outcomes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coronary Disease; | 1998 |
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
Topics: Blood Vessel Prosthesis Implantation; Coronary Disease; Drug Therapy, Combination; Female; Follow-Up | 1998 |
Coronary-artery stents--gauging, gorging, and gouging.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1998 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
[Reduction of in-hospital complications after elective percutaneous transluminal coronary angioplasty using a combined pretreatment with ticlopidine and aspirin].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coron | 1998 |
Thrombotic thrombocytopenic purpura: a rare but potential life-threatening complication following ticlopidine administration.
Topics: Aged; Coronary Disease; Humans; Male; Plasmapheresis; Platelet Aggregation Inhibitors; Purpura, Thro | 1998 |
Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting.
Topics: Aged; Coronary Disease; Coronary Thrombosis; Fatal Outcome; Female; Humans; Male; Middle Aged; Neutr | 1999 |
Ticlopidine-induced thrombocytopenia.
Topics: Coronary Disease; Female; Follow-Up Studies; Humans; Middle Aged; Platelet Aggregation Inhibitors; P | 1999 |
Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Cor | 1999 |
Antithrombotic therapy after coronary-artery stenting.
Topics: Anemia, Aplastic; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Therapy, Combination | 1999 |
Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent.
Topics: Aspirin; Coronary Disease; Hemothorax; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; R | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Adverse cutaneous reactions to ticlopidine in patients with coronary stents.
Topics: Aged; Aged, 80 and over; Biopsy; Combined Modality Therapy; Coronary Disease; Drug Eruptions; Female | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
Ticlopidine and TTP after coronary stenting.
Topics: Angioplasty, Balloon; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Compl | 1999 |
Ticlopidine and TTP after coronary stenting.
Topics: Angioplasty, Balloon; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Compl | 1999 |
Taming platelets in coronary stenting: ticlopidine out, clopidogrel in?
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Combined Modality Therapy; Cor | 1999 |
Safety and efficacy of ticlopidine after stent placement.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Coronary Vessels; Drug Administration Schedule; | 2000 |
[Imputable cutaneous eruption caused by ticlopidine after implantation of a coronary endoprosthesis: why not continue treatment?].
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Thrombosis; Dose-Response Relationship, D | 2000 |
[Clopidogrel--an expensive thrombocyte inhibitor with a small marginal benefit].
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Myocardial Ischemia; Platelet | 2000 |
Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disea | 2000 |
Is it time to offer elective percutaneous treatment of the unprotected left main coronary artery?
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Female; Humans; | 2000 |
Acute renal failure and thrombocytopenia after ticlopidine--not necessarily thrombotic thrombocytopenic purpura.
Topics: Acute Kidney Injury; Aged; Coronary Disease; Diagnosis, Differential; Embolism, Cholesterol; Female; | 2000 |
Combination therapy with clopidogrel and aspirin after coronary stenting.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged | 2000 |
Consider this: It's too little!
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Stents; Thrombosis; Ticlopid | 2000 |
Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent--a case report.
Topics: Agranulocytosis; Coronary Disease; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Age | 2000 |
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet | 2000 |
Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.
Topics: Adult; Clopidogrel; Coronary Disease; Cyclosporine; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2000 |
Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coron | 2000 |
Possible ticlopidine-induced cholestatic jaundice.
Topics: Aged; Cholestasis; Coronary Disease; Female; Follow-Up Studies; Humans; Liver Function Tests; Male; | 2000 |
[Impediment of cellular immune response under treatment with ticlopidine in a patient with Staphylococcus aureus endocarditis].
Topics: Agranulocytosis; Angioplasty, Balloon, Coronary; Anti-Bacterial Agents; Clarithromycin; Coronary Dis | 2000 |
Risk of neutropenia with clopidogrel.
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Disease; Graft Occlusion, Vascular; Huma | 2000 |
Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Femal | 2001 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |
Ticlopidine monotherapy following coronary stent deployment: "penny wise and pound foolish".
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Stent | 2001 |
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery].
Topics: Aspirin; Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative Compl | 2001 |
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
Topics: Aged; Coronary Disease; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregati | 2001 |
Diffuse alveolar hemorrhage after clopidogrel use.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Hemorrhage; Humans; Lung Diseases; Ma | 2001 |
Current perspectives on British use of adjunctive therapies during coronary interventions.
Topics: Abciximab; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagul | 2001 |
[Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial].
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Postoperative C | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
Clopidogrel in invasive management of non-ST-elevation ACS.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Humans; My | 2001 |
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disea | 2001 |
Statins do not affect platelet inhibition with clopidogrel during coronary stenting.
Topics: Aged; Clopidogrel; Coronary Disease; Coronary Vessels; Drug Interactions; Female; Humans; Hydroxymet | 2001 |
Evaluating the risks of therapies for acute coronary syndromes.
Topics: Clopidogrel; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Risk Assessment; Ticlopidine | 2001 |
Intracoronary stent implantation under intracoronary ultrasound guidance with aspirin and ticlopidine therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Female; | 2001 |
Clopidogrel and percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Coronary Disease; Double-Bli | 2002 |
Prolonged jaundice following percutaneous coronary intervention and ticlopidine therapy.
Topics: Aged; Coronary Disease; Fatal Outcome; Humans; Jaundice; Male; Middle Aged; Platelet Aggregation Inh | 2002 |
Guidelines for acute coronary syndrome without ST elevation.
Topics: Clopidogrel; Coronary Disease; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Glycopr | 2002 |
[Clopidrogel in Acute Coronary Syndromes with Non-ST Elevation].
Topics: Acute Disease; Clopidogrel; Coronary Disease; Electrocardiography; Humans; Platelet Aggregation Inhi | 2002 |
Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Computer Simulation; Coronary Disease; Cost-Be | 2002 |
When increased therapeutic benefit comes at increased cost.
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Drug Costs; Platelet Aggregation Inhi | 2002 |
ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
Topics: Adenosine Diphosphate; Animals; Apyrase; Bridged Bicyclo Compounds, Heterocyclic; Clopidogrel; Coron | 1992 |
Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs.
Topics: Animals; Arrhythmias, Cardiac; Benzimidazoles; Benzoxepins; Collagen; Coronary Disease; Cyclooxygena | 1991 |
[A case of hypertrophic obstructive cardiomyopathy with left atrial giant thrombus during anti-platelet therapy].
Topics: Aged; Cardiomyopathy, Hypertrophic; Coronary Disease; Coronary Thrombosis; Echocardiography; Female; | 1989 |
Intracoronary thrombodynamics in the early phase of acute myocardial infarction.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Disease; Coronary Thrombosis; Death, Sudden; | 1988 |
Effects of ticlopidine on platelet function and on coronary insufficiency in patients with angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Humans; Male; Middle Aged; Nitrogly | 1985 |
[Anti-aggregation therapy of patients with ischemic heart disease].
Topics: Aspirin; Coronary Disease; Dipyridamole; Drug Evaluation; Humans; Platelet Aggregation; Platelet Agg | 1988 |
Thromboxane A2 synthesizing activity of platelets in coronary artery diseases.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Blood Platelets; Coronary Disease; Female; Humans; Male; M | 1987 |
[Antagonism of collagen-induced ECG changes in rats by a thromboxane synthetase inhibitor, CV-4151].
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Collagen; Coron | 1986 |
Intracoronary platelet activation in ischemic heart disease: effects of ticlopidine.
Topics: Adult; Aged; Anticoagulants; Aorta; Blood Platelets; Coronary Disease; Coronary Vessels; Female; Hum | 1985 |
Ticlopidine as a hemorrhagic risk factor in coronary surgery.
Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Pos | 1985 |